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In 2015, American Heart Association (AHA) reported that 1 in 9 deaths are 
attributed to heart failure (HF), the number one killer in the world. While advancements 
in interventional cardiology in conjunction with pharmacotherapies have significantly 
reduced the rate of mortality following MI, there has been a corresponding rise in HF in 
surviving patients, largely attributed to the limited regenerative capacity of the heart and 
the inadequate healing response. Myocardial ischemic injury triggers an exuberant local 
and systemic inflammation, and the extent and quality of the cardiac wound healing 
process is intricately tied to the delicate equilibrium of this inflammatory response. While 
cardiac regeneration is an important goal, it is imperative in the meantime to explore 
therapeutic strategies that target these inflammatory mediators of early cardiac repair. 
These interventions to influence and improve cardiac wound healing can represent a new 
therapeutic window to halt the progression of heart failure between the few hours that 
may be used to limit infarct size by reperfusion and an irreversible non-contractile 
cardiac scar. This dissertation examines three therapeutic delivery strategies aimed at 
modulating the immune response to enhance cardiac repair in rodent models MI: 1) 
Polyketal nanoparticles as siRNA delivery vehicles for antioxidant therapy; 2) Spherical 
nucleic acid particles for anti-inflammatory therapy and; 3) Bioactive PEG 
(polyethyleneglycol)-based hydrogel for immunomodulation.  
 Antioxidant therapy has shown promise in battling the excessive ROS production 
caused by infiltrating immune cells, although scarcity of specific and effective inhibitors 
to oxidant enzymes has been a major shortcoming. Here, we describe the biocompatible 
polyketal polymer formulated nanoparticles as a viable delivery system for siRNA-
mediated gene silencing of a major oxidant enzyme Nox2-NADPH in the heart.  The 
non-acidic degradation products of polyketals make them a prime candidate for treating 
inflammatory diseases, and especially for nucleic acid delivery to such disease states, as 
most successful delivery vehicles for nucleic acids are cationic lipid/polymers that elicit 
 xix 
an immune response. We demonstrated intracellular localization of these particles in 
macrophages, the ability to knockdown Nox2-NADPH and scavenge extracellular 
superoxide levels in vitro. At a low dose of 5μg siRNA/kg, the delivery of these particles 
restored acute cardiac function following MI injury in mice.  
 TNF- is a critical regulator of the inflammatory response following MI. 
Catalytic DNA (DNAzyme) targeted against TNF- mRNA was functionalized to gold 
particles. These spherical nanostructures exhibited no cytotoxicity, and superior uptake 
and knockdown efficiency in primary macrophages compared to widely used cationic 
lipid particles. In vivo studies demonstrate significant anti-inflammatory effects conferred 
by the knockdown of TNF- by DNAzyme particles and significant improvement in 
acute cardiac function.  
 Increasing evidence suggests that macrophages exhibit remarkable plasticity, 
allowing them to adopt distinct activation states with specific functional roles according 
to changing cues. We employed a PEG-based hydrogel to deliver the polarizing cytokine 
IL-4 to the myocardium to influence cardiac repair via modulating the pro-inflammatory 
macrophages at the site of infarct towards a reparative macrophage phenotype. We 
validated this approach in vitro to demonstrate beneficial effects of alternately activated 
macrophages on endothelial tube formation and cardiac progenitor cell migration. We 
evaluated the functional effects of this approach in a rat model of MI and observed acute 
functional improvement compared to bolus delivery of IL-4, although future studies 
optimizing the delivery approach are needed to effect favorable chronic repair.  
 The work presented here applies novel nucleic acid delivery strategies for cardiac 
gene silencing and has contributed to new knowledge with regard to modulating the 





CHAPTER 1  INTRODUCTION 
1.1 Motivation 
  Heart failure (HF) is the leading cause of death in the developed world, 
and myocardial infarction (MI) is the dominant cause [1]. A million new and recurring 
MI events occur every year accounting for $300 billion in direct and indirect costs yearly, 
with an expectation for this cost to triple in the next decade [2].  Optimized reperfusion 
strategies employ sophisticated designs of stents to restore blood to the injured 
myocardium. In conjunction with neurohormonal and thrombolytic pharamcological 
agents, advancements in the management of acute MI has reduced the mortality due to 
MI [3-5]. Even with improvements in clinical interventions however, 25% of patients 
surviving MI develop HF, which poses an enormous burden for the healthcare systems 
worldwide [4, 6, 7]. Ultimately, the only cure for HF is transplantation, and given the 
shortage of donor organs and the continuous battles with organ rejections, there is a clear 
need to identify approaches that can halt the progression of HF.   
 Most research approaches focus on renewal of cardiomyocytes from existing 
cardiomyocytes or stem cells with the hope of garnering the heart’s limited regenerative 
capacity [8-10]. While some stem cell clinical trials have shown promise, cell survival 
and retention have been huge hurdles [11, 12]. These efforts are supplemented by efforts 
in gene therapy and exploration of growth factors or microRNAs as therapeutics, 
although none have been clinically translated thus far [8, 11-15], largely due to the 
limitations in the delivery technologies to the heart. Therefore identification and 
development of suitable delivery vehicles to the heart can drastically improve the efficacy 
of these existing promising therapies.  
 The progression to HF originates from the heart’s failed attempt to compensate 
for the ischemic injury. The dynamic network of complex molecular and structural 
processes initiated following the loss of viable myocardium often lead to adverse cardiac 
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remodeling, eventually culminating in cardiac dysfunction. Central to these processes are 
the inflammatory response to the MI injury, and interventions to modulate these 
responses favorably can represent a new therapeutic window between the few hours that 
may be used to limit infarct size by reperfusion and an irreversible non-contractile 
cardiac scar. 
1.2 Specific Aims 
 Recent studies have shed light on key roles of macrophages in MI injury [16-18]. 
In the early phase following injury, classically activated macrophages (M1) dominate the 
infarct and clear dead cells and debris from the wound. Production of reactive oxygen 
species (ROS) and upregulation of pro-inflammatory cytokines are key events involved 
in this phase. In later stages of wound healing, alternatively activated macrophages (M2) 
dominate and propagate tissue repair.  While the initial pro-inflammatory response is 
necessary, prolonging of these signals is detrimental to wound healing and could 
contribute to adverse cardiac remodeling [17]. Therefore, optimal healing response after 
MI requires a well-balanced biphasic macrophage response and the overall inflammatory 
response. In this thesis work, we explore several inflammatory mediators/regulators as 
therapeutic targets with the goal of controlling the overall inflammatory response.  
 Nox2- NADPH oxidase is a major source of reactive oxygen species (ROS) that 
are integral part of the inflammatory events in the myocardium [19-21], and we aim to 
inhibit this enzyme at the genetic level as an anti-oxidant therapeutic strategy that can 
suppress the excessive ROS levels in the heart following MI. TNF- is a key 
inflammatory mediator implicated in several pathophysiological processes in the 
progression of HF [22-24], and we seek to transiently suppress this cytokine to suppress 
the exuberant inflammatory response post-MI. Increasing evidence suggests that 
macrophages exhibit remarkable plasticity, allowing them to adopt distinct activation 
states with specific functional roles according to changing environmental signals [17, 25, 
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26] In a comprehensive approach to influencing cardiac repair, we aim to modulate the 
macrophages to transition from an inflammatory state (M1) to that of a reparative 
activation state (M2). To do this, we took advantage of the well-known fact that cytokine 
Interleukin-4 (IL-4) polarizes monocytes into alternatively activated macrophages, and 
explore the delivery of IL-4 to the myocardium.  
 Translation of such approaches, however, is limited by the key challenge facing 
the field of regenerative cardiology: technologies that enable delivery of therapeutics to 
the heart in a spatially and temporally controlled manner [12, 27]. In order for attempts to 
repair or regenerate the heart to be effective, temporal and spatial control of therapeutics 
become essential given the complex nature of the inflammatory and healing processes 
that ensue MI. Delivering a particular drug at the wrong time or location can either turn 
out to be futile or even worse, deleterious given the pleiotropic functions of many of the 
mediators of cardiac repair. Therefore, drug delivery vehicles appropriately tailored to 
deliver therapeutics to an inflammatory myocardial injury environment can afford 
spatiotemporal control over the drug concentration in the myocardium and can enhance 
therapeutic efficacy. 
 We focus on three different materials for drug delivery to the heart in this thesis 
work. Some of these materials have already been evaluated in the heart in the context of 
MI, and have been well tolerated. Polyketals are a class of polymeric drug delivery 
vehicles that contain acid-degradable ketal linkages and produce neutral degradation 
products, and have this advantage over many polymeric delivery vehicles in wide use 
today such as polyesters or polyimides. This biocompatibility is especially advantageous 
for nucleic acid delivery, and in stark contrast to the most widely used cationic lipid 
nanoparticles. Polyketals also offer a unique advantage of pH sensitivity for delivery of 
nucleic acids for gene silencing purposes. Endocytosis/phagocytosis is the most common 
mechanisms of drug/drug delivery vehicle uptake by cells, and polyketals degrade within 
the acidic endosomes to release the cargo in a timely manner to effect gene silencing. We 
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also explore spherical DNA structures to confer catalytic gene silencing activity in the 
heart [28]. These unique nanostructures created by modifying gold particles with catalytic 
DNA (DNAzyme) capable of site-specifically cleaving target mRNA offer the 
advantages of biocompatibility as well efficient cellular uptake not limited to phagocytic 
immune cells [29-31].  Finally, we evaluated a non-immunogenic, non-fouling PEG-
based hydrogel that incorporates a protease cleavable linker to confer enzymatically 
triggered release [32, 33]. This is a useful property in the inflammatory myocardial 
environment to release therapeutics in an on-demand fashion as macrophage-secreted 
proteases are abundantly present in the myocardium following MI. Hydrogels are also 
ideal delivery vehicles for proteins as they afford a 3-dimensional, hydrophilic  
environment that better preserve protein structures.   
 The main objective of this project was to evaluate therapeutic drug delivery 
systems that can modulate the immune response earlier in the process of myocardial 
inflammation. Long-term goal for this work is to open up a therapeutic window to 
enhance other molecular and stem-cell based therapeutics to regenerate the heart 
following MI. [12]. Our central hypothesis is that biomaterial-based therapeutic 
delivery strategies can modulate the initial immune response following myocardial 
infarction to create a pro-healing environment and improve cardiac function.  This 
hypothesis was evaluated by the following three specific aims:  
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Specific Aim 1: Evaluation of polyketal nanoparticle mediated siRNA delivery for 
silencing Nox2-NADPH oxidase following MI 
1
 
 We hypothesize that polyketal nanoparticles can deliver siRNA to the heart to 
silence a major oxidant enzyme Nox2-NADPH in the heart to improve cardiac function. 
Nox2-NADPH is primarily expressed in macrophages and upregulated following MI. 
Therefore, macrophages were used as an in vitro model for the evaluation of polyketal 
mediated Nox2-siRNA delivery. Nox2-NADPH gene expression in the infarct and acute 
cardiac function (day 3 post-injection) in response to delivery of these particles to the 
myocardium of a mouse model of permanent arterial occlusion MI were evaluated. 
 
Specific Aim 2: Evaluation of catalytic DNAzyme-gold nanoparticles for silencing 
pro-inflammatory cytokine TNF- following MI  
 We hypothesize that delivery of catalytic DNAzyme modified gold particles can 
knockdown pro-inflammatory cytokine TNF- expression in the myocardium to create an 
anti-inflammatory environment and improve cardiac function. DNAzyme particles were 
evaluated for biocompatibility and gene silencing effects in vitro in primary 
macrophages. These particles were directly injected into the myocardium in a rat model 
of permanent arterial occlusion MI, and particle biodistribution was evaluated ex vivo. At 
day 3 post-injection in vivo, cardiac function and inflammatory gene and plasma 
expression markers were evaluated. 
 




 Somasuntharam, I., Boopathy, A. V., Khan, R. S., Martinez, M. D., Brown, M. E., Murthy, N., & Davis, 
M. E. (2013). Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving 
cardiac function following myocardial infarction. Biomaterials, 34(31), 7790–7798.  
 6 
Specific Aim 3: Modulation of pro-inflammatory macrophages towards a reparative 
phenotype following MI via hydrogel-mediated IL-4 cytokine therapy.  
 We hypothesize that modulating pro-inflammatory (M1) macrophages towards a 
reparative (M2) functional phenotype during the initial inflammatory phase following MI 
can help direct an improved reparative process. In this aim, we take advantage of the fact 
that cytokine interleukin-4 (IL-4) polarizes monocytes into alternatively activated 
macrophages [34]. An injectable protease-cleavable polyethylene glycol (PEG) based 
hydrogel delivery system was evaluated for the delivery of IL-4 to the myocardium 
following acute MI. The overall strategy was validated in vitro and upon intramyocardial 
injection into a rat model of MI, acute (day 3) inflammatory marker expression was 
evaluated and the healing response was assessed via acute (day 7) and chronic (day 21) 
cardiac functional and immunohistological measures of capillary density and fibrosis 





CHAPTER 2  BACKGROUND 
2.1 Myocardial infarction and progression of cardiac dysfunction 
Ischemic heart disease is the major origin for heart failure (HF), the leading cause 
of death in the developed world today [2]. Myocardial infarction (MI), most commonly 
known as a “heart attack” is the initial occurrence, and it starts with a thrombotic 
occlusion of a coronary artery cutting off the oxygen supply to the myocardium in a 
segmental manner. Ischemic myocardial injury results in decreased oxygen tension with 
loss of oxidative phosphorylation and subsequent decreased generation of high energy 
phosphates (ATP), which leads to failure of the sodium pump, loss of potassium, influx 
of sodium and water, and cellular swelling. The major mode of metabolism in the 
myocardium shifts from aerobic oxidative phosphorylation in mitochondria to anaerobic 
glycolysis through glycogen breakdown, thus leading to ATP depletion and accumulation 
of byproducts like lactic acid within seconds of ischemia. This leads to loss of 
contractility, and within minutes, reversible ultrastructural cardiomyocyte changes 
appear, including cellular and mitochondrial swelling and glycogen depletion. After 20-
40 min of sustained ischemia, irreversible cardiomyocyte injury and necrosis take place, 
associated morphologically with mitochondrial and lysosomal swelling and loss of the 
integrity of the cytoplasmic membrane. [6, 35, 36]. Myocardial necrosis leads to a 
systemic activation of the humoral immune system increasing the regional cellular 
inflammatory response during an ischaemic event [6, 36, 37].  
Current clinical standards for MI rely largely on the crucial early reperfusion by 
way of primary percutaneous coronary intervention (PPCI) in order to limit the initial 
extent of hypoxic myocardial damage [7, 38]. While this has proven benefits in reducing 
infarct size and improving clinical outcomes as illustrated in Figure 1, paradoxically, re-
introduction of coronary flow triggers vascular inflammation and production of reactive 
oxygen species (ROS) that can further damage the myocardium, a phenomenon known as 
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Figure 1. Contribution of myocardial injury and reperfusion injury to infarct 
size. Figure from Hausenloy et al 2013.  
 
reperfusion injury [6, 7, 39-41], to which there is still no effective therapeutics and 
minimizes the best potential outcomes from PPCI Figure 1  [42].  
 The loss of viable myocardium affects the ventricular pump performance in direct 
proportion to the magnitude of lost tissue, initiating a dynamic network of genetic, 
molecular and structural processes that compensate for the ischemic injury [4, 43, 44]. 
The complex myocardial healing process is depicted in three distinct phases using a 
simplified schematic in Figure 2. The first acute inflammatory phase is where the 
inflammatory response is initiated to absorb necrotic tissue and clear the wound, and 
takes place within the 1–7 days following ischemia reperfusion injury. In the second 
proliferative/wound healing phase, myofibroblasts are recruited to the heart and they 
proliferate to increase the myocardial tensile strength and promote blood vessel 
proliferation thereby improving tissue perfusion and cell survival, and this phase lasts 
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about 1–3 weeks. In the final maturation/chronic scar phase, fibroblasts are formed and 
micro-vessel regression takes place generating the final collagen-rich scar tissue (~1 
month). However, myocardial infarct size is dynamic even after the loss of viable 
myocardium has terminated. In large infarcts, or if reperfusion is established too late, 
infarct expansion is often observed, and this process is mainly attributed to the extent and 
quality of the inflammatory response following MI that occurs during the wound healing 
response before scar tissue formation. Infarct expansion is closely related to adverse 
ventricular remodeling, a process that induces pathological epigenetic, molecular, 
cellular, structural and functional changes in both the infarcted and the remote viable 
myocardium. Ventricular remodeling is a powerful prognostic factor after acute MI and 
eventually leads to left ventricular dilatation and cardiac dysfunction [45, 46]. These 
multitudes of factors contribute to the prevalence of HF in patients that survive acute MI, 
which poses an enormous burden for the healthcare systems worldwide [4, 6, 7].  
 
Figure 2. Phases of myocardial wound healing. Adapted from Frangogiannis et al 
(2006) and [17] Nahrendorf et al (2010) [43] 
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2.2 Role of inflammation in the progression of heart failure 
 Interestingly, many of the underlying pathological mechanisms associated with 
ischemic injury and the ensuing healing process are tightly intertwined with the 
inflammatory response, signifying it as a logical therapeutic intervention for the 
prevention of HF. Systemically circulating cytokines originating from the heart, vessel 
wall or macrophages stimulate the liver to produce several inflammatory markers such as 
C-reactive protein (CRP) clinically used to quantify systemic inflammatory reaction, and 
has been shown to directly correlate to early and late post-MI morbidity and mortality. 
Therefore not surprisingly, many of the therapeutics with demonstrated efficacy for the 
clinical management of MI have anti-inflammatory properties distinct from their primary 
mechanism of action [6, 41]. For example, Angiotensin Converting Enzymes (ACE) 
inhibitors and Angiotensin receptor II blockers that target the renin-angiotensin 
neurohormonal system to dilate blood vessels and improve blood flow also diminish 
oxygen radical production and cytokine levels. Furthermore, both thrombolytic agents 
(“antiplatelet” therapies) aspirin and clopidogrel possess anti-inflammatory effects, and 
anti-inflammatory properties of cholesterol lowering statins are now well established. 
The hypothesis generated from these observations is that modulation of the inflammatory 
response following MI is at least partly responsible for the long-term clinical benefits 
ascribed to these medications. However, despite encouraging results from direct 
immunomodulation therapies in pre-clinical animal models, human trials have thus far 
not shown a convincing clinical impact [6, 41].  
While there is solid evidence that inflammation plays a central pathological role 
in the progression of coronary atherosclerotic disease, acute MI, and HF, the therapeutic 
strategies targeting the immune response likely need revision [47]. Judicious design in 
terms of not only the specific target, but also the temporal window of application, 
appropriate dosage and delivery systems, and additionally, careful patient selection are 
crucial factors to consider. Immune response following MI is incredibly complex in that 
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many components of the immune system are in play, and some considered double-edged 
swords that induce both beneficial and deleterious effects. The subsequent sections will 
in detail review the inflammatory response post-MI and outline some targets that may be 
master regulators capable of favorable manipulation to restore inflammatory balance and 
ameliorate remodeling after MI.  
2.2.1 Humoral mediators of inflammation 
 Myocardial necrosis results in the release of intracellular contents of cells that 
initiate an intense inflammatory response by activating the body’s non-specific innate 
immunity. Toll-like receptor (TLR)-mediated pathways, complement, chemokine and 
cytokine activation, and reactive oxygen species generation play a significant role in 
triggering the post-infarction humoral inflammatory response which regulates locomotion 
and trafficking of leukocytes [36, 48]. The chemokines constitute a family of small 
highly basic proteins with molecular weights in the range of 8-14 kDa. They are divided 
into two main families, according to the position of the first two cysteines, which are 
separated by one amino acid (CXC chemokines), or are adjacent (CC chemokines) [35]. 
Chemokines play significant roles in the recruitment of neutrophils and monocytes to the 
site of infarct and will be detailed further in the section 1.3 describing 
monocyte/macrophage roles in cardiac repair. Numerous studies show that myocardial 
necrosis and the subsequent release of subcellular membrane constituents that are 
abundant in the mitochondria activates the early acting components of the complement 
cascade (C1, C4, C2 and C3). As indicated in the section describing the cellular 
mediators of inflammation (section 1.2.2), complement activation also plays an important 
role in mediating neutrophil and monocyte recruitment in the injured myocardium. [37, 
49]. In this section, we focus on the role of reactive oxygen species and cytokines in 
mediating the inflammatory response post-MI.  
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2.2.1.1 Reactive oxygen species, oxidative stress and cardiac remodeling 
 Reactive oxygen species (ROS) such as superoxide (O2
.-







), hydrogen peroxide (H2O2) and free radical forming oxidants such as 
peroxinitrite (ONOO
-
) are highly reactive molecules characterized by the presence of 
unpaired electrons. They serve as signaling molecules under normal concentrations and 
play a role in several cellular processes [20, 50]. For instance, NO is essential for 
regulating the tension in blood vessels.  However, high levels of ROS and/or low levels 
of antioxidants (superoxide dismutase (SOD)), catalase or easily oxidized organic 
molecules like Vitamin E and C) can interfere with this natural redox balance within the 
cells, and lead to a state of oxidative stress where biological molecules are increasingly 
susceptible to oxidative damage. ROS have gained importance in the recent years due to 
their roles in the pathophysiology of numerous cardiovascular diseases [21, 40], and 
especially due to the oxygen paradox alluded to earlier with regard to PPCI procedures 
causing reperfusion-injury [39, 40].  
 Furthermore, ROS have been shown to modulate several of the processes 
underlying ischemic injury induced cardiac remodeling such as pro-inflammatory 
cytokine release, cardiomyocyte apoptosis, the activation and expression of matrix 
metalloproteinases (MMPs), interstitial fibrosis, cell proliferation and hypertrophy [40, 
50-52]. Pre-clinical studies have shown that overexpression or delivery of antioxidants to 
scavenge ROS has reduced myocardial injury and improved function in the setting of 
ischemia and reperfusion [53-56].   
2.2.1.1.1 Role of NADPH oxidases in cardiac remodeling 
 Potential sources of ROS in the heart include intracellular sources such as 
mitochondria and uncoupled nitric oxide synthase, as well as membrane bound proteins 
like the Nicotinamide adenine denucleotide phosphate (NADPH) oxidase and xanthine 
oxidase [21, 50]. Among these, NADPH oxidases are major sources of O2
.-
 in the heart. 
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Originally identified in phagocytes of the innate immune system, NADPH oxidases play 
a critical role in host defense by releasing a burst of O2
.- 
from molecular oxygen using 
NADPH as an electron donor.  The prototypic NADPH oxidase is a multi-subunit 
enzyme complex consisting of a membrane-bound cytochrome b558 composed of p22
phox 
and the catalytic subunit gp91
phox
, and four cytosolic regulatory subunits (p47phox, 
p67phox, p40phox and the small G protein Rac1 or 2) that associate with the membrane 
bound subunits in the activated enzyme. A family of gp91
phox 
homologues termed Noxs 
(Nox1-5) form the basis of distinct NADPH oxidases. In the cardiovascular system, Nox2 
and Nox4 are expressed in cardiomyocytes, fibroblasts and endothelial cells, while 
vascular smooth muscle cells express Nox1 and Nox4 [51, 57]. After MI, Nox2-NADPH 
oxidase expression is significantly increased in the infarcted myocardium, primarily in 
neutrophils, macrophages and myocytes in both animal models and human patients [19, 
20, 51, 58].  Suppression of Nox2 has shown beneficial effects in the setting of 
permanent occlusion MI in mice and therefore represents a potential target for 
modulation [51, 59, 60].  
2.2.1.2 Cytokine cascade 
 Induction and release of the pro-inflammatory cytokines TNF-, IL-1 and IL-6 
is consistently found in experimental models of myocardial infarction [61, 62]. Although 
the heart’s macrophages are a rich source of several inflammatory cytokines, other cell 
types and several humoral components can also effect cytokine production in 
experimental models of I/R or MI. Complement activation, mechanical stress, free radical 
generation and NF-κB activation are all such factors capable of stimulating cytokine 
mRNA synthesis in the immune cells populating the infarct as well as cardiomyocytes 
and endothelial cells in the face of injury, resulting in marked local and systemic cytokine 
upregulation [36, 37, 61, 63].  
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 TNF- release occurs early in the infarcted myocardium implicated in many of 
the pathophysiological processes associated with ischemia/reperfusion injury [22, 23, 64-
77]. It has been shown to stimulate the production of other pro-inflammatory cytokines 
such as IL-6 and IL-1 by infiltrating cells, promote chemokine and adhesion molecule 
expression on vessel wall, contribute to reactive oxygen and nitrogen radical mediated as 
well as other cytokine mediated endothelial as well as contractile dysfunction and overall, 
strongly implicated in the regulation of the inflammatory response post-MI as suggested 
by several studies [24, 78-81]. However, the role of TNF- in MI is complex. Its 
pleiotropic effects have been well demonstrated where it has been shown to be 
cardioprotective by inhibiting cardiomyocyte apoptosis [68, 70, 73, 82, 83] suggesting 
that complete negation TNF- in the context of MI is not beneficial. The mixed results 
regarding clinical outcomes in human clinical trials that attempted to neutralize TNF-in 
chronic HF patients (discussed in detail in Chapter 4) further highlight the need to 
identify an ideal temporal window, dosage and judicious design of therapeutic strategy 
for interventions that target TNF-in the context of MI.  
 Knowledge of the singular roles of other pro-inflammatory cytokines, such as IL-
6 and IL-1 is more limited compared to the wealth of knowledge available for TNF-
and partially it is because these cytokine effects are mediated by TNF-. IL-6 
synthesis is rapidly induced in mononuclear cells and cardiomyocytes of the ischemic 
myocardium and may mediate ligand-specific adhesion of neutrophils to cardiac 
myocytes by modulating cell adhesion molecule ICAM-1 expression [36]. IL-6 may also 
affect the phenotypic characteristics and gene expression of many cell types involved in 
infarct healing [61]. Furthermore, in a recent study, IL-1 was found to play a key role in 
triggering splenic monocyte production after MI, the site from which monocytes are 
deployed to the infarct [16, 84]. 
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2.2.2 Cellular mediators of inflammation 
 Myocardial inflammation is characterized by accumulation of circulating 
leukocytes, which, once stimulated by the vascular endothelium, migrate through the 
vessel wall into the ischemic myocardial region [35, 41]. Adhesion of leukocytes to the 
damaged vascular endothelium results in a massive migration of other inflammatory 
leukocytes such as neutrophils, monocytes as well as mast cells into the ischemic 
myocardium. Complement activation has an important role in the neutrophil chemotaxis 
in the infarcted myocardium demonstrating the complex interplay between the humoral 
and cell-mediated immune response that follows ischemia [37]. It is suggested that 
endothelial adhesion of leukocytes and the trans-vascular migration process may be 
enhanced by spontaneous or PPCI-induced coronary plaque rupture [41]. Neutrophils 
increase the infarct size by promoting tissue inflammation, and by their direct entrapment 
in the capillary micro-vessels, both leading to reduced myocardial local perfusion [41, 
48].  
As the number of neutrophils declines, monocytes arrive at the infarct, and 
differentiate into active macrophages, representing the predominant phagocytic cells in 
the infarct [17, 43]. Figure 3 depicts the spatial and temporal aspects of 
monocyte/macrophage kinetics following MI, and it shows that monocytes spend only an 
average of 20 hours at the infarct and within 24 hours, the majority of cells are 
replenished by a new generation of cells. This signifies the involvement of 
monocytes/macrophages as key factors in the development and progression of 
cardiovascular diseases. The function of macrophages is not limited to removal of dead 
cells and debris. Macrophages are capable of producing a wide range of growth factors 
and cytokines that stimulate fibroblast and endothelial cell proliferation and appear to be 
key regulators of the healing response. The next section will be devoted entirely to 
discussing the recent knowledge gathered with regard to macrophage biology in the 
context of MI as well as in the multi-faceted nature of these intriguing cell types. 
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 Mast cells are also implicated in the post-MI inflammatory response, and are 
stimulated by the complement 5a (C5a)-adenosine-reactive oxygen complex. These are 
multifunctional resident cells, capable of secreting a wide range of inflammatory 
mediators including TNF-, thus initiating a cytokine cascade. These cells are strongly 
implicated in the fibrotic processes, due to their secretion of pro-fibrotic factors and 
accumulation of these cells in areas of collagen deposition [37].   
 
Figure 3. Systemic monocyte kinetics in the inflammatory heart following MI [16] 
 
2.3 Macrophages as key regulators of cardiac repair 
 Macrophages and their circulating progenitors (monocytes) are key immune cells 
that respond to injury regardless of the type and location of injury. Ischemic injury and 
consequent loss of viable myocardium is followed by cardiac remodeling which includes 
 17 
progressive changes in the molecular and structural components of the myocardium. 
Macrophages are a central protagonist in all these diverse processes [17, 48, 85]. 
However, the potential of these cells as a therapeutic target has only come to light 
following a series of recent findings on the macrophage heterogeneity, disposition, and in 
the context of injury, their source of deployment and kinetics of recruitment to the site of 
injury.  
2.3.1 Heterogeneity of macrophage population 
The recent color wheel classification of macrophage activation type presents three 
classes based on their activation type; The “classically” activated (M1 or pro-
inflammatory) macrophages are induced by IFN-γ and/or bacterial endotoxin 
lipopolysaccharide (LPS) and characterized by the increased expression of nitric oxide 
synthase (NOS) and pro-inflammatory cytokines. The “alternatively” activated (M2 or 
reparative) macrophages are induced by IL-4 and/or IL-13 and characterized by the 
increased expression of Arginase 1 (Arg1) and mannose receptor 1 (Mrc1). The 
“regulatory” macrophages are activated by LPS in combination with immune complexes, 
IL-10 or apoptotic cells [26]. All these macrophages play specific functional roles; while 
classically activated macrophages display microbicidal activity, regulatory macrophages 
exhibit immune suppressive functions and alternatively activated macrophages play a role 
in tissue repair by producing anti-inflammatory cytokines, which mediate angiogenesis as 
well as ECM deposition [26, 34, 86]. However, macrophages exhibit remarkable 
plasticity, allowing them to adapt to changing environmental signals and adopt distinct 
activation states with specific functional roles, and even adopt hybrid phenotypes [17, 
26].       
2.3.2 Biphasic macrophage roles in inflammation and resolution 
 After MI, monocytes extravasate into the injured tissue and can give rise to 
inflammatory macrophages that accumulate at the target sites of injury. Interestingly, the 
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inflammatory response triggered by MI consists of two primary phases. During the first 
phase (~4 days), activation of cytokine and chemokine cascades lead to recruitment of the 
primary responders (neutrophils and pro-inflammatory Ly-6C
high
 that differentiate into 
M1 like macrophages) to the infarct zone within a day of ischemic injury as shown by 
Figure 3. These cells carryout phagocytosis and wound debridement to clear dead cells 
and matrix debris. Pro-inflammatory cytokine/chemokine cascades and excessive 
production of ROS are key characteristics of this phase [17, 85, 87]. These biological 
functions are regulated by secretion of cytokines and growth factors: Ly-6Chigh 
monocytes express IL-1β, TNF-α, myeloperoxidase, matrix metalloproteinases.  During 
the second phase (~5-7 days), resolution of inflammation takes place and the dominant 
population of monocytes/macrophages now represent a reparative phenotype (M2 or 
alternatively activated macrophages) which carries out matrix deposition, angiogenesis 
and remodeling [16, 17, 88].  
 It is well established that during the first phase of this inflammation,  monocyte 
chemotactic protein 1 (MCP-1) release initiated by the humoral immune system effects 
following MI recruits C-C chemokine receptor type 2 (CCR2) expressing pro-
inflammatory Ly-6C
high
 monocytes to the myocardium [84, 88]. It was initially thought 
that a different population of monocytes (Ly-6C
low
 monocytes) that can give rise to a 
reparative M2 like macrophages are recruited in a sequential manner partially brought on 
by Fractalkine (CX3CL1) release during the secondary healing phase. However, the field 
is now increasingly of the view that pro-inflammatory macrophages or Ly-6C
high
 
monocytes are capable of changing or differentiating into a M2 like phenotype in 
response to changing signals around the injury or as a recent discovery suggests, via a 
molecular nuclear hormonal switch, Nr4a1 [89, 90]. These recent findings give support to 
the idea of channeling the macrophage response towards a favorable cardiac repair mode 
by providing appropriate cues to the healing myocardium.  It has become increasingly 
clear that although the temporal singularity macrophages exhibit may be necessary for a 
 19 
very early time window following MI, inflammation often exhibits self-propagating 
behavior that likely delays the inflammation resolution phase of cardiac wound healing 
(Figure 4). Therefore mitigating the pro-inflammatory response and/or promoting 




Figure 4. Hypothetical relationship of monocyte numbers in the infarct and the 
healing outcome based on literature (Figure from Nahrendorf et al 2010) [17] 
 
2.4 Cardiac drug delivery systems  
 Many of the pharmacological therapies used in the clinical management of MI are 
systemically delivered and require multiple doses. The most modern drug delivery for the 
heart is achieved by drug eluting stents, but it is limited in the nature of therapeutics, 
expensive and placement is not ideal to localize/target the therapeutics to the 
myocardium, but rather to target vascular inflammation [91]. Local controlled delivery to 
the myocardium could be achieved via intramyocardial or transendocardial routes by 
exploiting advancements in catheter technology for minimally invasive delivery, reduced 
cost, shorter hospital times and potential for spatial and temporal control of 
administrations [92].  
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 The underlying principal of controlled release systems is that a depot of drug is 
implanted in the body, and through multitude of factors including diffusion, degradation, 
or more sophisticated stimuli-sensitive release mechanisms, the drug is slowly 
administered to the affected area [93]. The ultimate goal of controlled delivery is that 
therapeutic concentrations of the drug can be sustained over a longer period of time with 
fewer administrations. This is especially crucial for biotechnology based therapeutics 
such as proteins and nucleic acids than the traditional small molecule drugs, as many of 
these biological molecules have short half-life in circulation or can have pleiotropic/toxic 
effects at high concentrations.  
 However, cardiac-specific drug delivery vehicles are scarce, and controlled 
delivery is reported as one of the major challenges that face regenerative cardiology 
today [12]. One of the main challenges is that the heart is an extensively vascular organ 
subjected to constant blood flow, and therefore even localized delivery is challenging as 
therapeutics are quickly washed into the bloodstream, diluting the effective local 
concentration. Biomaterials that can provide sustained release formulations therefore 
present an attractive solution to this problem. Biodegradable polymers are most 
commonly explored for controlled drug delivery, and the most widely used are polyesters 
such as PLGA. Although not used for drug delivery directly to the myocardium, PLGA 
has been used as stent coating and in cardiac tissue engineering applications[94]. 
However, the hydrolysis and degradation products of microspheres based on these 
polymers are acidic, and they can lead to denaturation of pH sensitive proteins and cause 
an inflammatory response [95], thus making them less a less desirable material in the 
context of the inflammatory heart diseases. In this section, we discuss few of the most 
promising biomaterials for controlled delivery formulations of proteins and nucleic acids 
to the heart.  
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2.4.1 Protein delivery  
 Besides the ability for controlled and sustained release over prolonged periods of 
time, successful implementation of biomaterials for delivery of proteins to the 
myocardium depends on a variety of important factors including preservation of 
bioactivity, biocompatibility/lack of immunogenicity, controlled degradation with non-
toxic metabolites and ease of functionalization for incorporation/encapsulation of 
proteins. Furthermore, the material must be robust, and endure the fatigue cycling of the 
heart throughout the course of the delivery. If a biomaterial patch were to be used, 
mechanical properties that match that of the myocardium would be ideal as they can also 
provide mechanical support to the infarcted heart, influencing cardiac remodeling 
favorably [96]. Despite the numerous studies evaluating synthetic and natural materials 
for such properties, many of them have not yet been resolved for a single system. 
Traditional hydrophobic polymeric drug delivery vehicles have shortcomings when it 
pertains to protein delivery, as traditional organic solvents used in microencapsulation of 
small-molecule drugs could potentially denature proteins.   
2.4.1.1 Hydrogels as protein delivery platform for the myocardium  
 Hydrogels are cross-linked networks of hydrophilic polymers. They are porous, 
capable of retaining large amounts of water yet remain insoluble and maintain their 3D 
structure. The theoretical loading efficiency could be almost 100% (limited only by the 
solubility of the protein being encapsulated) inside a 1% weight percentage hydrogel 
since 99% in this case constitutes of water. These properties make them ideal reservoirs 
of protein therapeutics as they help preserve protein structural integrity and stability 
within the porous network. Injectability into the myocardium is a design criterion if these 
materials are to be delivered as injectable hydrogel. To ensure injectability, however, the 
material must facilitate loading into a catheter, fast gelation kinetics at the site but avoid 
premature gelation and catheter blocking. Advances in biomaterial design and fabrication 
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processes have led to tunable synthetic hydrogels engineered with physical or 
biochemical stimuli responsive gelation and/or degradation properties. These stimuli 
could include temperature, pH, enzymatic, redox, UV light and laser [97]. In order to 
achieve controlled protein delivery of proteins using hydrogel materials, the mesh size in 
the fibrous 3-D matrix has to match the particular size and composition of the protein 
molecule being delivered [98, 99], and it is this area that warrants further studies to 
optimize delivery systems to achieve desired release profiles for various proteins. The 
most established strategy is increasing the weight percentages of the macromer to form 
stiffer gels with smaller mesh size, but striking a balance of increased stiffness with 
injectability is challenging. Other approaches, discussed in detail in section 6.3 include 
physically tethering the therapeutics to the hydrogel to slow down the release. Further, 
while designing biomaterials for therapeutic protein delivery, it is critical to ensure that 
they are released in biologically active forms. This process of protein denaturation could 
occur at various stages of the process including the process of encapsulation, protein’s 
residence in the gel solution, or the release process. 
 An immense number of hydrogels have been developed and studied for a number 
of biomedical applications such as tissue engineering, contact lenses, drug delivery and 
coating for stents and catheters [100]. Naturally derived hydrogel scaffolds include 
extracellular matrix (ECM) proteins such as collagen, gelatin, matrigel, chitosan, 
hyaluronic acid or decellularized ECM and bioinspired self-assembling peptides. These 
materials are often supplemented with synthetic hydrophilic hydrogels, such as 
poly(ethylene glycol) (PEG) in order to improve mechanical properties or incorporate 
other functionalities [101]. Among these, self-assembling peptides are perhaps the most 
studied for protein/cellular delivery applications following MI [102-104]. Self-
assembling peptides have numerous inherent advantages amenable to protein delivery. 
Specifically advantageous for delivery to the heart is their lack of immunogenicity, 
biocompatibility and the ability to form stable nanofiber hydrogels that are injectable, 
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which allows catheter-based approaches in the context of MI. Peptides for self-assembly 
can be easily produced from naturally occurring building blocks with extreme sequence 
flexibility. This incredible advantage of programmability allows for rational design and 
modification of a scaffold network for properties desired in various applications. 
 Among the synthetic hydrogels, polyethyleneglycol (PEG) has been the gold 
standard biomaterial extensively studied due to their inertness, biocompatibility, and the 
synthetic ease with which chemical modifications could be made change material 
properties  [97, 105].  However, only few studies have explored PEG hydrogels in the 
application of post-MI [33, 106, 107]. Our group has previously studied a 4-arm PEG 
macromere end-functionalized with maleimide groups reactive with cysteines groups. 
Peptides with cysteines groups can be functionalized with ease on to this hydrogel as 
cross-linkers or cell-adhesion peptides motifs (RGD, a motif that binds to integrins) or 
even a therapeutic peptide/proteins with free cysteines. This hydrogel demonstrated 
excellent in situ gel formation upon injection into the myocardium, as the Michael-type 
addition reaction occurs rapidly to crosslink the gel at 37
0
C. This thesis work further 
evaluates this material for immunomodulatory cytokine IL-4 delivery to the myocardium.  
2.4.2 Nucleic acid delivery  
 The applications of nucleic acid delivery in the context of heart disease are 
numerous [8, 108-111]. Gene delivery and delivery of gene regulating nucleic acids such 
as siRNA/antisense/miRNA/mRNA or the catalytic Deoxyriobozyme (DNAzyme) [28, 
112, 113] as well as the recent advent of genome editing sgRNA of the CRISPR/Cas9 
system are of great interest as a therapeutic modality to the heart because of their potency 
in manipulating gene expression. However, successful translation of this class of 
therapeutics to the clinic is severely limited by the challenges in designing efficient and 
specific delivery systems to drive cellular uptake of these highly negatively charged 
molecules [114, 115], and further, sequestration by lysosomes make delivery into the 
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cytosol difficult [115, 116]. Transfection of phagocytic immune cells such as 
macrophages is especially challenging due to the presence of potent degradative enzymes 
that disrupt nucleic acid integrity [117]. Apart from viral delivery for genes, the most 
successful delivery vehicles for nucleic acids to date are cationic lipid nanoparticles or 
cationic polymers that facilitate condensing of nucleic acids via electrostatic 
interactions[116, 118]. However, cellular cytotoxicity induced by the positive charges of 
these vehicles make them less suited for therapeutic applications in the inflammatory 
myocardium following MI [118, 119]. Current methods being inadequate, successful 
applications of RNAi technology will require more research into appropriate carriers and 
efficient packaging of siRNA to improve local and systemic delivery in vivo.  
2.4.2.1 Polyketal nanoparticles as nucleic acid delivery vehicles 
 Polyketals (PKs) are a new class of delivery vehicles formulated from a novel 
class of polymers which contain pH sensitive, hydrolyzable ketal linkages in their 
backbone. Unlike the predominantly polyester based delivery vehicles (PLGA) currently 
in use, PKs do not generate acidic degradation products as they degrade into neutral, 
biocompatible components acetone and diols, and are ideal for applications in an 
inflammatory disease context without evoking further immune response [120]. The 
polymerization strategy is such that it is possible to form polymers between any diol and 
2,2-dimethoxypropane affording great flexibility for generating biomaterials with 
properties such as variable hydrolysis and pH sensitivities suitable for a variety of 
applications [120-125]. The properties of PKs can be easily modified to alter particle 
size, shape and porosity. Among these, the polyketal copolymer PK3 formed by reacting 
the diols cyclohexanedimethanol and 1,5-pentanediol with 2,2-diethoxypropane  
makes an excellent delivery vehicle for siRNA due to its faster hydrolysis at the acidic 
pH of the endosome (hydrolysis half-life of 1.8 days at pH 4.5 and 39 days at pH 7.4), 
thus allowing for escape from the phago/endosomes into the cytoplasm for gene 
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silencing. [123]. Oligonucleotides are first charge-neutralized by ion-pairing with a 
cationic lipid molecule prior to nanoparticle formulation, and previous work from our 
laboratory demonstrates that after phagocytosis, these particles hydrolyze and cause an 
osmotic imbalance in the phagosome, leading to release of siRNA into the cytoplasm in a 
timely manner [123]. Additionally, PK3 is a hard material that is water insoluble and can 
maintain their integrity in vivo due to the high energy cost of being exposed to water, 
providing serum stability [122, 123]. 
2.4.2.2 Spherical nucleic acids  
 Spherical nucleic acids (SNA) are polyvalent nucleic acid−nanoparticle 
conjugates employed for gene silencing. These spherical nanostructures were first 
described by Mirkin’s group with gold cores and densely functionalized with highly 
oriented nucleic acid shell and subsequently adapted for various commercial applications 
and other nucleic acid delivery applications [31, 126-128]. These particles exhibit unique 
abilities to efficiently transfect cell membranes without the need for co-carriers. 
Furthermore, they exhibit cooperative hybridization to complementary nucleic acids for 
efficient gene silencing (for instance, siRNA functionalized gold particle hybridizing to 
target mRNA for gene silencing). These properties are akin to similar nanostructures 
widely employed in nature such as the assembly of enzymes at the lipid membrane to 
enhance substrate channeling or alter catalytic activity. 
 




CHAPTER 3   Polyketal nanoparticle mediated siRNA delivery as 
an anti-oxidant therapy following myocardial infarction 
3.1 Introduction 
 Ischemic injury and consequent loss of viable myocardium is followed by adverse 
cardiac remodeling which includes progressive changes in the molecular and structural 
components of the myocardium [129] that eventually lead to cardiac dysfunction. An 
early step in this process is the inflammatory reaction that begins with the influx of 
neutrophils and macrophages in the infarcted area of the myocardium followed by 
invasion of myofibroblasts that deposit non-contractile scar tissue [4]. Production of 
excessive amounts of reactive oxygen species (ROS) is a key event involved in this 
pathogenesis [40, 52, 130, 131]. At high levels of ROS, cells undergo oxidative stress 
leading to many of the injury associated changes: proinflammatory cytokine release, 
cardiomyocyte apoptosis, interstitial fibrosis, fibroblast proliferation and myocyte 
hypertrophy [51, 57]. Although surgical reperfusion, angioplasty and thrombolysis have 
been traditionally used to restore blood flow to the ischemic myocardium, re-introduction 
of coronary flow triggers further production of ROS, a phenomenon known as 
reperfusion injury, causing further damage to the myocardium [39, 40]. Scavenging ROS 
have received great attention due to their contributions to reperfusion injury as evidenced 
by animal studies where overexpression or delivery of antioxidants has reduced 
myocardial injury in the setting of ischemia and reperfusion [53-56].  
 Among all the potential sources of ROS in the heart, NADPH oxidase, with Nox2 
as the catalytic subunit, has been identified as a major source for cardiac superoxide 
levels (O2
-
) and has been shown to be upregulated locally in neutrophils, macrophages 
and myocytes following MI in both animal models in human patients [19-21, 51, 57-59]. 
Complete knockout of Nox2 prevents cardiomyocyte apoptosis and adverse remodeling 
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following experimental MI in mice, and improves cardiac function [51]. Moreover, 
Nox2-NADPH oxidase is implicated in a direct functional role in the pathogenesis of 
Angiotensin-II induced cardiac hypertrophy [59]. In another study, Nox2
-/-
 mice were 
shown to exhibit attenuated interstitial fibrosis following aortic constriction, suggesting a 
possible role for Nox2-NADPH on cardiac remodeling post-MI [60]. These studies 
highlight the therapeutic potential of targeting Nox2-NADPH in the remodeling heart in 
order to prevent heart failure in MI patients.  Despite these results, clinical studies are 
lacking due to the unavailability of a Nox2-specific inhibitor.  This is critical as other 
members of the Nox family, specifically Nox4, offer protection against cardiac 
remodeling and hypertrophy [132, 133].  With specific inhibitors to NADPH oxidase 
lacking, silencing Nox2-NADPH oxidase gene expression in macrophages, the primary 
responders to ischemic injury, is an exciting potential therapeutic target to improve 
cardiac function and prevent progression heart failure following MI.  
 RNA-mediated silencing (siRNA) of gene expression holds great promise as 
therapeutics owing to high specificity and potency. However, delivery barriers for siRNA 
therapeutics have slowed down the successful translation of RNAi therapeutics into the 
clinic [114, 115].  Renal clearance and serum RNAses considerably reduce the half-life 
of naked siRNA in the blood stream [115]. Additionally, siRNA is highly membrane 
impermeable, and even upon endocytosis, endosomal escape into the cytosol for binding 
to the RNAi machinery is another challenging barrier to overcome [115, 116]. Further, 
endosomal/phagosomal compartments of macrophages contain nucleases that disrupt 
nucleic acid integrity to a larger extent, and therefore successful transfection of 
macrophages is especially challenging [117]. Chemical modifications that increase the 
stability of siRNA have had limited success due to often compromised RNA silencing 
activity and the expensive nature of these modifications [116].  Evolved delivery methods 
include complexing of siRNA to cationic lipids or polymers [116, 118]. However, 
inherent toxicity and the positively charged surface characteristics that elicit immune 
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responses deem such vehicles undesirable for in vivo disease applications [118, 119], 
especially for an inflammatory disease such as post-MI cardiac dysfunction.  
 Here, we demonstrate use of acid-degradable polymers, polyketals [120, 123, 
125], as delivery vehicles for Nox2 specific siRNA to the post-MI environment. 
Polyketals have controllable release kinetics and neutral degradation products and 
therefore cause minimal inflammatory responses [124]. The polyketal PK3 was chosen 
for this application due to its fast hydrolysis rate [120, 122, 123]. An endosomal 
disruptive molecule, chloroquine, was co-encapsulated with siRNA in order to enhance 
the endosomal escape of delivered siRNA [123].  Nox2 siRNA was delivered to 
macrophages and Nox2 expression and activity were evaluated, as well as whether this 
could be used as a delivery vehicle in vivo following MI.   
3.2 Materials and Methods 
3.2.1 Synthesis of polyketal PK3  
 PK3 was synthesized as described in Sungmun Lee et al [123]. Briefly, the diols, 
cyclohexanedimethanol and 1,5-pentanediol were dissolved in distilled benzene and 
heated to 100
0
C. Recrystallized p-toluenesulfonic acid (PTSA) was dissolved (~1 mg) in 
ethyl acetate and added to the benzene solution to catalyze the reaction. The 
polymerization reaction was initiated by the addition of equimolar 2,2-diethoxypropane 
(DEP). Additional 2,2-dimethoxy propane (DMP) and benzene were subsequently added 
to the reaction to compensate for loss of volume in the form of Ethanol/methanol and the 
solvent benzene that had distilled off. After 48 h, the reaction was stopped with 
triethylamine and isolated by precipitation in cold hexanes. The solid polymer was then 
filtered off, rinsed in hexanes and vacuum dried prior to storage at -20
0
C. Polymer 
molecular weight/Polydispersity was determined by gel permeation chromatography. 
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3.2.2 Preparation and characterization of siRNA loaded PK3 particles 
 Double stranded Nox2-siRNA (mouse) (sense strand: 
5’AGAGUUUGGAAGAGCAUAAUUUAGA3’) and a universal negative control 
siRNA (siNeg) were custom made (IDT) to contain a fluorescent FITC label. Fluorescent 
(FI)-siNox2 or FI-siNeg was ion-paired to the cationic lipid N-[1-(2,3-
Dioleoyloxy)propyl]-N,N,Ntrimethylammonium methylsulfate (DOTAP) as shown in 
Figure 5. Briefly, 1 mg siRNA in water and 2.2 mg of DOTAP dissolved in 
dichloromethane (DCM) were brought to one phase by addition of 1.05 mL of methanol. 
Following 15 min incubation, an additional 0.5 mL of water and DCM were added and 
the mixture was vortexed, and centrifuged at 750 rpm for 5 min. The siRNA:DOTAP 
complex in the bottom organic layer was encapsulated in PK3 via an oil/water single 
emulsion procedure, using DCM as the oil phase and polyvinyl alcohol (PVA) as the 
surfactant stabilizer [120]. Empty particles containing DOTAP not ion-paired to siRNA 
were also prepared to control for any effect on cells from DOTAP. Next, 1 mL of DCM 
containing ion paired FI-siRNA was added to 40 mg of PK3 with 1 mg of chloroquine 
free base. This solution was homogenized into 8 mL of 5% (w/v) PVA solution at the 
highest setting in the Power Gen 500 (Fisher Scientific) for 30 seconds, and sonicated at 
an intermediate speed (Sonic dismembrator model 100, Fisher Scientific) with 10 pulses 
of 1 sec duration. The emulsion was then dispersed in a 20mL 0.5% PVA solution and 
stirred for a period of 4-5 hours to allow the DCM to evaporate. The resulting particles 
were isolated by centrifugation (15000 rpm, 20min), washed three times, freeze-dried and 
stored in -20
0
C until further use. Particle size and shape were determined by scanning 
electron microscopy (Zeiss SEM Ultra60).  
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3.2.3 Quantitation of siRNA loading efficiency of PK3 particles 
 FI-siNox2 particles, FI-siNeg siRNA particles and empty PK particles were 
prepared as described above. In order to determine loading efficiency of siRNA within 
PK3, 2-3mg of particles were dispersed in a 1N HCl solution and incubated for 1 hr to 
allow for complete hydrolysis. Afterwards, the solution was neutralized with 1N NaOH 
solution, and the fluorescence of the total FI-siRNA released from the particles was 
measured (ex/em=494/510nm) using a fluorescent plate reader (Biotek Synergy 2). A 
fluorescent standard curve previously constructed using the FI-siRNA was compared 
against the obtained fluorescent intensity blank subtracted from any background 
fluorescence from empty PK particles in order to calculate the loading efficiency of 
prepared particles.  
3.2.4  Particle uptake by macrophages 
 RAW 264.7 macrophages obtained from American Type Culture Collection 
(ATCC number: TIB-71) were maintained at 37
0
C under a humidified atmosphere of 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (v/v) fetal 
bovine serum (FBS), supplemented with penicillin (100U/mL) and streptomycin 
(100mg/mL) and 2mM L-Glutamine. For flow cytometry, macrophages (1x10
6
 cells) 
were incubated with PK-FI-siNox2 (1µg siRNA) for 24 hours. Cells were then washed 
three times with ice cold phosphate buffered saline (PBS) and scraped into tubes for flow 
cytometry. Untreated control cell population was used to gate population of interest and 
the fluorescent population was measured by flow cytometer (FACSCalibur, Becton 
Dickinson) using a laser for fluorescein (lex/lem = 494/510 nm) and analyzed using FlowJo 
(TreeStar, Inc). 
 In order to confirm the intracellular distribution of siRNA delivered by PK3 
particles, we used laser scanning confocal microscopy (Zeiss LSM 510 META). 
RAW264.7 macrophages treated with PK-FI-siNox2 particles for 6 hours (1µg siRNA). 
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Cells were then washed in PBS three times and stained with DAPI for nuclei and 
rhodamine-phalloidin for actin filaments. 
3.2.5 In vitro delivery of Nox2-siRNA particles  
 For gene expression studies, RAW264.7 macrophages were plated in 6-well plates 
at a density of 1x10
6 
cells/well in 10% FBS DMEM media and left to adhere overnight. 
The following day, cells were treated with PK-siNox2, PK-siNeg, or empty PK3 particles 
at a concentration of particles equivalent to 1 µg siRNA/well or equivalent amount of 
empty particles. Following 24 hours of treatment, the cells were harvested and RNA 
extracted using Trizol (Invitrogen) for gene expression analysis. For assessment of 
functional activity of Nox2-NADPH in macrophages following treatment, RAW 
macrophages were plated at a density of 2x10
5
 cells/well in 24-well plates and treated 
with 1g siRNA/well or equivalent amount of empty particles as above for 72 hours 
following which cells were subjected to analysis of O2
-
production. 
3.2.6  Gene expression  
Total RNA from cells was isolated using Trizol (Invitrogen) according to the 
manufacturer’s protocol. Complementary DNA (cDNA) was synthesized using 
SuperScript III kit (Invitrogen).  Quantitative real-time PCR (qRT-PCR) was performed 
using Power SYBR Green (Invitrogen) master mix with Applied Biosystems StepOne 
Plus real time PCR system and the following primer pairs were used: Nox2, 5’ GTT 
GGG GCT GAA TGT CTT CCT CTT T 3’ (forward primer) and 5’ CCA CAT ACA 
GGC CCC CTT CAG 3’ (reverse primer); 18s rRNA, 
TTCCTTACCTGGTTGATCCTGCCA (forward primer) and 
AGCGAGCGACCAAAGGAACCATAA (reverse primer). Nox2 gene expression levels 
were normalized relative to the endogenous housekeeping gene 18s rRNA and expressed 
as a fold change compared to expression levels in untreated cells.  
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3.2.7 Detection of extracellular superoxide in vitro 
To determine Nox2 activity, extracellular production of O2
- 
 following stimulation 
with phorbol-12-myristate 13-acetate (PMA) was measured.  To determine levels of O2
-
 
following treatments in vitro, quantitative dihydroethidium (DHE) measurements were 
taken. DHE reacts with O2
-
 to form a cell impermeable, characteristic fluorescent 
product, 2-hydroxyethidium (ex=360nm, em=567nm) that can be measured quantitatively 
using HPLC [134-138] and/or a fluorescent plate reader.  Following 72 hours of particle 
treatment in 24-well plates, media was aspirated from the wells containing RAW 
macrophages and washed carefully with fresh cold Krebs-Hepes buffer (KHB) at a pH of 
7.35. Then KHB was added to all wells and 10 µM PMA (Sigma) added to the 
appropriate wells. Following incubation with PMA for 10 min at 37
0
C, 20 µM DHE 
(Sigma) was added to both PMA stimulated and unstimulated wells under dark conditions 
and incubated for 20 minutes while obtaining kinetic readings using a fluorescent plate 
reader (Biotek Synergy 2), after which 100 µl of the extracellular buffer from each well 
was taken in 300 µl of methanol for quantitative DHE-HPLC (reverse phase-HPLC over 
an acetonitrile gradient, (ex=360nm and em=570 nm) analysis [137].  
3.2.8 Myocardial infarction and particle injection 
 A randomized and blinded study was conducted using adult male C57BL/6 mice 8 
weeks of age weighing 25g. Mice were assigned to treatment groups (n=7-10) using a 
random number generator and the animal surgeon was only given letter codes to identify 
groups. While one group was subjected to sham surgery, the other four groups received 
myocardial infarction. Animals were subjected to myocardial infarction surgeries as 
described [121, 124]. Briefly, the animals were anesthetized (1-3% isoflurane) and 
following tracheal intubation, the heart was exposed by separation of the ribs. Myocardial 
infarction was performed by ligation of the left anterior descending coronary artery. For 
groups receiving particle injections, immediately after coronary artery ligation, 50 µL of 
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one of the following was injected into the cyanotic ischemic zone (3 locations) through a 
30-gauge needle while the heart was beating: empty PK3 particles, PK-siNeg particles or 
PK-siNox2 particles. The dose of siRNA injected was 5µg/kg or the corresponding 
amount of empty PK3 particles. Following injection, the chests were closed and animals 
were allowed to recover on a heating pad until functional assessments were made at 3 
days following MI surgery using echocardiography. These studies conformed with the 
Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and all animal studies 
were approved by Emory University Institutional Animal Care and Use Committee. 
3.2.9 In vivo gene expression 
 Animals were then sacrificed and left ventricle tissue was harvested and subjected 
to Trizol extraction for RNA isolation. Following reverse transcription of obtained left 
ventricle tissue RNA, the cDNA was subjected to qPCR for the gene expression analysis 
of Nox2 and the house keeping gene 18s rRNA. The copy numbers of Nox2 mRNA 
present in the tissue per million copies of 18s rRNA was determined using the 
quantitative standard curve method and results were normalized to copy number ratios 
from sham animals in order to minimize batch-to-batch variability in tissue processing.  
3.2.10 Echocardiography 
 Anesthetized rats were subjected to echocardiography at 3 days following MI 
surgery. Short axis values of left ventricular end systolic (ES) and end diastolic (ED) 
dimension were obtained using a Vevo 770 small animal ultrasound system 
(Visualsonics). An average of 3 consecutive cardiac cycles was used for each 
measurement and was performed three times in an investigator-blinded manner. 
Fractional shortening was calculated as (end-diastolic diameter – end-systolic 




All statistical analyses were performed using Graphpad Prism 5 software. Quantitative 
results were presented as means ± SEM. Statistical comparisons were performed by one 
way analysis of variance (ANOVA) followed by the appropriate post-test as described in 
the figure legends. P values of less than 0.05 were considered significant. 
 
3.3 Results 
3.3.1 Characterization of PK-siRNA particles 
 The encapsulation efficiency of siRNA within the PK3 particles was evaluated 
following ion-pairing with DOTAP as well as the final single oil/water emulsion step.  
Efficiency of ion-pairing was > 98% as measured by the fluorescence reading of the 
remaining FI-siRNA in the aqueous phase following extraction of DOTAP:siRNA into 
the organic phase.  After particles were generated, hydrolysis confirmed 10 µg of siRNA 
per 1 mg of particle, or roughly 40% encapsulation efficiency.  Further, particles were 
analyzed by SEM and the particle diameter measurements were made and averaged using 
ImageJ.  As the representative image and histogram in Figure 5 demonstrate, particles 
ranged from 200-1200 nm with an average size of 500 ± 175 nm. 
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Figure 5. Schematic of PK-siNox2 particle formulation and delivery.  
(A) Ion-paired siRNA:DOTAP and endosomal disruptive agent chloroquine are 
encapsulated into the PK3s via a single emulsion/solvent evaporation procedure 
generating submicron particles (500 ± 175 nm). (B) The PK3s encapsulating siRNA 
are intramuscularly injected into mice hearts following permanent coronary occlusion 
(MI) surgery. The particles are taken up my macrophages in vivo with high efficiency 
due to their ability to protect siRNA from serum proteins and stimulate phagocytosis 
and/or endocytosis. Once taken up, they degrade in the acidic environment within 
these compartments due to the acid-sensitive ketal linkages in PK3 (also aided by 
chloroquine) and escape the phagosome/endosome via a colloid osmotic mechanism to 






3.3.2 Particle uptake by macrophages  
Internilization of PK-siNox2 particles by macrophages was determined by flow 
cytometry. Macrophages treated with FI-siNox2 loaded PK3 particles (at 1 μg 
siRNA/well) for 24 hours demonstrated >80% uptake as shown in the representative 
histogram in Figure 6A. Further, confocal microscopy confirmed that the particles were 
not just sticking to the cell surface, but were internalized and localized within the cellular 
cytoplasm as shown in the representative 2D image and z-stack image (Figures 6B&C).  
 
3.3.3 In vitro gene knockdown 
To determine whether Nox2-siRNA particles knockdown Nox2 mRNA expression in 
vitro, we investigated the efficacy of Nox2-siRNA particles in the mouse macrophage 
cell line RAW 264.7. Following 24 hours of treatment, total RNA was isolated from cells 
and Nox2 mRNA expression levels were analyzed via qRT-PCR. Results were 
normalized to Nox2 expression levels in untreated macrophages. Figure 7 demonstrates 
that PK-siNox2 particles knocked down Nox2 mRNA expression by 41.3 ± 10.0% 
Figure 6. In vitro particle uptake by macrophages. RAW macrophages were treated with 
FITC labeled siRNA loaded PK3 particles. (A) Following 24 hours of treatment, flow 
cytometry was used to determine the percentage of FITC positive cells (Green) that are 
indicative of percent uptake of PK-FI-siNox2 particles compared to the control cell 
population (Black). Following 6 hours of treatment, cells were imaged using confocal 
microscopy to visualize cytoplasmic localization of siRNA. A representative 2D image (B) 
and Z-stack image (C) confirm  internalized siRNA within macrophages. FI-siNox2 (green). 
Nucleus (Blue, DAPI), Actin filaments (Red, Rhodamine phalloidin). 
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compared to the Nox2 expression levels in the untreated macrophage group (p<0.05), 
empty PK3 (p<0.01) and PK-siNeg (p<0.05) treatment groups.  The empty PK3 particle 


















Figure 7. In vitro Nox2 mRNA expression. Grouped data (mean ± SEM; n=3 per group) 
from 1 day following treatment of RAW macrophages. There was a significant decrease 
in Nox2 mRNA expression only in the PK-siNox2 treatment group compared to the 
untreated, empty PK3 and PK-siNeg particle treated groups. Gene expression was 
evaluated by qRT-PCR using a ∆∆CT method, and the results were normalized to 18S 
expression and reported as fold changes in mRNA expression (*p<0.05, **p<0.01; One-
way ANOVA followed by Newman-Keuls Multiple Comparison post-test). 
 
3.3.4  In vitro functional knockdown  
 To determine whether gene knockdown by Nox2-siRNA particles resulted in 
functional changes, we treated RAW macrophages for 72 hours with similar particle 
formulations as in the gene expression studies and then stimulated with PMA to induce 
O2
- 
production. The fluorescent DHE dye was then added in to the cells to determine 
kinetic activity of Nox2-mediated O2
- 
production over a 20 minute period of time. The 
fluorescent intensity was expressed as fold changes in O2
- 
production as normalized to 
basal O2
- 
levels. As shown in figure 8A, the traces from all treatment groups except PK-




siNox2 treatment showed little fluorescence over the entire 20 minute reading. These 
results were further confirmed by quantitative DHE-HPLC that PK-siNox2 treated 
macrophages demonstrated a significant reduction in Nox2 activity (p<0.05) compared to 
empty PK3 particle treatment (Figure 8B).     
 
3.3.5 PK-siNox2 delivery in vivo  
 To determine the in vivo efficiency of siRNA delivery using polyketal particles, 
adult male C57BL/6 mice were randomized into 5 treatment groups. While one group 
was subjected to sham surgery, the other four groups received MI surgeries followed by 
either no injections (MI) or injections of either empty PK3 particles (MI + Empty PK3), 
negative control siRNA encapsulating PK3 particles (MI + PK-siNeg) or siNox2 
containing PK3 particles (MI + PK-siNox2) (n≥8 for each group, N=47 total). At 3-days 
following injury, the expression of Nox2 at the mRNA level increased significantly (P< 
0.01) in MI group by 2.50±0.30 fold compared to sham mice. The treatment groups 
receiving Empty PK3 or PK-siNeg particle injections following MI showed no 
Figure 8. In vitro Nox2-NADPH activity. Grouped data (mean ± SEM; n=4 per group) 
from 3 days. (A) Kinetic measurement of PMA-stimulated O2
- 
production from 
macrophages using DHE fluorescence. (B) There was a significant decrease in the 
production of O2
- 
in PK-siNox2 treated macrophages compared to the empty PK3 
treatment group as quantitatively measured by DHE-HPLC method (*p<0.05 vs. empty 
PK3; one-way ANOVA 
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differences in Nox2 mRNA expression compared to the group receiving MI alone. In 
contrast, mice receiving PK-siNox2 particles following MI demonstrated a significantly 
lower levels of Nox2 mRNA expression than the MI group (P<0.05) (Figure 9). In order 
to determine the specificity of siRNA delivery towards the Nox2 isoform, Nox4 mRNA 
expression levels were also analyzed. There was a trend towards an increase in Nox4 
mRNA expression in all animals that received MI although it was not statistically 
significant. There was no observed knockdown of Nox4 mRNA expression in any 
treatment groups (Figure A2).  
 
Figure 9. In vivo Nox2 mRNA expression. Grouped data (mean ± SEM; n≥8 per group) 
from 3 days. There was a significant increase in Nox2 mRNA expression in animals that 
received an MI compared to sham. Among treatment groups, there was a significant 
decrease in mRNA expression only in the PK-siNox2 treated mice compared with 
untreated MI group. Gene expression was evaluated by qRT-PCR using the quantitative 
standard curve method, and the results were normalized to 18S levels and reported as fold 
changes in copy number of mRNA levels compared to sham animals (*p<0.05; **p<0.01 
vs. MI; one-way ANOVA followed by Dunnett’s Multiple Comparison post-test).  
3.3.6 Cardiac function following myocardial infarction  
 To determine the effect of sustained PK-siNox2 delivery on cardiac function 
following acute MI, echocardiography data was collected three days after MI surgery as 
described in methods. As shown in Figure 10, MI significantly reduced cardiac function 
(p<0.05) as measured in absolute change in fractional shortening 3 days post-injury 
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compared to sham animals. While there was no effect of empty PK3 or PK-siNeg 


































Figure 10. Echocardiographic measurement of function.  
Grouped data (mean ± SEM; n≥4 per group) from 3 days. There was a significant 
decrease in function animals that received an MI compared to sham.  Among treatment 
groups, there was a significant increase in function only in the PK-siNox2 treated mice 
compared with untreated MI group (*p<0.05; vs. MI; one-way ANOVA followed by 





 Considerable evidence supports a role for oxidative stress due to excessive ROS 
such as O2
-
 in the progression of HF [40, 50, 52]. Chronic antioxidant treatment 
following MI in animal models improves myocyte survival, attenuates ventricular 
remodeling, and leads to partial preservation of left ventricular function [53, 55]. While 
chronic antioxidant therapy may be feasible, the damage to the myocardium is local and 
oxidant signaling may be critical for homeostasis in many tissues. Therefore a localized 
and sustained antioxidant treatment that could be achieved by RNAi silencing during the 
critical earlier inflammatory stage following MI could be beneficial for the treatment of 
acute MI.  
 NADPH oxidases are major sources of O2
-
 in the heart. [21, 50]. Originally 
identified in phagocytes of the innate immune system, they play a critical role in host 
defense by releasing a burst of O2
- 
from molecular oxygen using NADPH as an electron 
donor.  The prototypic NADPH oxidase of the phagocytes is a multisubunit enzyme 





 (Nox2), and in association with four cytosolic regulatory 
subunits following activation. Over the past decade, there has been much interest in the 
cardiovascular NADPH oxidases [51, 57]. A family of gp91
phox 
homologues termed Nox 
(Nox1-5) form the basis of distinct NADPH oxidases. Nox2 is expressed in macrophages, 
cardiomyocytes, fibroblasts and endothelial cells and significantly upregulated in the 
myocardium following MI [51, 57]. Despite the fact that there are 5 distinct Nox family 
members, there are no specific inhibitors for any subtype. These proteins all have 
different functions in many cell types and there is strong evidence suggesting that broad 
inhibition of NADPH oxidase activity can exacerbate ischemic injury [133]. Therefore 
great care is needed to ensure specific targeting in relevant cells. 
 In this report, we successfully encapsulated Nox2-specific siRNA into the acid 
sensitive polyketal PK3 particle for silencing of the Nox2 gene in cardiac macrophages 
 42 
and inactivation of NADPH oxidase. Polyketals (PKs) are a class of polymers with 
tunable pH sensitivity afforded by the hydrolyzable ketal linkages in their backbone. 
They are highly suitable for applications in an inflammatory disease setting compared to 
other predominantly polyester based delivery vehicles such as PLGA currently in wide 
use that generate acidic degradation products. PKs degrade into neutral, FDA approved 
components, acetone and diols. [120-125]. This property of biocompatibility presents a 
unique advantage for siRNA delivery to the inflammatory heart following MI as 
compared to cationic lipid particles that cam exert cytotoxicity, potentially further 
damaging the mycoardium. The polyketal PK3 chosen for this study exhibits faster 
hydrolysis rates (half-life of 1.8 days at pH 4.5 and 39 days at pH 7.4) as reported in a 
previous study from our laboratory where PK3 was used to deliver TNF-α siRNA to liver 
macrophages in vivo [123]. This property makes PK3 an excellent delivery vehicle for 
siRNA as it can be degraded quickly at the acidic pH of the endosome, allowing for early 
endosomal escape prior to degradation in the late endosomal compartments. Published 
studies from our laboratory demonstrate that polyketal nanoparticles are retained in the 
myocardium following injection and are stable at neutral pH levels [121, 124]. When 
engaged by macrophages, present in high quantities during MI, particles are taken up and 
trafficked into phagosomes/endosomes where they degrade due to the acidic 
environment. Although the mechanism of release of siRNA is not clearly known, it is 
speculated that after phagocytosis/endosomes, these particles hydrolyze and potentially 
cause an osmotic imbalance within these compartments, leading to release of siRNA into 
the cytoplasm in a timely manner. 
As the schematic in Figure 5A illustrates, siRNA was loaded into PK3 particles in two 
steps. Firstly, the siRNA is ion paired to the cationic lipid DOTAP and the 
siRNA:DOTAP complex is extracted into the organic layer with greater than 95% 
efficiency. Chloroquine was then added to the complex and subsequently subjected to an 
oil-in-water single emulsion/solvent evaporation procedure to generate particles ranging 
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from 200-1200 nm and averaging 500 nm. Addition of another pH sensitive molecule 
such as chloroquine to these pH sensitive polymeric vehicles enhances their ability to be 
hydrolyzed at low pH of the endosomes/phagosomes while maintaining their integrity at 
the physiological pH of 7.4. Further, the weak base chloroquine gets protonated in the 
acidic environment of endo/phagosomal compartments, triggering swelling and 
destabilization of their membranes to facilitate release of siRNA into the cytoplasm 
[139]. Since chloroquine can inhibit acidification and maturation of endosomes, it can 
also protect siRNA from degradation.  Additionally, complexing siRNA with a cationic 
lipid such as DOTAP can enhance siRNA transfection ability by increasing siRNA 
stability and aiding in endosomal escape [140-142]. Further, in a previous study from our 
laboratory, complexing with DOTAP was shown to render nanoparticles with a positive 
charge which enhances phagocytosis by macrophages [125]. While we did not see 
toxicity with DOTAP in this or prior studies, alternative cationic molecules such as 
spermidine could be used in the future. Additionally, by altering the homogenization 
speeds and/or the sonication speeds during single emulsion procedure, we were able to 
obtain varying size distributions (Figure A1). The mechanism of particle internalization 
by macrophages is dependent on particle size, and accordingly, the size range chosen for 
our experiments facilitates uptake by both endocytosis as well as phagocytosis [143-145]. 
The siRNA loading efficiency of PK3 particles was calculated to be around 40%, which 
amounts to about 10μg siRNA/mg of particles. This loading efficiency allowed us to 
conduct in vitro and in vivo studies at less than 0.1mg/mL and 1mg/mL particle 
concentrations respectively.  
As depicted in Figure 5B, for in vivo studies, these particles were delivered into 
the heart via intramyocardial injection into the infarct zone of mice immediately 
following MI surgery. Two key requirements for the successful delivery of siRNA are 
cellular uptake and endosomal escape [114, 115]. We demonstrate the efficient cellular 
uptake of these particles in vitro by macrophages using flow cytometry following 
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treatment of RAW 264.1 macrophages with fluorescently labeled siRNA loaded PK-FI-
siNox2 particles (Figure 6A). This high transfection efficiency (>80%) in especially hard-
to-transfect-macrophages demonstrates the ability of these particles to be efficiently taken 
up. Further, using confocal microscopy, we observe non-punctate, diffuse fluorescence 
inside cells (Figure 6B-C) indicating that the siRNA is not trapped in endosomes, but 
localized in the cytoplasm.   
 We then investigated whether PK3 particles could deliver functional siRNA into 
macrophages and inhibit Nox2 gene expression and function in vitro. Compared to 
untreated cells, PK-siNox2 particles demorated significant reduction in Nox2 mRNA 
expression while PK-siNeg and empty PK3 particles showed no effect (Figure 7). In 
order to confirm the corresponding impairment in function due to the knockdown of 
Nox2 mRNA expression, we stimulated macrophages with PMA following particle 
treatment. PMA is known to stimulate Nox2-specific extracellular O2
- 
production in 
macrophages [146-148]. While other Nox isoforms are expressed, recent studies 
demonstrate that Nox4 mainly produces hydrogen peroxide and is likely an intracellular 
source [149].Thus, measuring the extracellular superoxide production in macrophages 
upon PMA stimulation can serve as an appropriate assay for Nox2 activity [134, 136]. 
The kinetic traces as well as the quantitiave results from the DHE-HPLC method (Figure 
8A-B) demonstrate the ability of PK-siNox2 particle tretament to significantly reduce the 
PMA induced O2
- 
production by macrophages compared to empty PK3 particle treatment. 
Encouraged by our in vitro functional results, we then investigated the ability of 
PK-siNox2 particles to knockdown Nox2 mRNA expression in vivo. At an acute 3-day 
time point following experimental MI, delivery of PK-siNox2 significantly reduced the 
Nox2 mRNA levels in LV tissue compared to MI only, as well as empty and negative 
control siRNA loaded PK3 particle injections (Figure 9). In most siRNA delivery studies, 
targeting cells such as macrophages is known to be difficult and requires high doses 
upwards of 2mg/kg doses at multiple time points [125, 150] while our study 
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demonstrated gene silencing at a low dose of 5μg/kg animal. We also sought to confirm 
the specificity of siRNA mediated knockdown of Nox2 by determining the mRNA 
expression of the structurally related Nox4 isoform in these tissue samples and 
demonstrated that the Nox4 mRNA levels are unchanged due to PK-siNox2 treatment 
(Figure A2). Corresponding to the Nox2 mRNA expression knockdown, an improvement 
in cardiac function was observed in this treatment group compared to MI alone with no 
effect from controls treatments (Figure 10). These results corroborate with published 
studies where upregulation of Nox2-NADPH expression and derived ROS was shown to 
play significant role in the pathophysiology of human congestive heart failure (CHF) [19] 
and genetic deletion of Nox2 in transgenic mice demonstrated significantly improved 
cardiac function and remodeling response [51].    
 Increased ROS in the heart can impact cardiac remodeling and function via 
several mechanisms. Most ROS are key signaling molecules and are critical in 
maintaining cellular homeostasis. Aberrant activation of redox-sensitive signaling 
pathways following ischemic injury can alter gene expression and has been implicated in 
cardiac hypertrophy, fibrosis and remodeling leading to cardiac dysfunction [151-153]. 
However, this study did not investigate the mechanistic aspect for the beneficial 
restoration in cardiac function observed in Nox2-siRNA treated MI animals. 
Additionally, the chronic effects of Nox2-siRNA delivery such as its effect on fibrosis as 
well as long-term functional improvement will need to be studied to determine whether 
higher dosage or repeated injections or targeting of other cardiac cell types that also 
upregulate Nox2-NADPH oxidases are necessary to sustain benefits of knocking down 
Nox2 at the initial inflammatory stage following MI. While limitations exist, our results 
uphold Nox2-NADPH as an important target in the treatment of acute-MI, and further, 
establish polyketals as biocompatible siRNA delivery vehicles to the myocardium.  
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CHAPTER 4  Catalytic DNA modified gold particles as anti-
inflammatory therapeutics to the infarcted heart 
4.1 Introduction 
 During the early stages of the cardiac repair process, loss of viable myocardium 
triggers a dynamic network of molecular and structural processes designed to compensate 
for lost function as well as repair the wound [4, 154, 155]. An early step crucial for this 
healing process is the inflammatory reaction that begins with the influx of neutrophils 
and macrophages that absorb the necrotic tissue [18, 36, 37, 84, 88, 90, 155, 156]. 
However, the delicate equilibrium of the myocardial inflammation is critical for an 
optimal healing response. Unbridled inflammation fueled by continuous up-regulation of 
pro-inflammatory cytokines can exacerbate tissue damage, thus contributing to adverse 
cardiac remodeling and non-contractile scar formation that ultimately culminates in heart 
failure [35, 41, 44, 80, 81, 157]. Specifically, the pro-inflammatory cytokine TNF is 
shown to be crucially involved in this pathogenesis and progression of myocardial injury. 
The pathological mechanism for TNF mediated myocardial dysfunction is thought to 
occur through a combination of factors that includes induction of reactive oxygen and 
nitrogen species, initiation of pro-inflammatory cytokine cascades and down-regulation 
of contractile proteins [22, 23, 64-75]. However, several reports have also indicated that 
TNF involvement in the early repair process as a double-edged sword in that 
physiological levels of TNF can be cardioprotective [68, 70, 82, 83]. Therefore, 
selection of an optimal therapeutic window as well as duration of action are critical in 
targeting TNF as an anti-inflammatory therapy in order to suppress the elevated 
inflammatory response immediately following MI. 
 Despite the numerous pre-clinical studies highlighting the therapeutic potential of 
targeting TNF in the remodeling heart, human trials employing TNF antagonists 
have failed to prove clinical benefit in chronic heart failure patients [158, 159]. Failure 
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analyses of these studies showed that these protein based therapeutics could act as 
agonists and stabilizers of TNF and even induce cytotoxicity in cells, which renders 
them highly unsuitable as therapeutic candidates in the context of heart failure [159, 160]. 
Gene silencing therapeutics derived from nucleic acid oligomers (ssDNA or siRNA) are 
excellent candidates since they are potent, yet transient in regulating TNF expression.  
We investigated catalytic DNA, a novel modality of gene silencing molecules, to inhibit 
TNF mRNA. These DNA enzymes (DNAzymes) are composed of a 15 base catalytic 
core and flanked by two recognition arms that can selectively degrade target mRNA 
independent of RNAi, thus avoiding the need to hijack the host cell’s machinery for 
catalysis [161]. Compared to siRNA mediated gene silencing, they offer the added 
advantages of enhanced stability (DNA versus RNA), cost-effecive synthesis and lack of 
immune response caused by double stranded RNA [162, 163]. However, delivery of 
therapeutic nucleic acids is an immense challenge due to the difficulties in getting highly 
negatively charged oligomers across a cell membrane and protecting them from nuclease-
mediated degradation [161, 164]. The most mature delivery approach involves 
complexing oligonucleotides to cationic lipids or polymers. Although very efficient, the 
positive charges often elicit an immune response which renders such vehicles unsuitable 
for applications post-MI, a disease setting characterized by inflammation [118, 119, 165]. 
A powerful, yet emerging approach for transfection entails spatially organizing 
therapeutic oligonucleotides into a compact spherical nanostructure.[166] Such structures 
enable very efficient transfection through a scavenger receptor mediated mechanism 
without eliciting an inflammatory response.[167]  In fact, transfection is so efficient that 
spherical nucleic acids have been shown to readily enter a mouse’s epithelial layer to 
regulate EGFR expression and even cross the blood brain barrier to treat 
glioblastoma.[168, 169]  
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 In previous work, when functionalized in similar spherical nucleic acid structures, 
DNAzymes exhibited enhanced catalytic gene silencing activity in vitro [170]. Here we 
describe, to the our knowledge, the first in vivo use of DNAzyme-gold nanoparticle 
conjugates as potent gene regulation agents following MI. Specifically, we show these 
particles can regulate TNF both in vitro in primary macrophages and in vivo in a rat 
model of MI without eliciting an immune response, and even favoring an anti-
inflammatory response. 
4.2 Materials and Methods 
4.2.1 Gold-DNAzyme nanoparticle synthesis  
 Citrate-stabilized gold nanoparticles (AuNP; 14±3 nm) were prepared using 
published procedures.[171] A 500 mL solution of 1 mM hydrogen tetrachloroaurate(III) 
trihydrate solution was brought to a vigorous boil, and once boiling, 50 mL of a 38.8 mM 
sodium citrate tribasic dihydrate solution was added and allowed to reflux for 15 min. 
The reaction mixture was filtered using a 0.45 μm acetate filter, producing monodisperse 
AuNPs. The resonance wavelength of the gold nanoparticles was determined using 
UVvis spectrometry, and particle size was determined using transmission electron 
microscopy (TEM). 
4.2.2 Preparation of DNAzyme-functionalized gold nanoparticles  
 Disulfide-modified oligonucleotides at either the 3’ end were purchased from 
Integrated DNA Technologies (IDT). The disulfide was reduced to a free thiol by 
incubating 50 nmols of lyophilized oligonucleotide with 1.0 mL of disulfide cleavage 
buffer (0.1 M dithiothreitol (DTT), 170 mM phosphate buffer at pH 8.0) for 3 hours at 
room temperature. The reduced oligonucleotides were purified using a NAP-25 column 
(GE Healthcare, Piscataway, NJ) with Nanopure water as the eluent. Subsequently, 40 
nmol of DNA was added to 10 mL of 14 nm gold nanoparticles (10 nM), bringing the 
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final concentration of oligonucleotide and gold nanoparticles to ∼3.0 μM and ∼7.0 nM, 
respectively. The pH of the solution was adjusted to pH 7.4 by adding 1/10
th
 the total 
volume (~133 μL) of 100 mM phosphate buffer, thus bringing the phosphate buffer 
concentration to 9 mM. The particles were stabilized by adding sodium dodecyl sulfate 
(SDS) to the solution and bringing the SDS concentration to 0.1% (g/mL) by using a 
stock solution of 10% SDS. The particles were successively salted with eight NaCl 
additions that were spaced 20 min apart using a stock solution of 2.0 M NaCl and 10 mM 
phosphate buffer. The final NaCl concentration of the DNA AuNP solution was increased 
to 0.7 M. The first two NaCl additions increased the concentration by 0.05 M increments, 
while the remaining six NaCl additions increased the NaCl concentration by 0.1 M 
increments. The particles were immediately sonicated for 10 s after each salt addition to 
maximize DNA packing, as indicated in literature.[172] Fully salted particles were then 
incubated overnight, in the dark at room temperature. We found that the 10-23 active 
catalytic core of the DNAzyme had a tendency to drive the formation of nanoparticle 
aggregates at 0.7 M NaCl due to partial self-complementarity of sequences. The 
formation of these aggregates did not result in any observable reduction in the quality of 
the particles (as measured by UVvis, TEM, DNA density, and ultimately TNF 
knockdown). The particles were stored as a stock solution (high salt and excess DNA) at 
4℃ until needed for a maximum duration of 1 month. This was due to diminished activity 
over time for washed particles stored in Nanopure water as shown in (Figure A3) (no salt 
or excess DNA). Prior to knockdown studies, particles were centrifuged four times at 
13,500 RPM, filtered using a 0.2 µm syringe filter, and reconstituted in PBS. 
Quantitation of DNAzyme loading density 
 The commercial Quant-iT
TM
 OliGreen® ssDNA kit was used to determine the 
total DNAzyme density per particle. The Quant-iT
TM
 OliGreen® ssDNA kit required 
preparation of a calibration curve by diluting a DNA stock solution (4 μg/mL) composed 
of the same thiolated oligonucleotide used during particle functionalization to 0.1, 0.2, 
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0.5, 0.75, 1.0, and 2.0 μg/mL at a final volume of 100 μL in 1x TE buffer. DNAzyme 
particle solutions were prepared by diluting a ~10 nM stock solution to 0.4, 0.6, and 0.8 
nM with TE buffer. The oligonucleotides were then released from the particle through 
oxidizing/dissolving the gold with potassium cyanide (KCN) by adding 1 μL of a 5 M 
stock solution of KCN to each well, including the calibration wells to be consistent. The 
solutions were incubated with KCN for 30 min to ensure complete dissolution. After 
complete dissolution of the gold nanoparticles, 100 μL of the freshly prepared 1x Quant-
iT
TM
 OliGreen® solution was added to each well and fluorescence intensities (485/528 
nm excitation/emission) of each well were then measured using a Bio-Tek Synergy HT 
plate reader to determine the total DNA density.  
4.2.3 Cell culture  
 RAW 264.7 macrophages obtained from American Type Culture Collection 
(ATCC number: TIB-71) were maintained at 37°C under a humidified atmosphere of 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (v/v) fetal 
bovine serum (FBS), supplemented with penicillin (100 U/mL) and streptomycin (100 
mg/mL) and 2 mM L-Glutamine. For primary macrophage culture, peritoneal 
macrophages were isolated from Sprague Dawley rats as described previously [173]. 
Briefly, cold PBS was infused into the peritoneal cavity of rats and cellular lavage was 
collected, spun down at 1000 x g at 4°C for 10 minutes, following which cell solution 
was resuspended in media described above. The cell solution was plated in 24-well plates 
(3x10
6
 cells/well) and left to adhere overnight for treatment the following day. Primary 
single ventricular myocytes culture from Sprague Dawley rat hearts is described in 
Appendix section A.3.1. 
4.2.4 Particle uptake by macrophages and myocytes  
 In order to confirm the intracellular distribution of DNA delivered by DNA 
modified gold nanoparticles, RAW264.7 macrophages or adult rat cardiomyocytes were 
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treated with Cy5 labeled DNAzyme functionalized gold particles for 1 hour (5 nM 
particle concentration equivalent to 666.7 nM DNA concentration) and then washed in 
PBS three times, fixed in 4% PFA and stained with DAPI for nuclei and calcein for 
macrophages or FITC Maleimide for cardiomycocytes to delineate the cell surface, and 
imaged using laser scanning confocal microscopy (Zeiss LSM 510 META) to identify 
Cy5 fluorescence within the cells to indicate internalization of Cy5-DNA modified gold 
particles. Further, particle uptake was compared to commercially available 
Lipofectamine® RNAiMAX reagent (Life Technologies) mediated transfection at 1, 4, 
18 and 24 hours using fluorescence microscopy in live cells for macrophages, and in 
fixed cells at 18 hours for cardiomyocytes. 
4.2.5 In vitro silencing of TNF with Dz particles 
For TNF knockdown studies, peritoneal macrophages were treated with three 
types of particles: catalytically active TNF specific (Dz) or inactive but with antisense 
binding ability to TNF(i-Dz)  or active but nonspecific (NS-Dz) at a particle 
concentration of 10 nM/well (1.3 M DNA). After 20 hours of treatment, the media was 
removed and the cells were re-treated with the same concentration of particles while at 
the same time receiving stimulation with LPS (5 ng/ml) to induce TNF production. 
After 4 hours of stimulation, 100 uL of media was collected from each sample and 
analyzed for secreted TNF via ELISA according to the manufacture’s protocol 
(eBioscience).  
4.2.6 Cytotoxicity  
Cytotoxicity of DNAzyme particles was compared with a commercially available, 
commonly used transfection reagent, using pro-inflammatory cytokine TNF itself as a 
surrogate cytotoxicity indicator. Primary peritoneal macrophages were transfected with 
either Lipofectamine® RNAiMAX containing scrambled DNA or NS-Dz for 20 hours, 
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and stimulated with LPS (5 ng/mL) for 4 hours to induce TNF production. 
Extracellular medium was collected and TNF production quantified by ELISA.  
4.2.7 Myocardial infarction and particle injection 
A randomized and blinded study was conducted using adult Sprague Dawley rats. 
The animals were assigned to treatment groups (n=6-9) using a random number generator 
and the animal surgeon was only given letter codes to identify groups. While one group 
was subjected to a sham surgery, the other four groups received myocardial infarction via 
permanent ligation of the left descending artery. Briefly, the animals were anesthetized 
(1-3% isoflurane) and following tracheal intubation, the heart was exposed by separating 
the ribs. Myocardial infarction was performed by ligation of the left anterior descending 
coronary artery. For groups receiving particle injections, immediately after coronary 
artery ligation, 100 µL of one of the following DNAzyme modified particles were 
injected into the cyanotic ischemic zone (3 locations) through a 25-gauge needle while 
the heart was beating: Dz, i-Dz or NS-Dz. The dose of DNAzyme injected was 0.07 
mg/kg (100 nM particle concentration). Following injection, the chests were closed and 
animals were allowed to recover on a heating pad until functional assessments were made 
3 days following MI surgery using echocardiography (Acuson Sequoia 512 with a 14 
MHz transducer) and invasive pressure-volume hemodynamics (Millar Instruments). 
These studies conformed to the Guide for the Care and Use of Laboratory Animals  
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1996) and all animal studies were approved by Emory University Institutional Animal 
Care and Use Committee. 
4.2.8 In vivo bioimaging 
 Rats were subjected to MI as described above and Cy5 labeled NS-Dz gold 
particle conjugates were injected in 3 areas in the border zone surrounding the infarct. 
Rats were sacrificed and the hearts, liver, spleen and kidneys were harvested and imaged 
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on days 0, 1, 2, and 3 post-injection (n=1 per time point) using Bruker In-Vivo Xtreme. 
The Cy5 fluorescent intensity in these organs was plotted as arbitrary fluorescence over 
time to demonstrate retention of the particles up to 3 days in the heart. 
4.2.9 Echocardiography and Invasive pressure-volume hemodynamics analysis  
In a separate study, rats were subjected to MI surgery and injections as described 
above, and 3 days post-surgeries and treatment anesthetized rats were subjected to 
echocardiography (Acuson sequoia 512) and invasive pressure-volume hemodynamics 
(Millar MPVS instruments) analyses to assess the functional effects of treatment. From 
echocardiography, short axis values of left ventricular end systolic (ES) and end diastolic 
(ED) dimensions were obtained. An average of 3 consecutive cardiac cycles was used for 
each measurement and was performed three times in by a blinded investigator. Fractional 
shortening was calculated as [(end-diastolic diameter – end-systolic diameter)/(end-
diastolic diameter)] and expressed as a percentage. For invasive hemodynamics, the 
pressure-volume probe was inserted into the left ventricle. After stabilization, baseline 
left ventricular pressure-volume loops were recorded for at least 10 cardiac cycles and 
data averaged to get mean values for each animal. Data extracted include +dP/dT, -dP/dT 
and left-ventricular Ejection Fraction (%EF).  
4.2.10 In vivo gene expression and plasma cytokine analysis 
Following functional measurements at 3 days, animals were sacrificed and the left 
ventricle infarct tissue was harvested and homogenized, which the total RNA contents 
were isolated using Trizol (Invitrogen) according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was synthesized using SuperScript III kit (Invitrogen) and 
the quantitative real-time PCR (qRT-PCR) was performed using Power SYBR Green 
(Invitrogen) master mix with Applied Biosystems StepOnePlus
TM
 real time PCR system. 
Absolute quantification method was employed to analyze gene expression levels of each 
of the target genes. Standard curves for each of the primer sets were constructed with 
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serial dilutions of input DNA templates and validated comparable amplification 
efficiencies (curve slopes: −3.32 to −3.64). Relative mRNA levels were obtained by 
extrapolation of Ct values from the slopes of the standard curve for each primer set. Gene 
expression levels were then normalized to the endogenous housekeeping gene GAPDH 
and further, expressed as fold changes compared to expression levels in sham animals in 
order to minimize batch-to-batch variability in tissue processing. Primer sequences used 
are listed in Appendix section A3.3. 
Prior to sacrificing the animals, blood was collected via cardiac puncture, plasma 
separated from blood cells and stored in -70
0
C until cytokine analysis using the Luminex 
multiplex analyzer system (Luminex LX100). A custom cytokine bead panel from 
ebioscience was used to analyze cytokines IL-12b, IL-1b, IL-6 and IL-10 in the plasma. 
4.2.11 Statistics 
All statistical analyses were performed using Graphpad Prism 5 software. 
Quantitative results were presented as means ± SEM. Statistical comparisons were 
performed by one way analysis of variance (ANOVA) followed by the appropriate post-
test as described in the figure legends. P values of less than 0.05 were considered 
significant. To make the variance independent of the mean for gene expression data sets 
that had significantly different variances according to Bartlett’s test (TNF-, IL-12 and 
iNOS), statistical analysis was performed after logarithmic transformation 
 
4.3 Results 
4.3.1 Characterization of Gold DNAzyme particles 
 Citrate stabilized gold nanoparticles were synthesized by reducing chloroauric 
acid (HAuCl4) with sodium citrate. The resulting particles were very homogeneous and 
monodisperse with a mean particle diameter of 14± 3 nm as determined by TEM analysis 
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and the extinction spectra showing a peak absorption at 525 nm correlating to the 
nanoparticle’s surface plasmon resonance (Figure 11B-D). The particles were 
functionalized with Dz, i-Dz, or NS-Dz (Figure 11A) and had a DNAzyme density of 
99±3, 109±7, and 65±2 oligonucleotides per nanoparticles respectively. This equates to a 
very high surface density ranging from 6 – 9 nm
2
/DNA, sufficiently high to ensure 
optimal activity. It should be noted that NS-Dz has a slightly lower DNA density on the 
particle due to possessing a stable secondary hairpin structure. After washing, the 
DNAzyme functionalized particles had a strong surface plasmon resonance in the 
extinction spectra (Figure 11D). 
 
Figure 11. Synthesis and characterization of DNAzyme-gold particles. 
(A) Schematic showing the approach to synthesize DNAzyme modified gold 
nanoparticles. Thiolated DNA was mixed with gold nanoparticles and the ionic strength 
was slowly increased over time. (B) Representative TEM image of the 14 nm citrate 
stabilized gold nanoparticles, where particle monodispercity was determined through a 
histogram analysis shown in (C). (D) Extinction spectra of citrate stabilized (AuNP) and 
DNAzyme functionalized gold nanoparticles (DzNP) showing the surface plasmon 
resonance at 525 nm. 
4.3.2 Particle uptake by macrophages and myocytes in vitro 
 Cellular uptake of Cy5-NS-Dz gold nanoparticle conjugates were visualized and 
compared to cells transfected with the same concentration of DNA using commercially 
available transfection reagent Lipofectamine® RNAiMAX through a 24 hour period. At 
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every time point, macrophages transfected with Cy5-NS-Dz modified nanoparticles 
exhibited superior transfection efficiency compared to Lipofectamine® assisted delivery. 
Detectable fluorescence within the cells was only observed at 24 hours with 
Lipofectamine® transfection (Figure 12B, right), compared to the superior transfection 
by Dz particles as early as 1 hour (Figure 12A & 2B, left), and were continuously being 
taken up 24 hours later (Data not shown). Further, internalization and cytoplasmic 
 
Figure 12. In vitro Cy5-NS-DzNP particle uptake by macrophages.  
RAW 264.7 macrophages were treated with Cy5 labeled NS-DNA modified gold 
particles. Following 1 hours of treatment, cells were imaged using confocal microscopy 
to visualize cytoplasmic localization of Cy-5-DNA. (A) Representative Z-stack image 
confirms internalized DNA within macrophages (scale bar,30m) (B, left) Uptake 
efficiency was compared in macrophages treated with Dz-particles at 1 hour and (B, 
right) lipofectamine® transfection reagent for 24 hours. DNA (red, Cy5), Nucleus (blue, 
DAPI). (Scale bar, 30m). 
 
localization within the cells was confirmed via confocal microscopy as shown by the 
orthogonal Z-slice in Figure A4. Although adult rat cardiomyocytes did not take the 
particles up as quickly as macrophages at 1 hour (data not shown), they showed 
internalization at 18 hours (Figure A5, left). At this time point, uptake of fluorescently 
labeled DNA by myocytes was not observed when Lipofectamine® RNAiMAX was used 
to transfect the DNA (Figure A5, right). Together, these data demonstrate that gold 
particles functionalized with DNA exhibit superior uptake efficiency than 
Lipofectamine® in macrophages and myocytes.  
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4.3.3 In vitro protein knockdown and cytotoxicity 
 To demonstrate the ability of DNAzyme to silence TNF-α expression in 
macrophages, we treated peritoneal macrophages with particles modified with either 
active DNAzymes specific towards TNF mRNA (Dz), inactive DNAzyme (i-Dz), or 
active but non-specific DNAzyme (NS-Dz) which were compared to the appropriate 
untreated controls for 24 hours (Figure 13A). Macrophages were activated with LPS at 20 
hours to stimulate the production of TNF. Figure 13C shows that treatment of Dz 
modified nanoparticles resulted in ~50% reduction in TNF production as compared to 
cells that received no treatment with LPS stimulation (p < 0.05) or Dz loaded with a non-
specific recognition sequence (NS-Dz) (p < 0.01). The NS-Dz and i-Dz particle treatment 
groups did not show any significant difference from the untreated cells stimulated with 
 
Figure 13. Biocompatibility of DNAzyme-gold particles and in vitro TNF 
knockdown in primary rat peritoneal macrophages. (A) Schematic of gold particles 
modified with either active DNAzymes specific towards TNF mRNA (Dz), inactive 
DNAzyme (i-Dz) specific to TNF mRNA but non-catalytic, or active but non-specific 
DNAzyme (NS-Dz). (B) Grouped data (mean ± SEM; n=3) from 1 day following 
treatment of peritoneal macrophages with commercial lipofectamine® + DNA complex 
induced several folds of TNF upregulation compared to untreated LPS stimulated cells 
while NS-Dz particles did not induce any additional cytotoxicity (C) Grouped data (mean 
± SEM; n=6) showing a significant decrease in TNF protein levels in the Dz treatment 
group compared to the untreated and NS-Dz particle treated groups. Protein levels were 
measured by ELISA and the results were normalized to untreated LPS stimulated cells 
and reported as fold changes in TNF (*p<0.05, **p<0.01, ***p<0.001; One-way 





LPS. In addition, we discovered that NS-Dz exhibited no additional cytotoxicity, while 
cells treated with Lipofectamine® loaded with scrambled DNA sequence exhibited 
TNF concentrations that were 3.5 fold higher than with LPS stimulation alone (Figure 
13B).  
4.3.4 In vivo biodistribution  
 Bio-distribution and extent of myocardial retention of DNA-gold particles was 
examined by ex-vivo fluorescence image analysis in a rat model of MI (Figure 14A). As 
shown in Figure 14B-C, time course ex-vivo fluorescence imaging indicated that the 
DNA-gold particles were retained in the heart for up to 3 days, and higher retention was 
observed in the heart compared to the other organs up to day 2.  
 
4.3.5 Cardiac function following myocardial infarction 
 To determine the effect of sustained Dz delivery on cardiac function following 
acute MI, echocardiography data and invasive hemodynamics measurements were 
collected 3 days after MI. As shown in Figure 15A, all groups receiving MI demonstrated 
significantly reduced cardiac function (p < 0.001) as measured in absolute change in 
fractional shortening 3 days post-injury compared to sham animals. While there was no 
effect for NS-Dz or i-Dz particle treated groups, Dz particle treatment significantly 
restored function by ~40% compared to MI (p < 0.01). The invasive hemodynamics 
measurements also indicate a trend towards improvement in % Ejection Faction (%EF) 
and parameters that measure the rate of change of pressure in the left ventricle chamber 
(dp/dt) in Dz particle treated group (Figure A6 A-B). 
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4.3.6 In vivo inflammatory marker expression 
 At 3-days following injury, the expression of TNF at the mRNA level 
increased significantly (p < 0.001) in rats that underwent MI by 3.55±0.54 fold compared 
to sham rats (Figure 15B). The treatment groups receiving NS-Dz or i-Dz particle 
injections following MI showed no differences in TNF mRNA expression compared to 
the group receiving MI alone. In contrast, rats receiving Dz particles following MI 
demonstrated significantly lower levels of TNF mRNA expression compared to the MI 
 
 
Figure 14. Ex-vivo fluorescence imaging of organs from animals injected with 
Cy5-NS-DzNP. (A) Schematic of ligation of the coronary artery to cause permanent 
ligation MI in rats followed by particle injection. (B) Images of hearts from each day 
following injection (B) Fluorescence intensity of all organs imaged from days 0, 1, 2 
and 3 days (n=1) is expressed as arbitrary units. 
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group as well as the groups receiving NS-Dz and i-Dz (P < 0.05). In order to determine 
the effects of TNF suppression in the infarcted heart, we also determined the gene 
expression of other inflammatory markers and immediate downstream targets of TNF. 
There was a signnificant upregulation of pro-inflammatory cytokines IL-12p < 0.001), 
IL-6 (p < 0.05), IL-1(p < 0.001) as well as the enzyme iNOS (p< 0.05) following MI 
compared to sham (Figure 16). We observed a significant reduction in IL-12(p < 0.01), 
IL-6 (p < 0.05), IL-1 (p < 0.05) and iNOS (p < 0.05) mRNA expression in groups that 
receied the Dz treatment compared to MI, and a strong trend in reduction in IL-12and 
IL-1n the plasma from these animals (Figure A7). We also tested the effect of Dz 
particles on anti-inflammatory cytokine IL-10, and interestingly there was a signficant 
upregulation of IL-10 mRNA expression following MI, However, none of the treatment 
groups showed any statistical difference from the MI group. Although plasma IL-10 
levels showed a trend of upregulation with Dz treatment, it was statistically not 
significant (Figure A8 and A7 D).  
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Figure 15. Effect of in vivo delivery of Dz particles on cardiac 
function and TNF- gene expression in a rat model of MI. 
Grouped data (mean ± SEM; n=5-9) from 3 days. (A) There was a 
significant decrease in cardiac function in animals that received an MI 
compared to sham as demonstrated by % FS.  Among treatment groups, 
there was a significant restoration in function only in the Dz treated rats 
compared with untreated MI and i-Dz groups. (B) A significant 
upregulation of TNF expression was observed in animals that received 
an MI compared to sham. There was a significant decrease in mRNA 
expression in the LV infarct issue only in the Dz treated rats compared 
with all controls. Gene expression was evaluated by qRT-PCR using the 
quantitative standard curve method, and the results were normalized to 
GAPDH levels and reported logrithmic transformation of fold changes in 
copy number of mRNA levels compared to sham animals (*p<0.05; 
(**p<0.01 ***p<0.001; one-way ANOVA followed by Tukey’s Multiple 




Figure 16. Downstream effects of inhibiting TNF- on pro-inflammatory cytokine 
and iNOS gene expression.  
Grouped data (mean ± SEM; n=5-9) from LV infarct tissue at 3 days following MI and 
injection. There was a significant upregulation in gene expression of pro-inflammatory 
cytokines (A) IL-12, (B) IL-1, (C) IL-6 as well as (D) iNOS enzyme in infarct LV 
tissue compared to sham animals, and was significantly reduced in Dz treated animals. 
Gene expression was evaluated by qRT-PCR using the quantitative standard curve 
method, and the results were normalized to GAPDH levels and reported as fold changes in 
copy number of mRNA levels compared to sham animals. IL-12 and iNOS gene  
expression data were transformed logrithmically prior to statistical analyses in order to 
make the variance indpendent of the mean (*p<0.05;**p<0.01;*** p<0.001 vs. MI; one-




 Over the last few decades, mortality due to MI has decreased due to the optimized 
reperfusion strategies employing sophisticated designs of stents/balloons, advancements 
in thrombolytic therapies and neurohormonal inhibitors. Despite these improvements, the 
incidence of heart failure as a direct consequence of MI remains high, suggesting that the 
current therapeutic regimen fails to target other key aspects of the pathophysiological 
mechanisms leading to cardiac dysfunction. Much interest has been devoted to studying 
the role of inflammation in the progression of heart failure, leading to a large volume of 
pre-clinical data illustrating the potential of anti-inflammatory therapies in prevention of 
heart failure post-MI. Interestingly, many pharmacological therapies with demonstrated 
efficacy for the treatment of acute MI have anti-inflammatory properties distinct from 
their perceived primary mechanism of action. [6, 41]. Reduced serum cytokine levels and 
inflammatory markers have been observed in patients receiving neurohormonal ACE 
inhibitors; statin therapies including simvastatin; and thrombolytic therapies such as 
aspirin, clopidogrel and GP IIb/IIIa. This suggests modulation of inflammation is a 
contributing factor to the clinical benefit ascribed to these medications. 
 The pro-inflammatory cytokine TNF is an extensively studied potential 
therapeutic target implicated in many of the processes involved in the development of 
heart failure. In the initial inflammatory phase post-MI, physiological levels of TNF 
have been shown to be cardioprotective [68, 70, 82, 83]. However, lingering 
inflammation and persistent high levels of pro-inflammatory cytokines contribute to 
unfavorable myocardial remodeling, leading to worsening clinical outcomes. Infusion of 
TNF to rats and dogs with normal cardiac function at levels comparable to that 
reported in patients with chronic heart failure (CHF) has been shown to depress 
ventricular function and cause adverse remodeling, recapitulating CHF conditions [64, 
72].   
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 Despite the volumes of encouraging pre-clinical data for TNF antagonism, 
human trials employing a soluble TNF receptor (etanercept) or a monocolonal 
antibody (infliximab) designed to neutralize TNF have failed to demonstrate long-term 
clinical benefit in patients with chronic heart failure post-MI. Post-mortem analyses 
revealed that both biological agents were highly unsuitable for TNF antagonism in a 
heart failure setting. Etanercept was shown to have a stabilizing effect on TNF by 
binding to it, thus accumulating bioactive TNF in circulation. Infliximab acts by 
exerting cytotoxicity to cells expressing TNF on the membrane, and while suitable for 
Crohn’s disease where its beneficial to remove activated T-cells, lysing already failing 
cardiomyocytes during heart failure would be detrimental [160, 174, 175] 
 Results from these trials demonstrate a clear need for careful selection of the 
mechanism of TNF antagonism, as the nature of inhibition is a crucial factor for an 
anti-inflammatory therapy in the setting of heart failure. Furthermore, while the past 
clinical trials have targeted patients with advanced chronic heart failure, mounting 
evidence suggests the importance of early intervention to contain the initial inflammatory 
phase post-MI in order to halt the progression of the disease as opposed to treating the 
symptoms of chronic inflammation at later stages [17]. Ischemic injury leads to systemic 
as well as an exuberant local inflammation, and therefore designing and evaluating 
approaches to deliver transient suppression of TNF during the critical acute 
inflammatory stage is an important step towards successfully translating TNF 
antagonism as a treatment strategy for acute MI.  
In order to circumvent the above mentioned limitations of the protein based 
strategies, we investigated a gene knockdown approach to inhibit TNF mRNA. 
Specifically, DNAzymes selective towards TNF mRNA were functionalized to gold 
nanoparticles and delivered to cells. DNAzyme therapies have shown great potential in 
pre-clinical trials in treating a wide variety of ailments ranging from cancer to spinal cord 
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injury including myocardial infarction, notably targeting transcription factor c-Jun for 
knockdown [28, 113, 176-178]. DNAzymes are also currently in human trials for treating 
nasopharyngeal carcinoma [28, 179]. However, all these studies employ cationic 
liposomes and are known to stimulate inflammatory pathways and induce cytotoxicity, 
which is detrimental for treating inflammatory pathologies. In this report, we tested 
whether DNAzyme functionalized gold nanoparticles could effectively regulate TNF 
expression to be used as an anti-inflammatory therapy for minimizing heart damage 
following MI, with the ultimate goal of preventing HF.  
  Intracellular uptake is a key requirement for the successful delivery of nucleic 
acids [24, 25]. We demonstrate the efficient cellular uptake of these particles by 
macrophages by measuring fluorescence of RAW 264.1 macrophages treated with Cy5-
NS-Dz in vitro. We qualitatively compared the particle uptake with the most commonly 
used commercial transfection reagent Lipofectamine® RNAiMAX through a time course 
of 24 hours. While the Dz-NPs were taken up by macrophages as early as 1 hour and are 
continually taken up through 24 hours, Lipofectamine® mediated transfection was 
mostly only detected inside cells at 24 hours, and in punctate signals indicating possible 
entrapment within the endosomal compartments (Figure 12, right). We observe non-
punctate, diffuse fluorescence inside cells (Figure 12A & Figure A4) in macrophages 
treated with the Dz-NPs indicating that the DNA is not trapped in endosomes, but 
diffusely localized in the cytoplasm. Phagocytic cells such as macrophages are difficult to 
tranfect and achieve gene silencing as they are programmed to take up foreign particles 
and ingest them, presenting a challenge for drug delivery to these cells. However, the 
mechanism of particle internalization is dependent on particle size. Particles below 500 
nm in size are usually taken up via endocytosis in phagocytic and non-phagocytic cells 
[143, 144], suggesting endocytosis as the primary mechanism of uptake for our particles 
(~14 nm), which is a more preferable method of uptake in the context of therapeutic 
delivery. Accordingly, we further show that these particles are taken up by non-
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phagocytic adult rat cardiomyocytes at 18 hours following transfection. Notably, there 
was no observable fluorescence in cardiomyocytes transfected with Cy5-DNA utilizing 
lipofectamine® RNAiMAX (Figure A5).  
 We then investigated whether DNAzyme functionalized gold particles are a 
biocompatible delivery vehicle and whether we could deliver catalytically active Dz into 
macrophages and inhibit TNF expression in vitro. In order to establish an in vitro 
model to demonstrate knockdown of TNF, we stimulated primary peritoneal cavity 
isolated macrophages with bacterial endotoxin LPS following particle treatment to 
stimulate the production of TNF. LPS stimulates TNF via activation of the Toll 
Like Receptor (TLR), orchestrating a potent inflammatory response, and therefore 
additionally served as a surrogate assay to evaluate cytotoxicity profile of particle uptake 
compared to the widely used transfection reagent Lipofectamine® RNAiMAX. Upon 
treatment with Lipofectamine®, macrophages exhibited ~4 fold higher TNF levels 
compared to the basal LPS stimulation, indicating a severe immune response elicited by 
cationic lipids widely used for nucleic acid delivery. The nonspecific DNAzyme particle 
(NS-Dz) treatment caused no additional cytotoxicity (Figure 13B) indicating that 
DNAzyme functionalized particles are biocompatible and highly suitable for applications 
in an inflammatory disease context.  
 To determine the intracellular catalytic activity of DNAzyme gold nanoparticle 
conjugates in this in vitro model, active and inactive DNAzymes modified particles were 
synthesized targeting the start codon (AUG), a region of the TNF mRNA with 
minimal secondary structure. The recognition arms were 7 and 10 base pairs in length, 
which was designed based on prior literature precedence (Supplemental Table 1) [113]. A 
single base mutation was made to the 15 base catalytic core to render the i-Dz from RNA 
hydrolysis activity, thus allowing one to distinguish antisense knockdown from 
DNAzyme mediated knockdown (Figure 13A). To ensure minimal degradation, four 2’-
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methyl ether modifications were added to either end of the recognition arms. 
Surprisingly, initial tests showed limited DNAzyme mediated knockdown where Dz and 
i-Dz treated macrophages showed only 14% and 2% knockdown, respectively (Figure 
A9). We hypothesized that this was caused by product inhibition due to high stability of 
the 10 base pair length recognition arm. To address this concern, the recognition 
sequence for this arm was shortened from 10 to 7 in addition to changing the two 
terminal thymidine bases in the T10 spacer region to two cytodines to ensure minimal 
interaction with the mRNA. In the optimized design, compared to untreated LPS 
stimulated cells, only Dz particles showed significant (~50%) reduction in TNF levels 
while NS-Dz and i-Dz particles showed no effect (Figure 13B). Together, these results 
show that spherical nucleic acids can deliver DNAzyme to macrophages protected from 
degradation in its catalytically active form and decrease the expression of TNF-α in 
activated macrophages. 
 We then investigated the ability of these particles to deliver DNAzymes to the 
myocardium in a rat model of MI. For these in vivo studies, particles were delivered into 
the heart via intramyocardial injection into the infarct zone of rats immediately following 
MI surgery. This is clinically relevant in the context of MI as routine interventional 
procedures, such as PCI following MI, require catheterization and can be leveraged for 
site-specific therapeutic administration [27]. Initially, to determine the myocardium 
uptake efficiency and particle retention, Cy-NS-Dz modified gold particles were injected 
into the myocardium. The time-course ex-vivo bioimaging revealed strong Cy5 
fluorescence emitting from the heart for all 3 days tested suggesting efficient particle 
uptake and that these nanoparticles are retained in the myocardium following injection 
for at least up to 3 days (Figure 14A-C). Due to the pulsatile nature of the heart, as 
anticipated, the particles are introduced to the blood circulation to a certain extent, and 
secondary to the heart, they predominantly biodistribute to the kidney and liver, 
suggesting renal and/or hepatobilary clearance.     
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 To test the potential of DNAzyme functionalized gold particles as anti-
inflammatory agents for the treatment of acute MI, we investigated the effect of injecting 
these particles to the myocardium of rats immediately following experimental MI using 
cardiac echocardiography and invasive hemodynamics measurements at a 3-day acute 
time point. A significant improvement in cardiac function was observed in Dz treatment 
group compared to MI alone with no effect from control treatments (Figure 15A). 
Corresponding to the functional improvement, delivery of Dz significantly reduced the 
TNF mRNA levels in LV tissue compared to all controls, exhibiting no statistical 
significance from sham controls (Figure 15B).  
 We also sought to analyze the impact of knocking down TNF gene expression 
on profiles pro-inflammatory markers involved in myocardial inflammation as well as 
systemic levels of these cytokines in the plasma collected from treated animals. Dz 
treatment demonstrated a strong anti-inflammatory effect that disrupted the gene 
expression of pro-inflammatory mediators IL-12, IL-1, IL-6 as well as iNOS, an 
inducible form of Nitric oxide (NO) synthase stimulated by cytokines such as 
TNFand IL-1[180]. Several studies have illustrated the central role that TNF 
plays in myocardial dysfunction by propagating pro-inflammatory cytokines such as IL-6 
and IL-1that acutely regulate myocyte survival/apoptosis and trigger further cellular 
inflammation including oxidative stress and recruitment of inflammatory cells to the 
infarct [24, 78-81]. Furthermore, there is substantial evidence showing that TNF and 
subsequent induction of IL-6 or IL-1 can attenuate myocyte contractility directly 
through the reduction of systolic cytosolic Ca
2+
 levels via alterations in sarcoplasmic 
reticulum function [80, 181], down-regulation of contractile proteins, ßadrenergic 
receptor uncoupling [78, 182, 183] or indirectly by decreasing myocyte contractility 
through nitric oxide-dependent attenuation of myofilament Ca
2+ 
sensitivity [24, 73, 80, 
180, 183] or oxidative effects on the RyR2 [184, 185]. It is well established that the 
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induced NO production has a negative inotropic effect on cardiac myocytes and that high 
levels of NO produced by iNOS are cytotoxic [24, 183, 186]. Interestingly, our data also 
demonstrates reduction of iNOS expression with Dz treatment, suggesting that knocking 
down TNF has beneficial effects on cardiac contractility via direct and indirect 
mechanisms, potentially contributing to the improvement in cardiac function we observe. 
We further substantiated this proposed mechanism in vitro by recording spatially 
resolved dyssynchronous Ca
2+
 sparks via line scan confocal imaging upon stimulating 
primary adult rat cardiomyocytes with LPS to induce TNF production followed by 
treatment with Dz particles. Our data (Figure A10) shows reduction in inhomogenous 
subcellular Ca
2+
 spark frequency in cardiomyocytes treated Dz particles compared to the 
untreated LPS stimulated myocytes, thus supporting the potential role that suppression of 
TNF has on preventing myocardial dysfunction.  
 Systemic levels of these cytokines measured from plasma reflected the local gene 
expression patterns and exhibited a strong trend of Dz treatment mediated anti-
inflammatory effect (Figure A7 A-C). An endogenous anti-inflammatory cytokine IL-10, 
although did not show any statistically significant changes in local gene expression 
(Figure A8), exhibits a trend of upregulation in plasma levels with Dz treatment (Figure 
A8 D). Combined with the trend for downregulation of IL-12 only in the Dz treatment 
group (Figure A7 A), these results suggest a lower ratio of IL-12/IL-10 in systemic 
circulation, a surrogate measure of anti-inflammatory response employed in several 
studies due to the apparent opposing relationship  of these cytokines and positive 
implications in resolution of inflammation [187].  
 Taken together, we demonstrate potent gene silencing in vivo via catalytic DNA 
particles, and specifically, the striking anti-inflammatory effects brought about as a direct 
consequence of suppressing the pro-inflammatory cytokine TNF in an acute MI 
setting. While this study shows promising acute functional improvement likely brought 
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about by the comprehensive anti-inflammatory effect of TNF mRNA specific Dz 
treatment at the initial inflammatory stage post-MI, follow up studies evaluating the 
chronic effects of this treatment on cardiac remodeling and chronic function are needed 
to determine whether repeated administrations are necessary to sustain the benefits of 
transient knockdown of TNF. High concentrations of TNF is shown to contribute to 
structural alterations in the failing heart such as cardiomyocyte hypertrophy and cardiac 
fibrosis and often used as an indicator of CHF as described earlier, and therefore merits 
further investigation beyond acute modulation [70, 73, 80]. Despite this limitation, this 
study presents a strong case for early anti-inflammatory intervention and the potential to 




CHAPTER 5  PEG-hydrogel mediated cytokine therapy as a    
strategy for immunomodulation in the heart 
5.1 Introduction 
 The complex myocardial healing process constituting of cellular, morphologic 
and histological changes to the myocardium takes place in multiple phases [4, 154, 155]. 
Immediately following MI and the acute cell death, the ensuing acute inflammatory phase 
involves an influx of phagocytic macrophages and neutrophils that are recruited to the 
area of infarct to absorb the necrotic tissue [18, 36, 37, 84, 88, 90, 155, 156] following 
which myofibroblasts appear in the wound and contribute to reconstruction of a new 
collagen network, ultimately leading to deposition of a collagen-rich scar tissue. Clinical 
standards today focus on strategies for an optimal reperfusion therapy during the first 
hours of MI which has proven benefits in reducing the extent of hypoxic myocardial 
damage, and prevented the rate of mortality following MI [7, 38]. However, prevalence 
of HF is on the rise in patients that survive acute MI or received reperfusion therapy too 
late due to infarct expansion that occurs during the wound healing response before scar 
tissue formation, a process mainly attributed to the extent and quality of the inflammatory 
response following MI [4, 44].  
 This delicate equilibrium of the loco-regional myocardial inflammatory response, 
in conjunction with the post-MI systemic inflammatory reaction is a crucial step for a 
balanced post-MI healing process, and presents a viable therapeutic target to influence 
effective cardiac repair [17, 41]. Recent studies have brought to light the role of 
monocytes/macrophages as key orchestrators of the myocardial healing process. 
Macrophages play an apparently paradoxical role, one in which they conduct destructive 
processes including release of inflammatory mediators and reactive oxygen radicals in 
the process of absorbing the damaged myocardium, and another where they promote 
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angiogenesis and proliferation of myofibroblasts to aid in infarct stabilization [18, 90, 
157, 188, 189]. Several studies have now definitively reported distinct macrophage 
populations that are responsible for these biphasic functions. In the initial inflammatory 
phase following MI (days 1-4), pro-inflammatory or classically activated macrophages, 
commonly known as M1 macrophages dominate the infarct and clear the wound, while 
reparative or alternatively activated of macrophages, known as M2, are present during the 
resolution of inflammation phase and propagate repair (days 4-8). Often however, 
prolonged pro-inflammatory responses stall resolution of inflammation and hamper the 
reparative functions of M2 macrophages essential for the formation of a stable scar [35, 
41, 44, 61, 62, 157]. There is significant evidence for the benefits of mitigating the influx 
of pro-inflammatory monocytes/macrophages in the initial injury response in multiple 
cardiac disease models including acute MI and atherosclerosis [16, 17, 190, 191]. Herein, 
we investigate an alternate therapeutic approach that can modulate the function of pro-
inflammatory macrophages to bring about inflammation resolution. This approach can 
mediate an effective repair process while at the same time suppressing the pro-
inflammatory response rather than depleting it. The strength in our approach is that even 
if the number of macrophages impacted is small, they have the ability to produce more 
anti-inflammatory and pro-regenerative factors that amplify the desired signals and 
improve the quality of healing. 
 While this system of classifying macrophages as distinct M1 or M2 phenotype is 
antiquated in light of studies attributing a spectrum of multiple functional phenotypes to 
macrophages based on activation type, it provides an operationally useful, simple 
framework to study the role of macrophages and form hypotheses that can then inform 
viable therapeutic applications in vivo. In an in vitro context, a classical activation is 
brought about by stimulation of macrophages or monocytes with pro-inflammatory 
cytokine IFN-γ and bacterial endotoxin LPS stimulation, and alternative activation is 
brought about by cytokine IL-4, IL-10 or IL-13 [192-195]. In the context of 
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immunomodulation for a regenerative application, of particular interest is IL-4, a 
cytokine that has emerged as a powerful mediator for regeneration in muscle and liver 
[196, 197] by directly acting on progenitor cells. Further, on a peripheral nerve injury 
model, IL-4 delivery demonstrates a regenerative bias brought about by its ability to 
promote a reparative macrophage phenotype [25].  
 One of the key challenges for molecular therapies targeted to the heart is 
controlled delivery [12]. Especially with a small 14 kDa protein such as IL-4, direct bolus 
delivery to the myocardium will be highly inefficient as it will be carried away in the 
highly vascularized and pulsatile cardiac tissue. In recent published work from our 
laboratory, we had utilized a protease cleavable 4-arm PEG-Maleimide (PEG-MAL) 
hydrogel for the safe and efficacious dual release of growth factors to the infarct of rats 
[32]. In this study, this injectable hydrogel is employed as an immunomodulatory 
material to delivers IL-4 to macrophages in the infarct site. We evaluate the functional 
effects of the delivery in vivo and propose strategies to optimize this immunomodulatory 
approach for future studies. 
5.2 Materials and Methods 
5.2.1 Cell culture  
 A mouse macrophage cell line RAW 264.7 from American Type Culture 
Collection (ATCC number: TIB-71) was maintained at 37 
0
C under a humidified 
atmosphere of 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) (Cellgro) 
containing 10% (v/v) fetal bovine serum (FBS) (Hyclone), supplemented with penicillin 
(100 U/mL) and streptomycin (100 mg/mL) and 2 mM L-Glutamine (Invitrogen). For 
primary macrophage culture, bone marrow-derived macrophages (BMMs) were isolated 
from Sprague Dawley rats as described previously [198]. Briefly, bone marrow cells were 
obtained by flushing the femurs with HBSS+. The bone marrow derived precursor cells 
were grown in 100mm
2
 cell culture dishes for 7 days in RPMI 1640 (Cellgro) media 
 74 
containing 10% FBS supplemented with 10ng/mL of mouse colony stimulation factor 
(M-CSF, Miltenyi Biotec) which directed the cell proliferation towards a purer 
population of BMMs. Media on the dishes was doubled on day 3 during the culture. The 
adherent cells at the end of 7 days were scraped and used for subsequent experiments, 
and confirmed as macrophages by immunofluorescence staining for pan-macrophage 
marker CD68 using mouse anti-CD68 (abcam). For endothelial cells, either immortalized 
mouse aortic endothelial cells (iMAECs) (a kind gift from Dr. Hanjoong Jo’s laboratory) 
or rat primary cardiac microvascular endothelial cells (CECs) (Cell Biologics R2111) 
were cultured in gelatin coated cell culture flasks with low-glucose DMEM (GIBCO) 
supplemented with 10% v/v FBS, penicillin/streptomycin at the same concentrations 
described above, 50 g/ml ECGS (Sigma), MNEAA 100X (GIBCO). For cardiac 
progenitor cell culture, c-kit-positive cells from the rat myocardium isolated as described 
previously [199] were cultured in growth media consisting of Ham's F-12 media 
(Cellgro) supplemented with 10% (v/v) FBS, L-glutamine/ penicillin/streptomycin as 
described above, 10ng/mL leukemia inhibitory factor and 10ng/mL basic fibroblast 
growth factor (Sigma). Before commencing the experiments, the cells were grown to 
80% confluence, serum starved in starvation media containing Ham's F-12 media 
supplemented with L-glutamine, insulin/transferrin/selenium (ITS) serum supplement 
(Cellgro), and penicillin/streptomycin.  
5.2.2 Macrophage polarization studies  
 RAW 264.1 macrophages were either treated with IL-4 (10ng/mL) or IFN-γ 
(10ng/mL) and LPS (5ng/mL) for 24 hours in order to alternately or classically activate 
macrophages. Following treatment, RNA was isolated from cells for gene expression 
analysis via qRT-PCR for expression of pro-inflammatory cytokine TNF- as an M1 
marker and Mannose receptor 1 (MRC-1) as M2 marker. Furthermore, the nitrite 
production by activated macrophages (as a surrogate for nitric oxide (NO) produced by a 
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characteristic M1 marker iNOS) was measured from the conditioned media (CM) using 
Griess reagent system (Promega). The M2 marker Arginase 1 (Arg1) activity was 
measured by a colorimetric enzymatic assay that measures the conversion of substrate L-
arginine to urea catalyzed by Arg1 using a chromogen that complexes with urea to form 
color [200].  Briefly, cells were washed in PBS and lysed in 70µL of 0.1% Triton X-100 
containing 1x protease inhibitor cocktail (AbD Serotec). The mixture was then incubated 
with shaking for 20 minutes at room temperature. After the cells were lysed, 50µL of 10 
mM MnC12, 50 mM Tris-HCl, pH 7.5 were added to 50µL of the cell lysate and the 
enzyme was then activated for 10 minutes at 55°C. Arginine hydrolysis was carried out in 
Eppendorf tubes and was initiated by the addition of 50µL of 0.5M arginine, pH 9.7 to 
the previously activated lysate. Incubation was performed at 37°C for 60 minutes and the 
reaction stopped by the addition of 400 l of an acid mixture containing H2SO4, H3PO4 
and H2O (1:3:7). Then 25µL of 9% alpha-isonitro (ISPF) dissolved in 100% ethanol was 
added to the mixture and heated at 100°C for 45 minutes. After 10 minutes of further 
incubation in the dark, the urea formed was colorimetrically quantified at 540 nm in a 
microplate reader (Biotek Synergy 2) using 200µL aliquots/per well. A calibration curve 
was prepared with increasing amounts of urea between 1.5 and 30µg. In this case to 
100µL of urea solution at the appropriate concentrations, 400µL of the acid mixture and 
25µL ISPF were added, and the procedure followed as described above. 
 For polarization studies where we attempted to steer macrophages already 
activated towards an M1 state towards an M2 functional phenotype, RAW 264.7 
macrophages or BMMs were either simultaneously treated with M1 (IFN-γ and LPS) 
stimuli and M2 (IL-4) stimuli in a simultaneous activation pattern or first treated with M1 
stimuli for 24 hours, following which the media was simply changed again without any 
additional treatment as a control, or changed to M2 stimuli in a staggered activation 
pattern. Post-treatments, conditioned media was harvested for NO measurements (M1 
marker) and cells lysed for Arg1 assay (M2 marker).  
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5.2.3 In vitro tube formation studies 
 The capacity of macrophage secreted factors to stimulate angiogenesis was 
assessed using a growth factor-reduced Geltrex (Invitrogen) assay. M1 or M2 conditioned 
media from RAW 24.7 macrophages in a ratio of 1:1 conditioned media and endothelial 
treatment media (2% of growth media described above) was applied to mouse endothelial 
cells (iMAECs) plated at 1x10
6
 cells/well in a 6-well plate for 24 hours. Cells were then 
lifted and counted so that 15,000 cells from each treatment group in endothelial treatment 
media could be plated onto 120 l thick Geltrex gels in 96-well plates. The cells were 
then incubated for 6 hours and imaged using phase contrast and the cumulative tube 
length was quantified in 3 fields of view from each well using ImageJ software analysis. 
For tube formation studies with rat BMM conditioned media, rat primary cardiac 
microvascular endothelial cells (CECs) were quiesced in treatment media overnight and 
seeded onto a 96-well plate coated with 120 L of Geltrex in media containing 2:1 ratio 
of the treatment media and M1 or M2 BBM conditioned media. Additional groups 
containing just the M1 (IFN-γ + LPS) or M2 (IL-4) stimuli in the treatment media were 
also added to the experiment to control for the added stimuli present in the conditioned 
media. Following 6 hours of treatment, cells were stained with 4M Calcein AM dye 
(Invitrogen) and imaged with a fluorescent microscope (Olympus IX71) and the tube 
length was quantified as above. In a separate study, the same procedure was performed 
on plates coated with gels made from rat tail collagen (Invitrogen) to mimic a growth 
factor deprived 3-D environment to clearly assess the effect of differentially activated 
BMM conditioned media on endothelial cell spreading and aggregation and results 
quantified using Cell Profiler.  
5.2.4 In vitro cell migration 
 The ability of conditioned media from macrophages to recruit cardiac progenitor 
cells (CPCs) was assessed using a modified Boyden chamber trans-well migration assay. 
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Cell Tracker Orange CMRA (Life Technologies) labeled CPCs were seeded in the top 
well of the Boyden chamber (Corning) at a density of 100,000 cells/ well and allowed to 
adhere to the wells. Conditioned media obtained from untreated and M1 or M2 polarized 
macrophages as well as plain media or media containing M1 or M2 stimuli was added to 
the bottom chamber. After 12 hours, the inside of the Boyden chamber was aspirated and 
wiped clean, and the bottom side of the chamber was incubated in cell-dissociation buffer 
while shaking for 1 hour in a 37
0
C to get migrated cells in solution. The extent of cell 
migration through the insert was then quantified by measuring CMRA fluorescence on a 
microplate reader (BioTek Synergy 2). A standard curve of CMRA fluorescence to cell 
number was used to calculate the percent of migrated cells, and reported as percent 
changes in cell-migration over appropriate untreated controls.  
5.2.5 Preparation and characterization of PEG-MAL hydrogel  
 A protease-cleavable hydrogel system with a 4-arm PEG macromer end-
functionalized with Maleimide groups (PEG-MAL) was prepared as previously described 
[32]. PEG-MAL macromers (20 and 10 kDa, 0.95% maleimide functionalization; Laysan 
Bio) were pre-functionalized with GRGDSPC (RGD) adhesion peptide in 1.0 mM 
triethanolamine (TEA) solution at pH 7.4 by allowing the PEG-MAL macromers to react 
with the cysteine groups of the RGD peptide for 30 minutes in 37
0
C. The cytokine IL-4 
(1% v/v) (Antigenix America) was then mixed in with the precursor solution to be 
encapsulated within when the solution is cross-linked into a hydrogel by addition of a 
cysteine-flanked protease-degradable peptide sequence GCRDVPMSMRGGDRCG 
(VPM) [32, 33]. Since IL-4 does not have any free cysteines, it is not expected to be 
physically tethered to the hydrogel. PEG polymer density used in animal studies was 5% 
w/v and RGD density was 2.0 mM. The final concentration of cytokine delivered was 1 
g IL-4 per 50 L hydrogel.  
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 Mass swelling ratio of 10 kDa PEG-MAL hydrogels at weight percentages of 5%, 
6% and 7% PEG was characterized. Firstly, hydrogels were formed (n=6 per group) in 
coverslips coated in Sigmacote® (Sigma-Aldrich). After cross-linking, hydrogels were 
allowed to freely swell in PBS for 24 hours and the swollen hydrogel mass measured. 
Hydrogels were then snap-frozen in liquid N2 and lyophilized followed by dry mass 
measurement. The mass swelling ratio is reported as the ratio of swollen mass to dry 
mass. 
5.2.6 In vitro release study 
 In order to characterize the passive and enzyme mediated release of IL-4, the 
protein was tagged with Alexa Fluor 488, Carboxylic Acid, Succinimidyl Ester, mixed 
isomers (Invitrogen) according to manufacturer’s instructions. Briefly, protein was 
incubated at 0.1 mg/mL at a 1:50 protein to dye molar ratio in sodium bicarbonate buffer 
for 2 hours at 37
0
C, and purified into PBS by 3 passes through a desalting spin column 
(Zeba Spin Desalting Column, Pierce, 7K MWCO). Labeled protein was stored at 4-8
0
C 
for short-term until use. PEG-MAL macromers of 10 kDa and 20 kDa at varying weight 
percentages (5, 6, 7 and 12%) were tested. Furthermore, in order to place the release 
characteristics in context of previously published work utilizing this gel, we compared 
the release profile of IL-4, which is only 14 kDa to that of a larger protein such as IgG 
(150 kDa). Gels were incubated in PBS alone or with 0.1 mg/mL or 0.075 mg/mL 
collagenase Type 1 (Worthington Biochemical, 385U/mg activity) for 3 days at 37
0
C. 
Individual hydrogel volumes were 50 L and 5 L of tagged protein. 
 In order to confirm release of bioactive IL-4 from the hydrogel, RAW 264.7 
macrophages were stimulated with 100ng/mL LPS in the presence of either empty or IL-
4 encapsulating hydrogel with Collagenase I at 0.1mg/mL over 48 hours to degrade the 
gels and release IL-4. The NO production in the media at 48 hours was determined to 
confirm the activity of IL-4 against LPS-activated macrophages. 
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5.2.7 Animal studies  
MI was induced via permanent ligation of the left anterior descending artery in 
adult male Sprague Dawley rats. Briefly, the animals were anesthetized (1-3% isoflurane) 
and following tracheal intubation, the heart was exposed by separating the ribs. Then 
ligation of the left anterior descending coronary artery was carried out and appropriate 
injections were administered in 3 areas of the ischemic zone. Following injection, the 
chests were closed and animals were allowed to recover on a heating pad until 
appropriate assessments were made at later time points. Three different randomized and 
blinded animal studies were conducted as follows: ex vivo bioimaging study, acute and 
chronic functional study with immunohistological evaluation at the chronic time point, 
and gene expression analysis study. In all studies, the animals were assigned to treatment 
groups using a random number generator and the animal surgeon was only given letter 
codes to identify groups. These studies conformed to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996) and all animal studies were approved by Emory University 
Institutional Animal Care and Use Committee. 
5.2.8 Ex-vivo bioimaging 
 Rats were subjected to MI as described above and DyLight 800 (Invitrogen) 
labeled IL-4 encapsulated hydrogel or bolus IL-4 (50L) was injected in 3 areas in the 
border zone surrounding the infarct. Rats were sacrificed and the hearts, liver, spleen and 
kidneys were harvested and imaged on days 0, 1, 2, 3 and 7 post-injection (n=3 per time 
point) using Bruker In-Vivo Xtreme using the same imaging settings and reported as 
arbitrary fluorescence units plotted over time. 
5.2.9 Echocardiography and invasive pressure-volume hemodynamics analysis  
For the animal study designed to evaluate cardiac function and 
immunohistological analyses to assess cardiac repair, one group of animals received 
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sham surgery while four other groups received MI surgery. For groups receiving 
injections, immediately after coronary artery ligation, 50 L injection of either an empty 
hydrogel or bolus IL-4 injection or IL-4 hydrogel (containing 1g IL-4)  was 
administered into the cyanotic ischemic zone (3 locations) through a 25-gauge needle 
while the heart was beating. Functional assessments were made 7 and 21 days following 
MI surgery using echocardiography (Acuson Sequoia 512 with a 14 MHz transducer) and 
additionally on day 21 using invasive pressure-volume hemodynamics (Millar MPVS 
Instruments). From echocardiography, short axis values of left ventricular end systolic 
(ES) and end diastolic (ED) dimensions were obtained. An average of 3 consecutive 
cardiac cycles was used for each measurement and was performed three times in by a 
blinded investigator. Fractional shortening was calculated as [(end-diastolic diameter – 
end-systolic diameter)/(end-diastolic diameter)] and expressed as a percentage. For 
invasive hemodynamics, the pressure-volume probe was inserted into the left ventricle. 
After stabilization, baseline left ventricular pressure-volume loops were recorded for at 
least 10 cardiac cycles and data averaged to get mean values for each animal. Parameters 
extracted include left-ventricular Ejection Fraction (%EF), +dP/dT and -dP/dT.  
5.2.10 Immunohistochemistry 
Following functional assessments on day 21, the animals were sacrificed and the 
hearts were fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin and 
sectioned to 5 m sections and adhered to a glass slide. Following rehydration, tissue 
sections were probed with Alexa fluor 647-labeled isolectin B4 (Invitrogen) to stain 
endothelial cells for angiogenesis/arteriogenesis determination and imaged using 
fluorescence microscopy. For quantification, 3 non-serial sections from each animal were 
analyzed by a blinded investigator using a custom written Matlab code that identified 
percent red pixels in the infarcted regions (identified as regions lacking auto-fluorescence 
which is normally exhibited by healthy myocardium in the green channel) [201].  
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Additionally, collagen deposition was determined by picrosirius red (Sigma) 
staining as previously described [124]. Briefly, 5 m tissue sections were stained with 
Sirius Red and imaged at 5x objective using a light microscope. Overlapping images 
were taken and then stitched together using Adobe Photoshop to generate an image of the 
entire heart. Total collagen area (red staining) was normalized to total left ventricular area 
in 3 separate sections per animal using a custom written Matlab program. 
5.2.11 In vivo gene expression and plasma cytokine analysis 
In order to assess whether IL-4 hydrogel delivery resulted in the transformation of 
M1 like macrophages towards M2 like macrophages even at acute time points (prior to 
the pre-determined shifts reported in the literature), we conducted a study spanning 
several acute time points with only two groups of main concern. Both of these groups 
underwent MI, while only one of those groups received the IL-4-hydrogel injection 
(n=3). At days 1, 2, 3 and 7 days following MI, animals were sacrificed and the left 
ventricle infarct tissue was harvested and homogenized from which the total RNA 
contents were isolated using Trizol (Invitrogen) according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was synthesized using SuperScript III kit (Invitrogen) and 
qRT-PCR performed using Power SYBR Green (Invitrogen) master mix with Applied 
Biosystems StepOnePlus
TM
 real time PCR system. Comparative Ct method was 
employed to analyze gene expression levels of each of the target genes. Gene expression 
levels were then normalized to the endogenous housekeeping gene GAPDH. Primer 
sequences used are listed in Appendix section A3.3. 
Prior to sacrificing the animals, blood was collected via cardiac puncture, plasma 
separated from blood cells and stored in -70
0
C until cytokine analysis using the Luminex 
multiplex analyzer system (Luminex LX100). A custom cytokine bead panel from 
ebioscience was used to analyze cytokines IL-12 and MCP-1 in the plasma. 
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5.2.12 Statistics 
All statistical analyses were performed using Graphpad Prism 5 software. 
Quantitative results were presented as means ± SEM. Statistical comparisons were 
performed by one way analysis of variance (ANOVA) followed by the appropriate post-
test as described in the figure legends. P values of less than 0.05 were considered 
significant. 
5.3 Results 
5.3.1 Effect of polarized macrophages on endothelial cell survival and tube 
formation and cardiac progenitor cell migration in vitro  
 A cell line of macrophages (RAW 264.7) treated with IL-4 upregulated M2 
marker MRC-1 and showed increased Arg1 activity, indicative of polarization towards an 
M2 functional phenotype (Figure 17 D-E). Similarly, IFN-γ and LPS treated cells exhibit 
polarization towards an M1 phenotype indicated by the increase in NO production 
induced by the classical M1 marker iNOS and upregulation of the pro-inflammatory 
cytokine TNF- gene expression (Figure 17 B-C). RAW 264.7 macrophages polarized 
towards an M2 functional phenotype induced favorable aortic endothelial tube formation 
in iMAECs in a Geltrex® tube formation assay (Figure 18A). Furthermore, on growth 
factor deprived collagen gels, IL-4 polarized BMM (M2) conditioned media (M2 CM) 
treated CECs exhibited significant improvements in cell viability and cell spreading 
(captured in a single metric of area of cells occupied) compared to cells treated with M1 
or untreated BMM conditioned media or media containing the polarizing stimuli IL-4 or 
IFN-γ + LPS alone (Figure 18B). In fact, it would seem that endothelial cells treated with 
conditioned media from M1 polarized macrophages (M1 CM) fare poorly compared to 
even untreated macrophage conditioned media, although not statistically significantly 
different. Furthermore, only M2 CM treated endothelial cells on collagen gels migrated 
towards each other and formed aggregate structures, potentially pre-cursors to tube 
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formation (Figure A12). Furthermore, M2 CM from RAW 264.7 macrophages attracted 
cardiac progenitor cells (CPSs) to a greater extent compared to other conditioned media 
controls (p<0.001 vs untreated CM, p<0.01 vs M1 CM), or media containing cytokine 
stimuli (Figure 19A-B).    
 
Figure 17. Characterization of polarized macrophages (A) Schematic of classical 
(M1) and alternate activation (M2) of macrophages represented by red and green arrows 
respectively. (B) Nitric oxide levels (C) TNF- mRNA (D) Arg 1 activity (E) MRC-1 
mRNA were assessed following activation of macrophages with either LPS + IFN-γ or 
IL-4. All mRNA expression was normalized to housekeeping gene hprt1 (Grouped data, 
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mean ± SEM; n=3-5*p<0.05, **p<0.01, ***p<0.001; One-way ANOVA followed by 
Tukey’s Multiple Comparison post-test) 
 
 
Figure 18. M2 polarized macrophages influence in vitro tube formation and cell 
survival in endothelial cells via paracrine mechanisms. Grouped data, mean ± SEM; 
n=4-6. (A) Tube formation of iMAECS in Geltrex® matrix upon treatment with M2 (top, 
left) or M1 (bottom, left) activated RAW 24.7 macrophage conditioned media, and tube 
length quantified (right) (scale bar, 1mm). (B) Cell spreading/count of CECs in rat tail 
collagen gels upon treatment with M2 (top, left) or M1 (bottom, left) activated 
macrophage conditioned media, and area occupied by cells quantified (right). Images 
taken in 10x objective, cells (green, Calcein) (scale bar, 100m) (*p<0.05, ***p<0.001; 
One-way ANOVA followed by Tukey’s Multiple Comparison post-test) 
 85 
 
Figure 19. Effect of M2 polarized macrophages on migraton of cardiac progenitor 
cells in vitro. (A) Migration of CPCs labeled with CellTracker Orange dye through the 
Boyden chamber insert towards conditioned media from either untreated or M1 or M2 
polarized RAW 24.7 macrophages or (B) migration towards plain media or media 
containing the polarizing stimuli IL-4 or LPS + IFN-γ. (Grouped data, mean ± SEM; 
n=4-6 *p<0.05, **p<0.01, ***p<0.001; One-way ANOVA followed by Tukey’s Multiple 
Comparison post-test) 
. 
5.3.2 Plasticity characteristics of macrophages   
 In order to determine the ability of macrophages to change their functional 
phenotypes depending on their environmental cues despite their disposition towards a 
certain phenotype, we either primed them towards an M1 phenotype first (IFN-γ + LPS) 
followed by M2 stimulation (IL-4) in subsequent days (staggered activation), or 
simultaneously activated them with M1 and M2 stimuli (IFN-γ + LPS and IL-4) for 2 
days. Simultaneous activation exhibits a hybrid phenotype that favors M2 activation, as 
shown by the significant suppression of NO production and increased Arg1 activity 
(Figure 20A-B, Figure A13). On the other hand, staggered activation pattern showed little 
to no tendency to revert to an M2 polarization status from M1 functional phenotype 
(Figure A13).  
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Figure 20. Simultaneous M1 and M2 polarizing stimuli on macrophage activation. 
Characterization of (A) NO production and (B) Arg1 activity following simultaneous 
activation of RAW 24.7 macrophages with IFN-γ + LPS and IL-4 treatment IL-4 for 24 
hours (Grouped data, mean ± SEM; n=5-6, *p<0.05, **p<0.01, ***p<0.001; one-way 
ANOVA followed by Dunnett’s Multiple Comparison post-test) 
   
5.3.3 Characterization of protein release from PEG-MAL hydrogel  
 To determine release of IL-4 in vitro, fluorescently-labeled IL-4 was encapsulated 
into the PEG-MAL hydrogels (Figure 21A). Firstly, the release profile of IL-4 (14 kDa) 
from 5% (w/v) PEG-MAL gel of 10 and 20 kDa molecular weight was compared to that 
of release of Alexa Fluor 488-labeled antibody IgG (150 kDa) from these gels (Figure 
A14).  The results demonstrate a more sustained release of the larger protein IgG and 
pronounced differences in release rate due to the differing mesh sizes formed by the 10 
kDa vs 20 kDa PEG-MAL hydrogels. The 10 kDa macromers form tighter networks and 
therefore smaller mesh sizes and thus higher entrapment and slower release. These 
differences in mesh sizes had no significant effect on the  
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Figure 21. Hydrogel design and release studies. A) PEG-maleimide (PEG-MAL) 4-
arm macromers of 10 kDa were pre-functionalized with RGD adhesion peptide and IL-4 
was encapsulated. The precursor molecules were cross-linked into a hydrogel by addition 
of cysteine-flanked protease- degradable peptide sequence GCRDVPMSMRGGDRCG 
(VPM). B) Fluorescently tagged IL-4 released from varying weight percentages of PEG-
MAL hydrogel (5%, 6%, 7% and 12%) swelled in either PBS or 2 different doses of 
collagenase Type 1 as measured by fluorescent plate reader sampling of incubation 
media. Grouped data were fitted with a two-phase exponential best-fit curve.  
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release of the small cytokine IL-4, although 10 kDa PEG-MAL hydrogels led to slightly 
slower overall release of IL-4. Further characterization of the IL-4 release profile from 
varying weight percentages (5, 6, 7 and 12%) of the 10 kDa PEG-MAL hydrogel was 
then performed to investigate potential for better controlled release of IL-4 (Figure 21B). 
Hydrogels subjected to higher collagenase I (Col I) treatment (0.25mg/mL)  were 
observed to degrade and release loaded IL-4 rapidly within the first 6 hours after 
treatment, and a lower concentration of Col I (0.075mg/mL) treatment released IL-4 
slower, but degraded the hydrogels completely within 24 hours, demonstrating a 
protease-dependent release of IL-4 in these bioactive hydrogels. Hydrogels encapsulating 
IL-4 and placed in PBS released IL-4 slower overall, although there was burst release 
observed during the first 10 hours, and a slower sustained release profile in the latter 
phase. This is substantiated by the two-phase exponential best-fit line that yielded R
2
 ≥ 
0.98 for all curves. The amount of IL-4 released varied inversely with the % weight of 
PEG in the hydrogel, with ~45% release in 12% PEG hydrogel in the initial 10 hours 
compared to 65% in 5% gel. Furthermore, in all weight percentages of hydrogels, beyond 
the burst release, there is a perceived inflection point at around 10 hours (Figure A16) 
beyond which the rate of release slows incredibly, with only 10-15% more IL-4 released 
from all gels. Interestingly, the release profile between 5 and 6% hydrogel was very 
similar through both phases of the release profile. As shown in Figure A15, the mass 
swelling ratio (related to the average distance between cross-links, and thus a measure of 
loose vs tight hydrogel network structure [32]) of 5, 6 and 7% hydrogels made from 
10kDa PEG-MAL macromers differ significantly from each other, but very moderately, 
which could partially explain the very little differences observed in the release of IL-4 
within these 3 weight percentage gels in the initial burst release phase.  
    Furthermore, Figure A17 demonstrates the ability of the PEG-MAL gel to 
encapsulate and release IL-4 in its bioactive form by the significant reduction in NO 
levels observed in the IL-4-hydrogel treated group which is comparable to the 50% 
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reduction in NO levels compared to LPS stimulation alone that is observed in all 
experiments conducted in this study where LPS and IL-4 were simultaneously used to co-
stimulate macrophages.  
5.3.4 In vivo IL-4 release characterization  
 In vivo biodistribution and retention of fluorescently tagged IL-4 in the heart upon 
IL-4-hydrogel (5% weight percentage of 10 kDa PEG-MAL macromere)  or bolus IL-4 
delivery to the heart was determined using ex-vivo fluorescence imaging of the internal 
organs at days 0, 1, 2, 3 and 7 following MI surgery and injection (n=3). Due to imaging 
artifacts on day 1 in the bolus IL-4 injection group, this time point was excluded from the 
dataset. As shown in Figure 22, IL-4-hydrogel injection exhibited greater than 3 times the 
fluorescence to that of bolus IL-4 injection in the heart on day 0 immediately after the 
injection (within 5 minutes of injection, the rat was sacrificed and heart excised for 
imaging) , and sustained a 2 times higher fluorescence intensity through day 3. At day 7, 
the fluorescence levels in IL-4-hydrogel injected group decreased to below detected 
levels (Figure 22A, right). Higher retention was observed in the heart than any other 
organs in IL-4-hydrogel injected group (Figure 22A, right). Secondary to the heart, levels 
of fluorescence was highest in the kidneys and it is uncertain whether it is the cleaved 
fluorophore or the protein that is being eliminated from the kidney. Similar lower levels 
of fluorescence were observed in all organs in the bolus IL-4 injection group (Figure 
22B, left).  
5.3.5 Cardiac function following myocardial infarction 
 To determine the in vivo efficiency of IL-4 delivery utilizing PEG-MAL hydrogel, 
adult male Sprague Dawley rats were randomized into 5 treatment groups. The injected 
hydrogels were composed of 5% (w/v) PEG-MAL from 10 kDa macromer, and the 
injections were of 50L volume with or without 1g IL-4. While one group was 
subjected to sham surgery, the other four groups received MI surgeries followed by either 
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no injections (MI) or injections of either empty hydrogel, bolus IL-4 (50L with 1g IL-
4) or hydrogel encapsulating IL-4 (n=5-9 for each group, n=40 total). At the acute 7 day 
time point following surgery and injection, all groups receiving MI demonstrated 
significantly reduced cardiac function (p < 0.001) as measured in absolute change in 
percent fractional shortening (%FS) compared to sham animals, and only the IL-4-
hydrogel treated animals showed about 30% restoration in function compared to MI (p < 
0.001) as well as the empty hydrogel (p<0.001) and IL-4 bolus (p<0.05) injected groups 
(Figure 23). However, this improvement is lost at the chronic 21 day time point in terms 
of %FS (Figure 24A), although the invasive hemodynamics measurement derived % 
 
Figure 22. Ex-vivo fluorescence imaging upon IL-4 delivery to the myocardium.  
(A) Representative mages of hearts from day 0, 2 and 3 following either a bolus IL-4 
or IL-4-hydrogl injection (left) and mean fluorescent intensity for the heart expressed 
in arbitrary fluorescent units through day 7 (right)  (B) Fluoresent mean intensity of 
all organs expressed as mean arbitrary fluorescent intensity units for bolus IL-4 
injection (left) and IL-4 hydrogel injection (right) (Grouped data, mean ± SEM; n=3) 
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Ejection Fraction values suggest perhaps a moderate improvement in function compared 










Figure 23. Effect of in vivo delivery of IL-4-hydrogel delivery on acute cardiac 
function in a rat model of MI. Grouped data (mean ± SEM; n=6-9) at day 7 following 
MI and injections. Cardiac function was evaluated by echocardiography using % 
fractional shortenting measurements. (*p<0.05; **p<0.01; ***p<0.001; one-way 
ANOVA followed by Tukey’s Multiple Comparison post-test). 
5.3.6 Fibrosis 
 To determine levels of fibrosis following MI, tissue sections were stained with 
picrosirius red 21 days following MI and fibrotic area was normalized to total heart tissue 
section on each respective slide. Animals that received no treatment had a fibrotic area of 
56.3±20% (Mean ± SD) of total area (Figure 25A), although the variability in this group 
was the highest leading to no statistically significant differences in any of the treatment 
groups despite the trend of reduced fibrosis in groups treated with bolus IL-4 or IL-4-
hydrogel. 
5.3.7 Angiogenesis 
 To determine levels of angiogenesis, sections were probed with an Alexa Fluor 
647-labeled isolectin conjugate and percentage of the infarcted tissue section showing 
staining for endothelial cells/vessels was quantified to determine percent changes in 
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angiogenesis in the IL-4-hydrogel treated animals compared to untreated animals that 
underwent MI.  IL-4-hydrogel treated animals exhibited a trend towards increased 
percent vessel formation in the infarct area than the untreated animals (Figure 25B) 
suggesting the potential of IL-4 encapsulated PEG hydrogel to enhance angiogenesis 
following MI. 
5.3.8 In vivo acute gene expression profile and plasma cytokine levels 
 In order to determine whether IL-4-hydrogel delivery contributed to changes in 
the inflammatory milieu of the infarct, at 1, 2, 3 and 7 days following MI and IL-4-
hydrogel injections (n=3 at each time point), the gene expression levels of classic M1 
macrophage markers pro-inflammatory cytokines TNF-, IL-1, chemokine MCP-1 as 
well as iNOS enzyme was evaluated and expressed as fold changes in gene expression 
from sham levels (Figure 26). Although this study is a survey of gene expression and not 
powered enough to reliably perform statistical analyses (ongoing studies thoroughly 
characterize them in these 2 groups as well as the bolus IL-4 delivery group) there is a 
general overall trend for the reduction of TNF- in IL-4 hydrogel treated group compared 
to untreated animals and perhaps of IL-1 on day 7 and MCP-1 on day 3 and 7. Other 
genes examined did not show any notable trends (Figure A18).   
 We further analyzed the plasma obtained from day 3 in these animals for the 
chemokine MCP-1 and pro-inflammatory cytokine IL-12levels and show a strong trend 
for reduced levels of IL-12 and significant reduction in MCP-1 levels (p<0.05) in the 
IL-4-hydrogel treated animals (Figure 27). 
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Figure 24. Effect of IL-4 hydrogel delivery on chronic function. Grouped data (mean 
± SEM; n=6-9) at day 21 following MI and injections. Cardiac function was evaluated by 
echocardiography using (A) % Fractional shortenting measurements and (B) % Ejection 
fraction from invasive-hemodynamics measurements (*p<0.05; **p<0.01; ***p<0.001; 
one-way ANOVA followed by Tukey’s Multiple Comparison post-test). 
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Figure 25. Evaluation of cardiac repair following in vivo delivery of IL-4-hydrogel. 
Grouped data (mean ± SEM; n=6-9) from immunohistological analysis at day 21 
following MI and injections. (A) Fibrosis was measured by staining for collagen using 
picrosirius red (red stain, images taken at 4x magnification). (B) % Area of isolectin 
staining was calculated as a measure of new vessel density (red stain) (Scale bar, 50m) 




Figure 26. Effect of IL-4-hydrogel delivery on pro-inflammatory cytokine gene 
expression levels over a course of a week. Grouped data (mean ± SEM; n=3 per group) 
LV infarct tissue gene expression of (A) IL-1, (B) TNF-, (C) MCP-1 as well as (D) 
iNOS from animals on days 1,2,3 and 7 after MI with or without IL-4 hydrogel treatment. 
Gene expression was evaluated by qRT-PCR using the comparative Ct method and the 
results were normalized to GAPDH levels and reported as fold changes in copy number 
of mRNA levels compared to sham animals.   
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Figure 27. Effect of IL-4-hydrogel on plasma levels of MCP-1 and IL-12. 
Grouped data (mean ± SEM; n=3 per group) from plasma at 3 days. Levels of chemokine 
(A) MCP-1 and cytokine (B) IL-12 determined from Luminex Multiplex system and 
reported as plasma cytokine concentrations quantitatively derived from standard curves 
of each cytokine. (*p<0.05; one-way ANOVA followed by Tukey’s Multiple 
Comparison post-test). 
5.4 Discussion 
 Current regenerative approaches to prevent cardiac dysfunction following MI 
focus largely on stem cell therapy or molecular therapies aimed at enhancing the 
regenerative capacity of the heart, an organ long thought to be terminally differentiated. 
Even with recently found niches of endogenous cardiac stem-cells capable of 
differentiating into many cardiac lineages, human heart is no zebra fish or adult newt 
heart with enviable cardiac regenerative capacity. While the ideal therapy for cardiac 
dysfunction would bring about complete cardiac regeneration, it is imperative in the 
meantime to explore processes that can influence and improve cardiac wound healing. 
Interventions to enhance wound healing may open up a new therapeutic window between 
the few hours that may be used to limit necrosis by reperfusion and an irreversible 
cardiac scar that can better respond to other promising regenerative interventions. 
 Much interest has been devoted to studying inflammatory pathways as therapeutic 
targets to halt the progression of heart failure, specifically the role of 
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monocytes/macrophages and several immunomodulatory strategies have emerged in the 
field [191, 202-204]. A notable example is work from Nahrendorf’s group where 
chemokine receptor CCR2 that localizes the pro-inflammatory Ly-6C
high
 monocyte subset 
to the site of infarct was targeted for therapeutic silencing. This subset of monocytes 
gives rise to the pro-inflammatory M1 macrophages following MI, and reducing their 
influx to sites of injury by suppressing CCR2 attenuated their accumulation in 
atherosclerotic plaques and reduced infarct size after MI in mice [191]. However, in light 
of recent evidence demonstrating that biphasic macrophage responses likely derive from 
the same recruited pool of Ly6C
hi
 monocytes regulated by a nuclear hormone receptor 
switch (Nr4a1) [89], the previous theory of sequential recruitment of the biphasic 
macrophage population has been revised. This new direction for the field would suggest 
providing local biochemical cues to differentiate pro-inflammatory 
monocytes/macrophages towards a reparative phenotype rather than reducing the influx 
of monocytes to the site of infarct to be a more suitable approach to aid balanced and 
effective cardiac repair. An approach in line with this thought process exploited the anti-
inflammatory propagating properties of apoptotic cells by devising liposomes that mimic 
apoptotic cells. Delivery of these liposomes augmented anti-inflammatory response while 
suppressing pro-inflammatory response rats following MI, bringing about inflammation 
resolution and preventing infarct expansion [203]. Similarly, our approach aims to induce 
classically activated pro-inflammatory monocytes/macrophages to switch to an 
alternately activated reparative phenotype by delivering the polarizing cytokine IL-4 to 
the infarcted myocardium, with the ultimate goal of creating a balanced inflammatory 
environment that can influence cardiac wound healing in a favorable manner. 
 One of the hallmarks of regeneration is revascularization of injured tissue, and 
role of macrophages in angiogenesis is extensively studied and several reports have 
implicated them as key contributors to the process of angiogenesis [87, 205] and our in 
vitro results confirm that the IL-4 treated alternately activated macrophages enhance tube 
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formation in endothelial cells. Further, in a serum/growth factor limited (1% serum), 3D 
collagen environment, paracrine factors secreted from alternatively activated 
macrophages contribute significantly to cell viability, spreading and tube pre-cursor 
structures of endothelial cells. This is an indicator of angiogenic potential crucial to 
effective cardiac repair. Another important aspect of wound healing is the recruitment of 
progenitor/stem cells to the area of injury and the modulation of stem cell populations to 
promote repair. An elegant study conducted in adult salamanders that possess 
extraordinary regenerative capacity shows lack of limb regeneration when macrophages 
were depleted from their system [206]. The authors speculate a potential mechanism 
whereby macrophages promote dedifferentiation and formation of the progenitor pool 
that contributed to regeneration. Furthermore, several studies have suggested a critical 
role for macrophages in the beneficial outcomes observed from stem-cell therapy to treat 
the infarct [207-209]. Taken together, there is compelling evidence suggesting a crucial 
interplay between macrophages and progenitor cell populations in a regenerative 
environment. A majority of studies exploring this phenomenon only tested the hypothesis 
that mesenchymal stem cells influence macrophage phenotype in favor of effective 
cardiac repair [207, 210, 211]. While it has been shown that alternately activated (M2) 
macrophages promote MSC growth and viability [212], in our study we sought to explore 
the possibility of macrophages influencing stem cell recruitment. Our in vitro migration 
studies demonstrate enhanced migration of Cardiac Progenitor Cells (CPCs) towards 
conditioned media from M2 differentiated macrophage. While this study did not provide 
a mechanism for paracrine effects involved in this increased migration of stem cells 
observed, future studies could build on these encouraging results to further explore the 
roles M2 macrophages may have on endogenous stem cell populations in the heart, and 
the recruitment of mobilized bone-marrow derived stem-cell populations. 
  Macrophage plasticity has been an interesting area of study with implications in 
many disease areas. From the M2 like tumor-associated macrophages to deleterious 
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effects of M1 macropahges in atherosclerosis, to our very interest in the biphasic nature 
of macrophage role after MI, the two-faced characteristics of macrophages has raised 
several questions as to the plasticity of macrophages in the interest of therapeutic 
modulation [90, 156, 157, 188, 189, 213-216]. Monocyte/macrophage lineage is 
generally thought to be plastic with remarkable abilities to change their activation type 
based on external microenvironmental cues [194, 195, 217, 218]. However, various 
studies have shown mixed results in the ability of macrophages to completely switch 
phenotypes in a sequential manner, and the jury is still out on definitive outcomes [219-
221]. The general consensus is that macrophages exist in a continuum of a spectrum of 
activation states with M1 and M2 phenotypes being the extremes [193-195, 217, 222]. 
Re-polarization studies in our hands in both RAW 264.7 macrophages and BMM 
macrophages demonstrate that sequential activation from M1 to M2 has little effect on 
reversing the M1 characteristics, while simultaneous activation suppresses the M1 
characteristics and promotes M2 activation, suggesting the possibility of achieving a 
hybrid functional phenotype of macrophages favoring M2 activation from a therapeutic 
strategy that attempts to provide IL-4 as a cue to re-polarize pro-inflammatory 
macrophages towards a reparative phenotype. These results make a case for earlier 
presence of IL-4 in the pro-inflammatory myocardial environment to achieve such 
modulatory efforts, and this has several implications for the design criteria for the 
delivery system, especially that of temporal control of release. Furthermore, monocyte 
kinetics studies following MI suggest rapid turnover of the monocyte/macrophage 
populations recruited to the infarct, with a continuous flux and an average of 20 hours at 
the infarct for each wave of recruited cells. Taken together, an ideal delivery system for 
the desired application would release IL-4 in a controlled manner starting at the time of 
injection following MI over a period of 3-4 days during which the pro-inflammatory 
response peaks.    
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 We evaluated the PEG-MAL hydrogel cross-linked with protease cleavable 
linkers for their ability to release IL-4 in a controlled manner with and without the 
enzymatic trigger in the form of Collagenase I enzyme. Hydrogels formed from 5 and 6% 
in either the 10 kDa or 20 kDa exhibited similar release profiles for IL-4 (~14kDa). In 
comparison, the 10x larger IgG (150 kDa) displayed more controlled and distinct release 
profiles when weight percentages or the molecular weight of the PEG macromere was 
altered. These differences suggest that the mesh size of the PEG-MAL hydrogel may be 
too large to enable controlled delivery of IL-4 from this material. However, interestingly, 
the release tapers off after the first 10 hours to only release 10-15% more of the IL-4 in 
the span of the next 38 hours. This suggests an interior pocket of tightly cross-linked 
hydrogel that traps the protein tightly, thus causing an inflection point in the release 
profile when this region is just about tapped. Enzymatically triggered release would be 
ideal at this layer to release this remaining depot of trapped IL-4. However, to make the 
best use out of the enzymatic trigger, the burst release from the hydrogel would need to 
be controlled to leave a larger percentage of the IL-4 remaining, so that even when 
proteases secreted by macrophages during the initial inflammatory phase during MI act 
on the gel, the release would be controlled, and not bulk release. One of the many ways to 
achieve this outcome would be to engineer fusion proteins of IL-4 with a cysteine group 
that can then be physically tethered to the gel.  Another strategy would be to functionalize 
the hydrogel with biotinylated peptides that can then use the streptavidin-biotin linkages 
to tether IL-4 to the hydrogel. An alternate strategy could, for instance, encapsulate IL-4 
in polymeric microspheres or present IL-4 on the surface of the particles, and the 
hydrogel could encapsulate these particles, affording a multi-layered controlled release. 
Further studies would build upon these strategies to optimize the delivery system, and in 
the meanwhile, we seek to gain proof-of-concept from this initial in vivo study with a 5% 
PEG-MAL hydrogel encapsulating IL-4. 
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 Other important criteria for the successful implementation of biomaterials for 
delivery of proteins to the myocardium include preservation of bioactivity and 
biocompatibility. Our in vitro studies confirm that IL-4 is released from the PEG-MAL 
hydrogel in bioactive form (Figure A17). Additionally, previous studies from our group 
have shown active release of growth factors from the PEG-MAL hydrogel in vivo and the 
hydrogel has not shown any adverse immunological reaction in the myocardium [33], 
which is substantiated by the extensive characterization of PEG hydrogels for a variety of 
biomedical applications that show these materials to be non-fouling, inert and non-
immunogenic [32, 97, 223, 224].  
 Delivery of IL-4 from the PEG-MAL hydrogel was compared to bolus IL-4 
delivery into the myocardium of a rat model of MI. The time-course ex-vivo bioimaging 
revealed strong fluorescence signals in the hearts for 3 days in the animals receiving IL-4 
hydrogel injection, suggesting retention of the delivery system in the heart. The 
fluorescence signals were 2-3 times higher in the heart than the bolus IL-4 delivery 
approach, and very minimal fluorescence was observed in other organs with the hydrogel 
mediated IL-4 delivery. We investigated the effect of IL-4 delivery on cardiac function. 
At an acute 7-day time point, there was a significant improvement in cardiac function in 
the IL-4 hydrogel treated group compared to all controls including the bolus IL-4 
delivery. Interestingly this improvement is not as definitively sustained at the chronic 21-
day time point. Histological analysis of new vessel formation at this chronic time point 
shows only a modest trend of increased percentage of endothelial vessels in the IL-4 
hydrogel treated group compared to rats that received no treatment post-MI. In addition, 
there were no changes in levels of fibrosis in any of the treatment groups as compared to 
untreated MI group. These results are in contrast to our original hypothesis that effective 
IL-4 delivery to the heart during an earlier window through the inflammatory process 
could stimulate a balanced cardiac repair process resulting in chronic functional 
improvement. However, the initial acute improvement in function is encouraging, and 
 102 
although there were no significant changes in the local inflammatory gene expression 
profile upon IL-4 hydrogel delivery in this low powered pilot exploratory survey, there 
were some encouraging trends in reduction of pro-inflammatory mediators. One such 
trend within 2-3 days post-MI is of pro-inflammatory cytokine TNF-Figure 26) a 
powerful upstream inflammatory mediator of many of the pathophysiological processes 
that take place in the progression of cardiac dysfunction [37]. Another notable decreasing 
trend is the expression levels of MCP-1 from day 3-7, the chemokine responsible for the 
recruitment of monocytes to the infarct [37]. This reduction in MCP-1 levels was 
corroborated by a significant reduction in the plasma MCP-1 levels at day 3 (Figure 27). 
 While these results potentially give support to the merits of IL-4 delivery to exert 
anti-inflammatory effects at the very least, the lack of improvement in chronic function 
raises two possibilities: one possibility is that the modest anti-inflammatory effects and 
other untested mechanisms through which IL-4 potentially acted to provide acute 
functional improvement may not have been sufficient to enhance the wound healing 
process as originally hypothesized; another possibility is that the delivery system was not 
ideally suited to deliver IL-4 in sufficient quantities to effect the changes desired in 
macrophage phenotype. While IL-4-hydrogel delivery better retained IL-4 in the 
myocardium, it is possible that during the bulk of the release of IL-4 in the first 12 hours 
(as suggested by the in vitro release studies with 5% PEG hydrogel), the inflammatory 
phagocytes were not present in abundance to effect sufficient functional modulation of 
the monocyte/macrophage phenotype to translate to functional cardiac repair. 
Furthermore, as suggested by the bioimaging study, the hydrogel likely degraded by day 
7, and perhaps employing a less protease-sensitive cross-linker could minimize the 
protease-mediated degradation and allow the gel to remain in the heart longer, affording 
mechanical support which has been shown to be beneficial in cardiac remodeling 
following MI [96]. Taken together, our in vivo study employing IL-4-hydrogel delivery 
suggests that the retention of IL-4 in the heart is higher than with bolus IL-4 delivery, and 
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that there is promising acute functional improvement and potential ant-inflammatory 
effects induced by IL-4 hydrogel delivery which warrants further study and thorough 
characterization of gene expression at these acute time points in comparison with bolus 
IL-4 delivery. While chronic functional improvement or improved cardiac remodeling are 
not observed, optimization of the hydrogel delivery system to achieve a more controlled 
delivery of IL-4 to the heart could potentially elicit a stronger polarizing effect on the 




CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS  
6.1 Polyketal-siRNA delivery for antioxidant therapy  
 Antioxidant therapy has shown promise in battling the excessive ROS production 
caused by infiltrating neutrophils and macrophages during the initial stages of 
inflammation post-MI in pre-clinical models. However, to date none has been clinically 
translated to successful treatment options. Identification of appropriate therapeutics, 
temporal window of administration as well as delivery hurdles have all contributed to 
lack of translation. Chapter 3 describes polyketal nanoparticles as a viable system for the 
local delivery of siRNA against a major oxidant enzyme Nox2-NADPH in the heart 
following MI. We were able to demonstrate their intracellular localization in 
macrophages in vitro and the ability to knockdown Nox2-NADPH oxidase at the genetic 
and protein levels in vitro. At a low dose of 5μg siRNA/kg, the delivery of Nox2-siRNA 
by polyketal particles was able to restore acute cardiac function following MI injury in 
mice. These results point to the potential of Nox2-NADPH as a therapeutic target in 
acute-MI and consideration of polyketal particles as siRNA delivery vehicles for future 
large-animal studies.  
 The infarcted heart is an inflammatory environment and special care should be 
devoted in designing drug delivery approaches that do not exacerbate those conditions. 
The major strength of PK3 polymers for siRNA delivery in the context of MI is their 
biocompatibility, especially in light of the alternative approaches of cationic lipids that 
can generate cytotoxicity. However, a cationic lipid DOTAP was used to ion-pair to 
siRNAs in order to charge neutralize them prior to formulation, and while the cationic 
residues are not exposed on the surface of the particles, it would be ideal to eliminate 
these from the formulation process. Future generations of this delivery system could 
explore the use of biological cationic molecules such as spermidine for efficient 
complexation of siRNA [225].  
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 Polyketal polymeric particles are also ideal vehicles for intracellular delivery of 
therapeutics to target phagocytic macrophages, as they are taken up efficiently by these 
cells. Further, since PK3 polymers are synthesized using acid degradable ketal linkages, 
they enable design of nanoparticles with pH sensitive degradation properties, and in the 
setting of siRNA delivery following endocytosis/phagocytosis, this represents a unique 
opportunity [122, 226]. When a nanoparticle formulation is endocytosed, intracellular 
trafficking begins in early endosomal vesicles which subsequently fuse with sorting 
endosomes, which in turn transfer their contents to the late endosomes (pH of 5 -6) The 
late endosomal content is then relocated to the lysosomes (pH ~4.5) and contain various 
nucleases that could degrade the siRNAs. To avoid lysosomal degradation, siRNAs must 
escape from the endosome into the cytosol, in order to associate with the RNAi 
machinery. In the field of nucleic acid delivery, endosomal escape is thought to be the 
rate-limiting step, and one of the most challenging barriers for efficient siRNA delivery 
[164]. As our particles are acid sensitive, they potentially degrade in the moderately 
acidified endosomes and enable release of siRNA. In order to ensure faster degradation of 
the particles, we incorporated another pH sensitive small molecule chloroquine to the 
formulation. However, there is potential to further engineer the polyketal polymers to 
afford even better spatial and temporal control of degradation without the incorporation 
of chloroquine, for instance, by synthesizing polyketal polymers that are highly sensitive 
to changes in pH so that they degrade faster, even at the slightly acidified pH of 6, 
ensuring protection of siRNA from nucleases of the late endosomal/lysosomal 
compartments. 
 Furthermore, in terms of endosomal escape, there can be many other potential 
improvements to the system. A recent study tracked endosomal trafficking of siRNA 
Lipid Nanoparticles (LNPs) and found that only a very minor fraction (1–2%) of siRNAs 
were released from endosomes [164]. Further, the authors found that the bulk of these 
siRNAs were released from moderately acidified early endosomal compartments, and 
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interestingly they were not released due to bursting of endosomes or permeabilization of 
the limiting membrane of endosomal compartments, but rather from individual siRNAs 
escaping from multiple endosomal compartments. This concerning fraction of only 1-2% 
of siRNA reaching the cytosol necessitates re-thinking of the nucleic acid delivery 
problem in terms of design of delivery vehicles. We incorporated the chloroquine into the 
particles not only to enhance pH-mediated degradation, but also to aid in endosomal 
escape. As a weak base, chloroquine gets protonated in the acidic environment of 
endo/phagosomal compartments, which can trigger swelling and destabilization of their 
membranes to facilitate release of siRNA into the cytoplasm [149]. However, it is not 
clear whether the endosomal contents are released at once due to endosomes bursting, or 
the effect is more destabilization of the compartment, permeabilizing the membranes to 
allow for siRNA to leak out of the endosome, somewhat similar to that demonstrated in 
the study describing LNP tracking. Further studies would have to be done to ensure the 
mechanism of endosomal escape and to optimize the system to obtain even lower 
therapeutic concentrations. Incorporation of fusogenic lipids or membrane interacting 
peptides with high buffering capacity to the polyketals could contribute to rapid 
endosomal escape and warrants further study. . 
 A variation of the polyketal polymers that contain thioketal linkages sensitive to 
ROS has been used to encapsulate pro-inflammatory cytokine TNF- targeted siRNA in 
a similar manner as in our study. When orally delivered to an intestinal inflammation 
mouse model, these particles degraded in response to the high levels of ROS in the 
intestine, knocked down TNF-and protected mice from ulcerative colitis. This study 
illustrates the versatility to engineer these polymers to respond to various stimuli such as 
pH and ROS and substantiates the utility of polyketals as nucleic acid delivery vehicles in 
an inflammatory disease application. Future studies could incorporate antioxidants (small 
molecules, proteins or nucleic acids) in polythioketals to deliver to the myocardium as an 
on-demand delivery system that degrades in the presence of ROS, to suppress ROS.  
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 In a related study employing polyketals, Seshadri, et al. delivered antioxidant 
protein superoxide dismutase (SOD) to the rat myocardium of an ischemia-reperfusion 
(IR) model of MI. This study was similar in the nature of modulation (antioxidant 
therapy) and acute time point of assessment (day 3 post-MI), and demonstrated sustained 
release of SOD as well as the ability to scavenge both intra- and extra-cellular superoxide 
in the myocardium following IR. This contributed to a four-fold reduction in cardiac 
myocyte apoptosis compared to IR-surgeries alone at an acute day-3 time point, which 
reflected in restored cardiac function. While our study employing PK-siNox2 did not 
investigate the mechanistic aspect for the beneficial restoration in cardiac function 
observed, the study delivering PK-SOD suggests that prevention of apoptosis could be 
one of the mechanisms of action. Interestingly, the SOD delivery did not sustain 
functional improvement in the chronic time point, and using a second polyketal-based 
therapy to target chronic inflammation (PK-p38i microparticles) had synergistic effects as 
animals that were treated with both PK-SOD and PK-p38i achieved significant 
improvement in chronic function [121, 124]. Our study did not assess the chronic effects 
of Nox2-siRNA delivery such as its effect on fibrosis as well as long-term functional 
improvement, and in light of results from the PK-SOD study, it is imperative to conduct 
these chronic studies to determine whether higher dosage or repeated injections or other 
synergistic therapies that target long-term chronic inflammation are necessary to sustain 
benefits of knocking down Nox2 at the initial inflammatory stage following MI. Further, 
oxidative stress markers (lipid and protein peroxidation markers) should be assessed as 
well, to confirm the direct antioxidant mechanism of action. 
 Further, our study did not confirm in vivo knockdown of Nox2 mRNA expression 
to be primarily in macrophages, although in previous studies, non-modified PK particles 
have not shown effective uptake by non-phagocytic cell types [123, 227]. However, 
while the infiltrating inflammatory cells represent a large source of O2
-
 following 
infarction, Nox2 is also expressed on other cardiac cell types, and is indeed 
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overexpressed in cardiomyocytes following infarction. It is possible that for long-term 
functional improvement other cell types will need to be targeted. A recent publication 
from our laboratory demonstrates that PKs modified to present N-acetylglucosamine 
ligands on the surface are taken up by cardiomyocytes, and this could allow for dual 
targeting of Nox2 in other cell types [227].  Studies to assess the efficacy of this approach 
would be an exciting possibility to further polyketals as targeted siRNA delivery vehicles 
to the myocardium, potentially even extending this approach to a completely non-
invasive I.V delivery route.  This approach then widens the scope of nucleic acid delivery 
mediated by polyketal nanoparticles to non-phagocytic cells, and especially to mycocyte, 
a cell type that scarcely takes up foreign particles, and is of utmost interest to the field of 
regenerative cardiology in terms of drug delivery.  
 Finally, use of polyketals for nucleic acid delivery can extend beyond 
inflammatory disease applications. In vitro, phagocytic bone marrow derived 
mononuclear cells derived from the hematopoietic linage were able to express pluripotent 
gene expression when a cocktail of embryonic stem cell specific microRNAs were 
delivered to them via PK3 polyeketal nanoparticles [228]. The application of these 
particles was well tolerated by these primary mononuclear cells and opens up the 
possibility to use polyketals as effective reprogramming tools with implications in the 
field of regenerative medicine and stem cell technologies.  
6.2 Spherical nucleic acid delivery for anti-inflammatory therapy 
 Chapter 4 describes an efficient gene silencing methodology for anti-
inflammatory therapy in a rat model of MI. Catalytic DNA (DNAzyme) targeted against 
mRNA of pro-inflammatory TNF- was functionalized to gold particles in a spherical 
nanostructure to impart enhanced substrate binding, stability and cellular uptake. The 
advantages of this system include stability and low cost of DNA over RNA for gene 
silencing,  and the simple synthesis scheme employing the gold-sulfur self-assembly 
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technology. A significant advantage of this system is the non-inflammatory nature of the 
gold-DNA conjugates that make them ideal nucleic acid delivery vehicles in the context 
of the inflammatory post-MI environment, and this is demonstrated by our comparative 
studies with widely used cationic lipid particles. In vitro results from our studies show 
efficient uptake of DNAzyme particles by primary macrophages (as well as myocytes) 
and 50% knockdown of TNF-at the protein level. In vivo studies demonstrate 
significant anti-inflammatory effects conferred by the knockdown TNF- by DNAzyme 
particles and significant improvement in acute cardiac function compared to untreated 
rats.  
 While these results are promising, it is important to keep in mind that the 
inflammatory cascade that follows MI is a complex network of molecular events dictated 
by cellular, spatial and temporal variables and mediated by molecules with pleiotropic 
effects such as chemokines and cytokines. Further, cytokines in an inflammatory disease 
state exhibit redundancy, synergistic activity and antagonistic effects upon each other. 
Therefore while these inflammatory mediators such as TNF-  appear to be appropriate 
therapeutic targets when considering their deleterious effects in the early stages of the 
inflammatory response, it may also be necessary to carefully consider their roles as 
regulators of cardiac repair [37]. In the case of TNF-, it may very well be the case that 
complete or prolonged inhibition of this critical inflammatory mediator may be 
dangerous for the progression of HF, albeit crucial to modulate in the earlier stages. This 
was the rationale for utilizing transient gene silencing in the early stages of MI in this 
study as the first step in a long road to reviving such an anti-inflammatory therapy to the 
clinics.  
 The next step in this process is to explore the optimal temporal window to employ 
TNF- antagonism, and a few modifications to the current drug delivery system could be 
used to test this possibility in a minimally invasive manner. The DNAzyme orientation on 
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the gold particle is shown to be important for the catalytic activity, and in previous work 
published, it has been shown that DNAzyme anchored through the 5’ terminus were 
inactive. Gold particles functionalized in this fashion were photoactivated by irradiation 
with a 532nm pulsed laser to partially release the DNAzyme to trigger catalytic activity 
[31]. Such a mechanism could be used deliver the therapeutic particles to the 
myocardium following MI surgery as was done in this study, and systematically trigger 
the release at various time points to induce TNF- suppression, enabling a wealth of 
information with regard to the effects of temporal control of release.  
 Further in vitro studies could accompany and lend support to this approach to 
achieve temporal control of silencing activity. Kinetic studies evaluating the catalytic 
activity through a time course of 1 hour to 72 hours would be ideal to evaluate the earliest 
time of knockdown following particle uptake and the temporal window of maximum 
knockdown. The biggest challenge to this study is establishing a model of TNF- 
upregulation, as even macrophages do not produce TNF-unless subjected to injury. We 
have been employing bacterial endotoxin LPS to stimulate TNF-production, and for 
these kinetics studies planned, the kinetics of TNF-production upon LPS stimulation 
would have to be determined at an appropriate concentration in order to provide a steady-
state level of TNF-in the in vitro model to then apply the DNAzyme particles for the 
kinetic study. Multiple dosages should also be evaluated in this study, and extended to in 
vivo studies as well in order to determine the optimal therapeutic levels of DNAzyme 
particles for maximum desired biological effects (silencing and anti-inflammatory and 
functional measures). 
 Implementing the optimal temporal window and therapeutic dosage, future studies 
should entail evaluating the efficacy of these particles in chronic functional studies. In 
addition to cardiac function, immunohistochemical analyses evaluating extent of cardiac 
fibrosis and angiogenesis should be evaluated to assess the effect of TNF-antagonism 
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on cardiac repair. These studies would definitively address whether other therapeutic 
mechanism should supplement regulation of TNF-to achieve effective cardiac repair 
and prevent progression of HF.  
 Often touched on, but not explored further in my thesis work is the ischemia-
reperfusion (IR) model of MI, arguably the more clinically relevant model for the study 
of post-MI treatment strategies as early reperfusion therapies are the gold standard in the 
management of MI. As discussed in various section of my thesis, the paradoxical 
reperfusion injury stimulates ROS and vascular inflammation. TNF-is an established 
regulator of ROS production and directly implicated in many of the processes associated 
with vascular inflammation such as upregulation of leukocyte adhesion molecules [70, 
77, 229], and therefore employing IR models of MI to test gene silencing by DNAzyme 
particles may be of significance to move this approach along towards translation.  
6.3 Bioactive PEG-hydrogel for immunomodulation  
 The overall objective of the study described in chapter 5 was to deliver polarizing 
cytokine IL-4 to the heart to alternately activate monocytes/macrophages recruited to the 
infarct following MI, and assess the effect of this strategy on the inflammatory 
environment in the myocardium, cardiac repair and functional recovery. We validated 
this approach in vitro by polarizing primary and immortalized cell line of macrophages 
and testing the beneficial paracrine effects of conditioned media from alternatively 
activated macrophages on endothelial cell survival, tube formation and cardiac progenitor 
migration. In order to demonstrate proof-of-concept of this strategy in vivo, we utilized an 
injectable polyethylene glycol (PEG) based hydrogel end-functionalized with maleimide 
groups (PEG-MAL hydrogel) to allow for functionalization with cysteine containing 
peptides or proteins. This allows the incorporation of a protease cleavable peptide cross-
linker, thus enabling a protease degradable delivery system. Macrophages upregulate 
proteases in the myocardium during the initial inflammatory phase following MI, and 
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could potentially trigger degradation of the gel to release IL-4 in an on-demand fashion. 
However, in vitro release characteristics of IL-4 from most variations of the PEG-MAL 
hydrogel compositions indicate high levels of burst release of this small cytokine (14kDa)   
and therefore indicate further need for optimization of the delivery system for this 
application. In vivo evaluation of IL-4-hydrogel delivery conferred acute functional 
improvement and trends of low levels of pro-inflammatory markers TNF- and MCP-1, 
although chronic functional study (day 21) did not show any significant improvement in 
function. This accompanied by lack of significant improvement in fibrosis or 
angiogenesis indicate the need to carry on future studies that can investigate mechanisms 
to sustain the initial improvement in cardiac function observed with the IL-4 hdyrogel 
delivery. One of the primary efforts would be focused on optimizing the delivery system 
and some of the potential strategies to optimize the release profile of IL-4 from the PEG-
MAL hydrogel to prevent burst release and sustain controlled release were outlined in the 
discussion of chapter 5. Further alternative strategies are discussed here along with other 
potential materials to consider for this immunomodulatory application as well as other 
potential parallel or synergistic approaches to IL-4 delivery.  
 With the PEG-MAL hydrogel, an alternative strategy to intramyocardial injection 
would be to design a multifunctional hydrogel scaffold that could be applied as a patch, 
with non-uniform loading distribution, accentuating what we already see with the tightly 
trapped inner layer. For instance, a center layer of hydrogel could be made up of a high 
wt% such as 12% PEG-MAL in order to minimize the mesh size and encapsulate IL-4, 
which is then re-encapsulated by another layer of the hydrogel, preventing burst release 
and allowing for controlled release. This strategy could also allow for truly on-demand 
enzymatic release when macrophages infiltrate the hydrogel and release proteases to 
degrade the gel. Further, several studies demonstrate that hydrogels themselves can 
acutely improve function due to mechanical support of the LV wall [96] and therefore an 
application of a patch for drug delivery could lend the additional benefit of mechanical 
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support, to further enhance cardiac repair. Alternately, microgels formed from PEG-MAL 
hydrogel, previously used for cell microencapsulation [230], could be utilized to 
microencapsulate IL-4 and then re-encapsulated by the hydrogel to allow for controlled 
release via this multilayered system. This hydrogel could be cross-linked with peptide 
linkers less sensitive to proteases so as to slow down the enzymatically-triggered release 
as well.  
 While PEG is a material desirable for many biomedical applications due to their 
non-fouling surface characteristics, in an application where the goal is to modulate the 
immune response to achieve a certain regenerative outcome, a biomaterial with known 
immunomodulatory properties may even be more ideal. Chitin is a non-toxic, 
biodegradable and biocompatible natural polymer (amino polysaccharide) used in various 
biomedical applications. Notably they have been used to create tissue engineering 
hydrogel scaffolds and as wound dressing material due to their ability exert Th2 like, 
anti-inflammatory effects on immune cells including macrophages [231-234]. Recent 
advances in chitosan chemistry have proposed numerous controllable gelation 
methodologies for these materials, and would be an interesting avenue to test out their 
ability to induce M2 polarization to enhance myocardial wound healing.   Self-ssembling 
peptides are another class of materials that have found numerous tissue engineering and 
protein delivery applications for myocardial regeneration, and possess numerous inherent 
advantages amenable to protein delivery, especially that of programmability that allows 
for incorporation of small fusion proteins [235] as well as assembly triggers [236] and 
stimuli-responsive degradation properties such as MMP cleavable sites [237]. Further, as 
peptides, they provide numerous functional moieties to facilitate physical tethering of 
cytokines/growth factors to these injectable peptide nanofiber gels.  
 While our existing knowledge of the M1/M2 paradigm has expanded in the recent 
years, further understanding the regulatory mediators that facilitate the M1 to M2 shift in 
following MI needs to be explored further. Several studies have definitively shown that 
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the spleen deploys the pro-inflammatory monocytic population (Ly6C
high
) to the site of 
infarct immediately following MI in response to the release of chemokine MCP-1 in the 
myocardium. IL-4-hydrogel treated group exhibited lower local and systemic MCP-1 
levels, and this suggests a crucial role MCP-1 may play in preventing further recruitment 
of pro-inflammatory monocytes to the infarct upon exposure to IL-4. This also signifies 
chemokine MCP-1 as a potential target for immunomodulation, and careful inhibition of 
MCP-1 in the initial inflammatory phase might pave way to a controlled inflammatory 
response. This approach however, would be very similar to that of knocking down the 
CCR2 receptor in the splenic monocytes that reduced the influx of inflammatory cells 
and resulted in decreased infarct size following MI [191]. However, the MCP-1 
downregulation could be targeted to the myocardium or delivered systemically. Strategies 
as such aiming to reduce the influx of monocytes, however, should be deployed with care 
as inflammatory cells are a crucial step in the wound healing process, and absence of 
these inflammatory mediators may even lead to infarct destabilization and cardiac rupture 
[17, 157]. Furthermore, the sequential recruitment theory of the pro-inflammatory Ly6C
hi 
monocytes followed by the reparative Ly6C
low
 to the infarct has been somewhat 
disproven, with new evidence demonstrating a role for a nuclear hormone receptor switch 
(Nr4a1) in modulating the pro-inflammatory Ly6C
hi
 monocytes to differentiate towards 
the reparative or M2 macrophage phenotype found in the wound healing phase following 
MI (day 4-8) [89]. The role of chemokine Fractalkine (CX3CL1) in the recruitment of the 
Ly6C
low
monocytes has been well established. However, in light of these new turn of 
events with Nr4a1 emerging as a new target for the modulation of macrophage phenotype 
towards M2, the role of Ly6C
low
 monocytes is unclear in terms of the role these 
monocytes play. However, further studies should be performed to confirm whether 
delivery of Fractalkine may serve as a trigger for the recruitment or local polarization 
towards a reparative macrophages without hindering the recruitment of pro-inflammatory 
Ly6C
hi 
monocytes.    
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 Our study looked at only the effects of IL-4 delivery. While there is a strong 
rationale for evaluating ability of IL-4 to polarize macrophages in vivo, other modes of 
macrophage activation such as the regulatory functional phenotype of macrophages 
activated by IL-10 merit further investigation. Numerous studies have shown the strong 
anti-inflammatory effects induced by IL-10 and its role in bringing about inflammation 
resolution [37, 174, 238, 239]. Further, an IL-10 mimetic peptide is available [240] which 
makes incorporation into a biomaterial scaffold such as PEG-MAL or self-assembling 
peptides a simple process, and a rational next step to test out synergistic effects of 
encapsulated IL-4 and tethered IL-10 on the inflammatory response in the myocardium. 
Our data from this study, and from previous work employing antioxidant SOD delivery to 
the myocardium [121] discussed in section 6.1, it is clear that immunomodulation therapy 
of a singular kind may not be the “magic bullet” to improve cardiac repair, and rather, 
synergistic effects with another therapeutic may enhance the cardiac repair process. With 
cardiac regeneration as the ultimate goal for regenerative cardiology, an immune 
modulatory therapy could enhance stem-cell therapy by creating a pro-regenerative 
environment that improves cell survival and stimulates endogenous cues to differentiate 
stem-cells. 
 It could not be denied that conditions accompanying or preceding MI in humans, 
such as obesity, atherosclerosis and diabetes have inflammatory components that disrupt 
the balanced inflammatory response following MI, causing impaired healing [204, 241]. 
Many of these factors cannot be easily replicated in rodent animal models. Further, part 
of the wealth of information on the inflammatory response post-MI comes from animal 
models that underwent permanent occlusion MI while some others from ischemia-
reperfusion (IR) models. While both are valid and accepted models in the field, the nature 
of the inflammatory response is likely different, and it is difficult to reconcile these data 
to draw the appropriate conclusions regarding targets for modulation as well as outcomes 
of such attempts. Inflammation induced by the reperfusion-injury in IR may influence the 
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healing process differently than the permanent occlusion model, not to mention the 
variability in animal models and surgical procedures that would likely affect the 
inflammatory milieu from one study to another. Therefore, it is critical to fully 
characterize the inflammatory response in the animal model we work with prior to 
reconciling information in the field to create testable hypotheses regarding modulating 
that immune response. These would not only include temporally resolved local gene 
expression analyses of macrophage markers, but also local and systemic cytokine and 
chemokine levels in order to accurately assess the inflammatory network of events, as it 
is not uncommon for macrophages characterized as M1 to stimulate production of anti-
inflammatory cytokines and vice versa [242]. The cytokine and chemokine milieu may 
represent the inflammation and inflammation resolution phases following MI more 
accurately than the extreme classifications of macrophage markers.   
6.4 Perspective 
 The immune system is closely tied to the development of many chronic diseases 
we are faced with today, whether it is cancer where the immune system is defective or 
heart disease where it is often the culprit for worsening conditions. Scientists have for a 
while now recognized the immune system as an avenue for therapeutic modulation. 
Given this knowledge, the lack of effective therapies that target the immune system for 
the treatment of acute MI is significant. This is in some part due to heart being a difficult 
organ to achieve effective drug delivery. While drug delivery to the heart has come a long 
way, the future biomaterial designs need to be bolder and more comprehensive in order to 
tackle the immune system, the regenerative aspects as well as the mechanical aspects of 
the heart. Further, many limitations exist when drawing comparisons from rodents to 
humans in the progression of disease and even the nature of drug delivery is a different 
beast in humans vs rodents. Biomaterials are much more amenable to testing in large 
animals than rodent models. My thesis work described three strategies to modulate the 
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immune response in the infarct using biomaterials based delivery systems, progressively 
choosing therapeutic targets that are key regulators of the disease. However, from a 
translational point of view, the disease characteristics need to be studied much more 
intensively in more clinically relevant larger animal models, especially the immune 
system with regard to heart disease, as the wealth of information that exists is for mice 
models of the disease. Then, a multidisciplinary approach to careful selection of network 
regulators and design of multifunctional materials should be applied to move promising 


































Figure A2. In vivo Nox4 mRNA expression. Grouped data (mean ± SEM; n≥8 per 
group) from 3 days. There was a trend towards an increase in Nox4 mRNA expression in 
animals that received MI although not statistically significant. In animals that received 
MI and PK-siNox2 treatment, there was no observed knockdown of Nox4 mRNA 
expression.  Gene expression was evaluated by qRT-PCR using the quantitative standard 
curve method, and the results were normalized to 18S levels and reported as fold changes 
in copy number of mRNA levels compared to sham animals (One-way ANOVA followed 
by Dunnett’s Multiple Comparison post-test).  
Figure A1. Modified particle sizes depending on homegenization speeds. 
A) Lower magnification image of particles generated with only homegenization for 60 
sec and no sonication (d=1.36 ± 0.43μm). B) Particles generated with sonication at 
intermediate speeds (d=0.83 ± 0.30μm). C) SEM of particles generated with sonication at 




Figure A3. DNA stability in water. A plot showing Dz (7/7 b.p. recogntion arms) 
mediated in vitro TNFknockdown in primary macrophages for cells treated with 
particles that were stored in Nanopure water for varied amounts of time (t= 1d, 8d, and 
15d). Cells were treated with 10 nM particle concentration for 20 h. TNF expression 
was measured by ELISA and the results were normalized to NS-Dz treated cells and 
reported as percent TNF expression. Approximately 1.5% decrease in particle activity 
per day was observed due to instability of the particles stored in Nanopure water. For in 
vitro and in vivo studies, freshly modified particles were used and were stored in the 





Figure A4. Cy5-NS-DzNP internalization by macrophages. 
RAW 264.7 macrophages were transfected with 5 nM Cy5 labeled NS-DNA. Following 
1 hour of treatment, cells were imaged using confocal microscopy and representative 
orthoganol Z-stack slice allows visualization of internalized Cy5-DNA modified gold 
particles. DNA (red, Cy5), Nucleus (blue, DAPI), cellular morphology stain (green, 




Figure A5. Cy5-NS-DzNP uptake by primary adult rat cardiomyocytes. 
Adult rat cardiomyocytes were fixed and imaged 18 hours post-transfection with 5 nM 
Cy5 labeled DNA by (left) Cy5-dzNPs or (right) Lipofectamine® mediated transfection. 
DNA (red, Cy5), Nucleus (blue, DAPI), cellular morphology stain (green, FITC-





Figure A6. Effect of in vivo delivery of TNF-Dz particles on invasive hemodynamics 
Pressure-Volume (PV) measurements. Grouped data (mean ± SEM; n=5-9 for each 
group, n=41 total) from 3 days. (A) There was a trend towards depression of function 
using the dp/dt parameter in all animals that underwent MI except for the Dz treated 
group. However, there was no statistical significance in these parameters in any of these 
groups. (B) A significant reduction in % Ejection Fraction (%EF) was observed in all 
animals that underwent MI compared to sham animals. Although not statistically 
significant compared to MI group, Dz treated group showed a trend of improved %EF 




Figure A7. Effect of TNF-Dz delivery on plasma levels of inflammatory and anti-
inflammatory cytokines. Grouped data (mean ± SEM; n=3-9 per group) from plasma at 
3 days. Although there was no statistically significant differences in any of the groups, 
there were consistent trends towards downregulation of pro-inflammatory cytokines (A) 
IL-12, (B) IL-1 and potential trend towards an increase in anti-inflammatory cytokine 
(C) IL-10 in the plasma of Dz treatment groups. Data was analyzed using the Luminex 
Multiplex system and reported as plasma cytokine concentrations, quantitatively derived 
from standard curves of each cytokine.  
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Figure A8. Effect of TNF-Dz delivery on anti-inflammatory cytokine IL-10 gene 
expression. Grouped data (mean ± SEM; n=5-9 per group) from LV infarct tissue at 3 
days. A significant upregulation of IL-10 expression was observed in animals that 
received an MI compared to sham, and no significant changes in IL-10 mRNA expression 
in any of the treatment groups. Gene expression was evaluated by qRT-PCR using the 
quantitative standard curve method and the results were normalized to GAPDH levels 
and reported as fold changes in copy number of mRNA levels compared to sham animals 





Figure A9. DNAzyme 7/10 arm. (A) Schematic showing the original DNAzyme design 
targeting TNF mRNA (green) with recognition arm lengths of 10 and 7 baseparis and 
eight 2’ methyl ether modifications (*, yellow) to enhance stability. The inactive 
DNAzyme has a single base mutation shown in red to inhibit RNA hydrolysis. (B) In 
vitro TNF knockdown in primary macrophages where cells were treated with either 
active (Dz), inactive (i-Dz), or non-specific (NS-Dz) DNAzyme modified gold 
nanoparticles at 10 nM or 20 nM concentrations. TNF expression was measured by 
ELISA and the results were normalized to NS-Dz treated cells and reported as percent 
TNF expression. Little knockdown (2% and 14% for Dz and i-Dz, respectively) was 
observed for cells treated with particles at 10 nM concentration where higher knockdown 
(23% and 30% for Dz and i-Dz, respectively) was observed for cells treated with 20 nM 
concentration. At both concentrations, little difference was observed between Dz and i-
Dz modified particles due to product inhibition. In the optimized design, the 10  base pair 
recognition sequence was decreased to 7 base pairs, which significantly increased 
knockdown and difference in knockdown for Dz and i-Dz modified partices (Figure 3.  
~50% and ~0% TNF knockdown for Dz and i-Dz treated macrophages at 10 nM 





 sparks characteristics in adult rat cardiomyocytes following LPS 
stimulation and Dz particle treatment. Ca
2+
 sparks are elementary SR Ca
2+
-release 
events through a cluster of ryanodine receptors (RyR2s) that occur spontaneously during 
diastole and summate in time and space during systole to form the global Ca
2+
 transient 
during E-C coupling. To monitor Ca
2+
 sparks, we utilized line scans via laser scanning 
confocal microscopy to enable visualization of rapid fluorescence intensity changes with 
time on myocytes treated with Dz particles following LPS stimulation. (A) Frequency of 
release events decreased with particle treatment (blue bars), and increased in (B) 
Amplitude, width (FWHM), and duration (FDHM) indicative of a higher SR load that 
can be attributed to the observed decreased frequency of diastolic release with particle 
treatment. These data indicate that the knockdown of TNF- with the particles is able to 
decreasing aberrant diastolic Ca
2+
 release (Grouped data from n=1, 6-8 cells per group, 
particle treated group is significantly different from the untreated group by one-way 







Figure A11. Bone-marrow derived macrophages (BMM) stained for pan-
macrophage marker CD68. Macrophages (Red, CD68), Nucleus (blue, DAPI). (Scale 
bar = 50m) 
 
 
Figure A12. Endothelial cell migratory/aggregatory behavior on collagen gels.  
CECs treated with M2 macrophage conditioned media treatment showed an increased 
tendency to migrate towards each other and form aggregates, a possible pre-cursor to 




Figure A13. Staggered vs simultaneous M1 and M2 polarizing stimuli on BMM 
macrophages. Characterization of (A) Arg1 activity and (B) NO production following 
staggered (IFN-γ + LPS on day 1, stimuli removal and IL-4 addition on day 2)  or 
simultaneous (IFN-γ + LPS and IL-4 combined for 2 consequtive days) activation of 
BMM (Grouped data, mean ± SEM; n=5-6, *p<0.05, **p<0.01, ***p<0.001; one-way 
ANOVA followed by Dunnett’s Multiple Comparison post-test). Simultaneous activation 
shows better tendency for reversal of M1 characteristics, possibly indicating a hybrid 




Figure A14. Comparison of relase of IL-4 with IgG from PEG-MAL gels.  
Fluorescently tagged IL-4 (~14kDa) or IgG (150kDa) released from 5% weight 
percentage of PEG-MAL hydrogels of two different molecular wieghts, 10 and 20 kDa 
swelled in PBS by fluorescent plate reader sampling of incubation media.  
  
 
Figure A15. Mass swelling ratio of 10kDa PEG-MAL hydrogels.  
Influence of polymer weight percentage on equilibrium swelling ratio for hydrogels made 
from 5,  and 7% PEG-MAL of 10kDa MW. Grouped data, mean ± SEM; n=4 *p<0.05, 




Figure A16. Log transformation of release study shown in Figure 21. Fluorescently 
tagged IL-4 released from 6 ,7 and 12% PEG-MAL hydrogels compared to collagenase 
mediated release of 2 different concentrations over a 48 hour period. Two phases (burst 





Figure A17. Bioactive IL-4 release from PEG-MAL hydrogel. NO production in LPS 
stimulated macrophages in the presence of empty or IL-4 encapsulating PEG-MAL hydrogel 
degraded by COL-I application through day 2. (n=3, t-test, *p<0.05) 
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Figure A18. Effect of IL-4-hdyrogel on a plannael of genes of significance for 
inflammation. Grouped gene expression data (mean ± SEM; n=3 per group) over a 
course of a week after MI with or without IL-4 hydrogel treatment. Gene expression was 
evaluated by qRT-PCR using the comparative Ct method and the results were normalized 
to GAPDH levels and reported as fold changes compared to sham animals.   
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A.2. Supplemental Results 
A.2.1. Effect of Dz treatment on Ca2+ transients on LPS-treated adult rat 
cardiomyocytes  
 It has been well established that TNF and subsequent induction of other pro-
inflammatory cytokines IL-6, IL-1 or ROS generation in cardiac myocytes leads to a 
high frequency of Ca
2+
 sparks. These effects can attenuate myocyte contractility directly 
through the reduction of systolic cytosolic Ca
2+
 levels via alterations in sarcoplasmic 
reticulum function [80, 181], down-regulation of contractile proteins, ßadrenergic 
receptor uncoupling [78, 182, 183] or indirectly by decreasing myocyte contractility 
through nitric oxide-dependent attenuation of myofilament Ca
2+ 
sensitivity [24, 73, 80, 
180, 183] or oxidative effects on the RyR2 [184, 185]. In Chapter 4 we have shown that 
knocking down TNF in the myocardium utilizing Dz particles following MI resulted 
in downregulation of several pro-inflammatory cytokines and iNOS, and we wanted to 
test whether Dz particles can reverse dysregulation of calcium transients. 
 Ca
2+
 sparks are elementary SR Ca
2+
-release events through a cluster of ryanodine 
receptors (RyR2s) that occur spontaneously during diastole and summate in time and 
space during systole to form the global Ca
2+
 transient during E-C coupling. To monitor 
rapidly changing phenomena such as fluorescence signals from Ca
2+
 sparks, laser 
scanning confocal microscopy can be utilized and these line scans enable visualization of 
rapid fluorescence intensity changes with time. We pre-treated myocytes with Dz 
particles (20nM particle concentration for 12 hours) and stimulated with LPS (50ng/mL) 
for 1 hour, and observed that the spark frequency was significantly decreased compared 
to cells not pre-treated with particles. These data indicate that the particles are able to 
prevent the production of ROS intracellularly (potentially iNOS and others), thus 
decreasing aberrant diastolic Ca
2+
 release. We hypothesize that the main mechanism for 
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this observation may be that knockdown of TNF- in cardiomyocytes lessen the extent of 
oxidation of the RyR2. Although release events became less frequent with particle 
treatment (blue bars), they were of increased amplitude, width (FWHM), and duration 
(FDHM) indicative of a higher SR load that can be attributed to the observed decreased 
frequency of diastolic release with particle treatment. The properties of the recorded Ca
2+
 
sparks were analyzed and summarized in Figure A10. 
A.2.2. Superoxide levels acutely upregulated following MI and IR 7 days after MI 
or IR surgery (n = 3-4, assessed by DHE-HPLC) 
 
A.2.3. Nox2-NADPH oxidase levels stay upregulated 7-days after MI (n=7, gene 
expression using qRT-PCR) 
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A.3. Supplemental Methods 
A.3.1. Adult rat cardiomyocyte culture 
 Single ventricular myocytes were isolated from male Sprague-dawley rats. Rats 
were anesthetized with ketamine (1 mg/g) and xylezene (0.1 mg/g), and hearts were 
excised and mounted on a Langendorff apparatus. Hearts were retrogradely perfused 
with nominally Ca
2+
-free Tyrode’s solution for 5 min followed by minimal essential 
medium Eagle (MEM) solution containing 20 µM Ca
2+
 and 22.5 µg/mL Liberase 
Blendzyme TH (Roche Applied Science, Indianapolis, IN) for 20-25 min at 37°C. 
The right ventricular free wall was removed from the heart, minced, filtered, and 
washed in MEM solution containing 50 µM Ca
2+
 and 10 mg/mL BSA. Isolated cells 
were kept in MEM solution with 50 µM Ca
2+
 at room temperature (22-24°C) until 
indicator dye loading and subsequent experimentation. All protocols were approved 
by the Institutional Animal Care and Use Committee. 
A.3.2. Ca2+ sparks imaging 
 Confocal microscopy (FV1000, Olympus) was used to image Ca
2+
 sparks, with 
excitation at 488nm and emission collected at >500nm. Cardiac myocytes were 
loaded with 20 µm fluo-4/AM for 20 min at room temperature (RT), followed by a 20 
min wash in 2mM Ca
2+
 Tyrode’s at RT. Ca
2+
 spark measurements were acquired 
from intact myocytes perfused with 2 mM Ca
2+ 
Tyrode’s solution during rest after 1 
Hz stimulation in line scan mode at 2 ms/line with a pixel size of 0.155 µm. All 
fluorescent signals were background subtracted. Changes in [Ca
2+
]i are expressed as 
ΔF/F0, where ΔF is the change in fluorescence [measured fluorescence (F) – F0] and 
F0 is resting baseline fluo-4 fluorescence. For all subsequent Ca
2+
 imaging 
experiments, cells were placed on laminin-coated coverslips. Action potentials and 
global Ca transients were elicited by electrical field stimulation using a pair of 
platinum electrodes. Experiments were conducted at room temperature (22-24°C) 
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A.3.3. List of primers 
 
 Gene Species Sequence (5' => 3')   
Hprt1 Rat F: GCTGACCTGCTGGATTACAT 
  R: TTGGGGCTGTACTGCTTAAC 
      
18S Rat F: TTCCTTACCTGGTTGATCCTGCCA 
  R: AGCGAGCGACCAAAGGAACCATAA 
      
IL6 Rat F: CAGAGTCATTCAGAGCAATAC 
  R: CTTTCAAGATGAGTTGGATGG 
      
IL-1 Rat F: TAAGCCAACAAGTGGTATTC 
  R: AGGTATAGATTCTTCCCCTTG 
      
IL-10 Rat F: CCTGGTAGAAGTGATGCCCC 
  R: TGCTCCACTGCCTTGCTTTT 
      
IL-12 Rat F: AGACCCTGCCCATTGAACTG 
  R: CAGGAGTCAGGGTACTCCCA 
      
TNF- Rat F: TCTTCTGTCTACTGAACTTCG 
  R: AAGATGATCTGAGTGTGAGG 
      
GAPDH Rat F: CCAGCCCAGCAAGGATACTG 
  F: GGCCCCTCCTGTTGTTATGG 
      
TNF- Mouse F: CCCATTACTCTGACCCCTTT 
  R: TGAGCATCGTAGTTGTTGGA 
      
MRC-1 Mouse F: GCA AAT GGA GCC GTCTGT GC 
  R: CTC GTG GAT CTC CGT GAC AC 
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